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In recent years investigation of the biological mode of action of the 
antimalarial compound atovaquone has validated the Plasmodium falciparum 
bci protein complex as a target for the development of novel antimalarials. 
This project is concerned with the design, synthesis and development of 
quinolone based antimalarial compounds targeting the Q0 site of the 
Plasmodium falciparum bci protein complex.
A small array of quinolone-based compounds, substituted at the 3 and 7 
positions, has been developed utilising the Gould-Jacobs methodology. The 
synthesised compounds express activity as low as 0.46 nM versus 
Plasmodium falciparum malaria parasites in vitro. Activity at the bci protein 
complex has been confirmed and selectivity for the parasite protein over the 
mammalian equivalent has been demonstrated. Poor solubility has been 
highlighted as a potential issue; however steps have been taken towards the 
development of carbamate prodrugs with encouraging results.
Docking studies performed in silico, using the crystallised structure of 
yeast bci protein, demonstrate a key role for residues His181 and Glu272 in 
the recognition of high potency inhibitors and have aided in the rationalisation 
of the observed biological activities. The orientation of the quinolone group in 
the active site and interaction of the inhibitors with the hydrophobic channel 
leading to the active site have both been shown to be of significance for 
biological potency.
Computer lead design of a new chemotype has resulted in the 
development of a second array of quinolone based compounds synthesised 
by a divergent method based on the Huisgen 1,3-dipolar cycloaddition. 
Docking studies predicted the synthesised compounds to be potent inhibitors 
of Plasmodium falciparum bc\. However, in vitro results for the array proved 
disappointing, an outcome attributed to a failure to account for membrane 
permeability and the physical location of the targeted bty protein complex.
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Chapter 1
Introduction
1. Introduction
1.1 Malaria
Malaria is potentially the oldest infectious, parasitic disease known to man 
and it continues to be one of the most prevalent and deadly even today. 
Evidence suggests that malaria existed as far back as 50,000 years ago and 
that the parasites have evolved alongside mankind.1
Although once far more widespread than it currently is, malaria is still a 
global issue, with almost 50% of the world population living in regions 
considered high risk for the disease.2 The most recent figures from the World 
Health Organisation (WHO) show that it is responsible for 500 million cases 
of severe illness each year, at least 3 million of which will be fatal.3
The burden of malaria is not simply a medical one; it is also an economic 
problem. Areas with intense transmission rates show an average loss of 
1.3% of their annual economic growth compared to regions with lower levels 
of infection 4 resulting in a stark correlation between malaria and poverty. 
The disease distribution centres firmly on the tropical and sub-tropical 
regions of the globe which includes some of the poorest nations on the planet 
and they are likely to remain that way for as long as malaria remains 
prevalent.4
In the early 20th century malaria was even more widespread than at 
present; however a concentrated effort following the Second World War and 
extending in to the 1960’s saw the disease eradicated from most of the 
world’s temperate zones. Unfortunately the incidence of malaria has 
increased dramatically in recent years and malaria is returning to regions 
from which it had previously been eliminated.5
This is largely due to the spread of resistance to current therapies both in 
the parasites themselves and the Anopheles mosquitoes that spread the 
parasites from host to host. It is also the result of a symbiosis between 
malaria and other infections such as tuberculosis (TB) and human 
immunodeficiency virus (HIV) which have similar global distributions and 
inhibit an individual’s ability to fight the malaria parasite.2
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1.1.1 The Malaria Parasite
There are four separate species of the malaria parasite that infect 
humans, Plasmodium malariae, P.ovale, which are milder, P.vivax and 
P.falciparum, each with different distributions and subtly different biology 
giving rise to differences in lifecycles and disease mechanisms.6 There is 
also a fifth species, P.knowlesi, a monkey form of malaria common in 
macaques. However it is a zoonosis, an infection capable of crossing to 
humans, this species is potentially fatal and infection rates in south-east Asia 
have recently increased dramatically.7
Plasmodium vivax is the most widespread of the species, occurs in a 
number of drug resistant strains and causes a more severe infection than 
P.ovale and P.malariae, but still only infrequently results in death of the 
patient, usually when their immune system is compromised in some way.8 
P.vivax also has the most complex biology of the five species with a 
peculiarity of the lifecycle leading to the condition known as chronic malaria, 
in which symptoms can reoccur for years after the original infection.9 This is 
due to the ability of P.vivax parasites to enter a dormant liver stage called 
hypnozoites, where they are hidden and protected from the host’s immune 
system in vesicles contained within the host’s hepatocytes. If not treated with 
one of the 8-aminoquinolines, e.g. primaquine, these dormant parasites 
sporadically become active, reinfecting the blood cells leading to the 
characteristic debilitating bouts of fever.9
Plasmodium falciparum, the focus of this work, is by far the deadliest form 
of the disease, causing severe acute infections responsible for over 90% of 
malaria attributed fatalities.8 In the most severe cases P.falciparum parasites 
can cross an individual’s blood brain barrier resulting in a condition called 
cerebral malaria, invariably fatal if not identified and treated rapidly. 
P.falciparum is notoriously difficult to treat effectively as its biology allows it to 
mutate rapidly resulting in multiple resistant forms. WHO estimates that 85% 
of P.falciparum cases are now chloroquine resistant, with multi-drug 
resistance rising rapidly.3
The majority of the deaths due to P.falciparum infection occur in sub- 
Saharan Africa where it is estimated to kill a child every 30 seconds3, 5,
-11
however P. falciparum is endemic in 87 countries 10 and it is the resistant 
forms of this species in particular that are responsible for the re-emergence 
of malaria in areas cleared of the disease in the mid 20th century. In 2007 the 
Malaria Atlas Program (MAP) at Oxford University published the results of 
the first global survey of P.falciparum incidence and distribution in over 4 
decades (Figure 1.1).10 The results of the MAP survey state that 2.4 billion 
people live in regions considered high risk for P.falciparum, with a further 1 
billion living in regions with unstable or spreading risk, that’s a combined total 
of 40% of the world population.10
Figure 1.1: The results of the MAP survey showing the 2006 global distribution of 
Plasmodium falciparum.10
1.1.2 Parasite Lifecycle
As has already been alluded to, part of the difficulty with the effective 
treatment of malaria is the complex parasite lifecycle (Figure 1.2). In the 
course of a complete lifecycle malaria parasites go through eight separate 
parasitic forms, not including hypnozoites in P.vivax6 Each of these forms 
have different intra and extracellular structures, metabolic processes and 
lifespan, meaning that drug therapies can rarely target more than one 
parasite form effectively.
A bite from an infected female Anopheles mosquito results in 
transmission of parasite sporozoites as the mosquito injects its salivary 
cocktail of anticoagulants and begins feeding. These sporozoites travel 
rapidly through the host bloodstream and within half an hour of the bite taking
-12-
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Figure 1.2: A general schematic showing the lifecycle of malaria parasites.11
place are hidden in the hepatocytes of the liver where they enter the primary 
exo-erythrocytic division cycle. 12This stage of the lifecycle is difficult to study 
and little is known about the precise changes that occur to the parasites while 
they are in the liver. Until recently it was believed that sporozoites settled in 
the first liver cell that they entered, however extensive studies published in 
2001 by Dr. Rodriguez and her colleagues at the New York University School 
of Medicine have now established that sporozoites may penetrate as many 
as five hepatocytes before settling on one in which to develop further.13 This 
is the longest single stage of the parasite lifecycle and varies in length 
according to species, in P.falciparum it lasts around 5 and a half days.12
The primary exo-erythrocytic phase ends with the infected hepatocytes 
rupturing and flooding the host bloodstream with the second parasitic form, 
merozoites. It was only in 2006 that work by Dr. Sturm et al. first established 
the method by which merozoites escape the liver into the blood stream 
without triggering the host immune system.14 The merozoites directly 
manipulate the biology of the hepatocyte they inhabit inducing the first stage 
of apoptosis in which the cell detaches from its neighbours allowing it to 
move freely within the liver. Once the hepatocyte has detached however the 
merozoites subvert the usual cell death processes and prevent apoptosis
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from progressing by blocking the release of Ca2+ ions that would normally act 
as a signal to phagocytes to engulf the dead cell. This means that the host 
immune system does not recognise the detached cell as being dead and it is 
allowed to drift undetected through the liver, giving the occupying merozoites 
a safe, secure ride to the bloodstream.14 To access the red blood cells 
required for the next stage of their lifecycle the parasites must enter the small 
blood vessels of liver (sinusoids) which are separated from the hepatocytes 
by a layer of extracellular matrix, called the space of Disse and single layer of 
endothelial cells. This is achieved by the formation of parasite filled vesicles 
dubbed merosomes, which are extruded through the endothelium into the 
bloodstream (Figure 1.3).14
Figure 1.3: Cartoon of the current hypothesis for merosome formation; hepatocytes (pink) 
infected with merozoites (green) bud through the space of Disse and sinusoidal endothelium 
(orange), forming a parasite filled vesicle eventually breaking away into the bloodstream 
avoiding detection by the phagocytic Kupffer cells (blue) 14
The released merosomes can contain just a few or many thousands of 
merozoites and drift through the cardiovascular system for up to 72 hours 
before rupturing. Upon release the merozoites instantly begin to invade the 
red blood cells and begin the next stage of development, the asexual 
erythrocytic division cycle.6
The blood borne stage of the parasite lifecycle is the most extensively 
studied, particularly in P.falciparum, and it is at this point that the majority of 
drug therapies and prophylactic compounds have their action. As merozoites 
invade erythrocytes (red blood cells) their structure changes, first becoming 
immature trophozoites, also referred to as a ring form parasites (Figure 1.4a), 
then mature trophozoites (Figure 1.4b) before dividing into between 8 and 32 
merozoites within a self contained vacuole called a schizont (Figure 1.4c) 
which can occupy up to two thirds of the infected erythrocyte.15 This 
progression is fuelled by the digestion of the protein portion of haemoglobin,
- 14-
a process which releases haem which when in solution is toxic to the 
parasite.6 The parasite counteracts this by polymerising the haem to form 
hemozoin, also called malaria pigment, which is crystalline and precipitates 
out of solution.16 Once the new merozoites are fully matured, after around 48 
hours, the schizont ruptures releasing them into the bloodstream to repeat 
the cycle.
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Figure 1.4: Thin blood smears showing P. falciparum as a) ring form parasites, b) mature 
trophozoites c) a schizont and d) a light microscopy image showing a rosette of infected 
cells15'17
The rupturing of the erythrocytes releases various toxins and waste 
products into the host’s bloodstream causing the characteristic fever 
associated with the disease. As with the liver stages, because the parasites 
are hidden within host cells they are rarely detected by the immune system 
and the only threat to the parasite is the body’s natural periodic destruction of 
erythrocytes in the spleen. To reduce the risk of this occurring before the 
parasites are fully matured they again manipulate the biology of the cell they 
occupy causing the infected erythrocytes to express adhesive surface 
proteins on their exterior membranes. This results in infected red blood cells 
adhering to each other, forming rosettes (Figure 1.4d)17 and the endothelial 
linings of smaller blood vessels where the flow of blood is slower. The 
narrow, slow flowing blood vessels of the alveoli are particularly susceptible 
and pulmonary emboli are a common result of infection with malaria.
1.2 Antimalarial Chemotherapy
Herbal remedies for malaria have existed for millennia, but many consider 
the discovery of quinine (Figure 1.5) in the 17th century as the advent of 
antimalarial chemotherapy.18 Not successfully synthesised until 1918, 19,20 
the natural source of quinine is the bark of the cinchona tree native to Peru. 
Quinine was the first effective treatment for malaria and continued to be of
-15-
great importance up until the development of its fully synthetic derivatives in 
the 1940’s, since that time it continues to be an important alternative to more 
recently developed drugs in resistant malaria infections.
Figure 1.5: The structure of quinine.
1.2.1 Chloroquine and the 4-aminoquinolines
The first class of fully synthetic antimalarials, chloroquine and its related 
compounds such as amodiaquine, all have the same core structure based on 
a quinoline ring system (Figure 1.6).
Figure 1.6: The structures of 4-aminoquinoline compounds chloroquine and amodiaquine.
Antimalarials of this structure have two key features; the quinoline ring 
itself and the secondary amine at the 4 position of the quinoline ring paired 
with the tertiary amine with four carbon atoms in between. The presence of 
this pair of nitrogens is the key to the mechanism of action for this class of 
compounds. They are blood schizonticidal agents,6 meaning they kill the 
parasite in its blood borne form. During development of the trophozoite 
parasite form, host haemoglobin is broken down in acidic vacuoles within the 
parasites and haem is crystallized into hemozoin. The 4-aminoquinolines are 
absorbed into the acidic vacuoles and the nitrogens in their side chains are 
protonated preventing them from passing back out of the vacuole and 
allowing them to accumulate in high concentrations. The quinoline ring 
portion of their structure then comes into play as they chelate with the
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porphyrin ring system of haem and prevent its conversion into hemozoin, 
poisoning the parasite with its own feeding mechanism.21
Chloroquine was originally called Resochin when it was developed in 
Germany by Bayer in 1934. It was initially considered too toxic for use in 
humans and it wasn’t until 1946 that British and American scientists 
searching for an alternative to quinine following the Second World War 
rediscovered the compound and it was licensed for use. As a class, the 4- 
aminoquinolines have very few severe side-effects, though chloroquine has a 
narrow therapeutic index in children.22 The most common side-effects are 
itching and disturbed sleep although long term use at high doses can result in 
damage to the eye 6 More problematic than the side-effects for this class is 
the emergence of resistance.
Overuse of chloroquine, and in particular improper use, have led to 
resistant strains of parasite that have rendered the class as a whole almost 
completely obsolete 6 Resistant forms of the parasite express a mutated form 
of “Plasmodium falciparum Chloroquine Resistance Transporter” (PfCRT) 
protein in the membranes of their digestive vacuoles. Under normal 
circumstances this protein is believed to be involved in the passive transport 
of amino acids and short chain peptides out of the digestive vacuole. In its 
“wild-type” form the opening of the protein has a lining of basic residues that 
would repulse the active, doubly protonated form of chloroquine maintaining 
a high concentration within the digestive vacuole. In the mutant forms of 
PfCRT these basic residues are absent meaning that protonated chloroquine 
can leak rapidly out of the digestive vacuole down a steep electrochemical 
gradient dramatically reducing the concentration of chloroquine at its point of 
activity and consequently conferring resistance to the parasite 23
With few alternative therapies available when the 4-aminoquinolines were 
first compromised the resistant strains have spread rapidly and the need for 
novel antimalarials grows ever greater.
1.2.2 Artemisinin based therapies
In the mid 1960’s a Chinese army study of over 200 traditional herbal 
remedies for malaria identified a breakthrough for malaria chemotherapy 24 
That compound was artemisinin and it remained a closely guarded secret for
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many years. When the structure (Figure 1.7) was eventually released to the 
wider world in the late 1970’s25 the proposed sesquiterpene lactone and 
particularly the endoperoxide bridge, were met with scepticism by western 
scientists who claimed that the structure would be too reactive and fragile to 
be useful as a drug.
Artemisinin
Figure 1.7: The structure of artemisinin.
It was not until 1984, when the compound was reisolated by a team in 
Washington D.C.26 that interest in the compound really began to mount. 
However it still took a further 17 years for the compound to be internationally 
licensed as a treatment by the World Health Organisation (WHO). This was 
in part because the WHO were desperate to avoid a repeat of chloroquine’s 
story with indiscriminate overuse of the drugs leading to resistance and loss 
of efficacy. It was, in part, this issue which led WHO to ban the use of 
artemisinin derivatives as monotherapies.
The other reason that artemisinins are not used a monotherapies is their 
rapid metabolism. Artemisinin itself has very poor bioavailability, therefore a 
range of semi-synthetic derivatives, such as artemether and artesunate 
(Figure 1.8), have been developed. These compounds are still metabolised 
relatively rapidly however and so are used in combination with traditional 
antimalarials such as amodiaquine (+ artesunate = Coarsucam™) or other 
antimalarials not ordinarily used on their own such as lumefantrine (+ 
artemether = Coartem®) (Figure 1.8). These mixtures are referred to as 
artemisinin-based combination therapies (ACTs) and are only licensed for 
treatment and not for use as prophylaxis.
Despite these efforts resistance is still being seen to emerge in south-east 
Asia in cases of P. falciparum27 The necessity for dual therapies and the 
difficulty inherent in obtaining large quantities of artemisinin also means that
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ACTs are very expensive compared to the 4-aminoquinoline class, limiting 
their use where they are needed most.
OMe
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Figure 1.8: Structures of the semi-synthetic artemisinin derivatives artemether and 
artesunate and of lumefantrine an antimalarial agent used in combination with artemether to 
form the ACT Coartem^.
Like the 4-aminoquinolines, artemisinins are blood schizonticidal agents 
acting on the developing trophozoites. The exact mechanism of the 
artemisinins’ therapeutic effect has been a matter of debate for the past 
decade. What is known is that the endoperoxide ring system is the active 
pharmacophore, both in artemisinin and the related synthetic compounds in 
development, as analogues lacking this structural motif are inactive.28 It is 
generally accepted that the key step in activation of the artemisinins is iron- 
mediated cleavage of the endoperoxide bridge resulting in carbon-centred 
radicals that go on to damage key parasite targets.28
The issues of debate are both the iron source, haem bound or free iron, 
and the key target of the generated radicals.29 There is compelling evidence 
that an important target is the porphyrin ring system of haem,30, 31 but 
evidence also exists for attack of key proteins32 and parasite DNA.33 The
-19-
development of fully synthetic endoperoxide based drugs such as OZ277 and 
OZ439 (Figure 1.9) has further complicated the issue.29,34
o-o
OZ277
0-0
OZ439
Figure 1.9: Structures of OZ277 and OZ439, examples of the fully synthetic trioxolane 
compounds currently in development.
It may be that the compounds have a multi-target mode of action and that 
it is this that has staved off the development of widespread resistance thus 
far.29
1.2.3 Atovaquone
In 2000 the drug preparation Malarone® was released by GlaxoSmithKline 
for the treatment and prevention of uncomplicated, multidrug resistant 
malaria. The active ingredient of Malarone® (Figure 1.10) is atovaquone but it 
is administered in combination with the dihydrofolate reductase inhibitor 
proguanil, to slow the development of resistance.
o
Atovaquone Proguanil
Figure 1.10: The structures of atovaquone and proguanil, the ingredients of the antimalarial 
preparation Malarone^.
Atovaquone is a hydroxynapthoquinone that acts as a selective 
mitochondrial poison, competitively inhibiting the cytochrome bci protein 
complex in the parasite mitochondria disrupting the membrane potential that 
provides energy for mitochondrial function.35 It is the first drug of any kind in
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clinical use to do this and represents a completely new drug class. Proguanil 
has does not kill P. falciparum parasites but prevents their proliferation at the 
schizont stage and is synergistic in use with atovaquone as the combination 
completely prevents the biosynthesis of pyrimidines required for nucleic acid 
replication.36 The inhibition of mitochondria by atovaquone is of critical 
importance as these organelles are present at every stage of the parasite 
lifecycle, meaning that atovaquone is the only currently licensed drug proven 
to act on the parasite during both the erythrocytic and exo-erythrocytic stages 
of its lifecycle.36'38
However, atovaquone is far from perfect; as with the ACTs, Malarone® is 
relatively expensive and its widespread use in the resource-poor, disease- 
endemic areas where it is needed most is limited.39 The relationship of the 
groups on the central cyclohexane ring of the compound must be trans or 
activity is lost, raising the complexity and therefore the cost of preparation. 
The necessity for proguanil to be included in the therapeutic dose also raises 
the cost but when used as a monotherapy, resistance to atovaquone 
develops within days and once present renders even the combined therapy 
ineffective.40, 41 The factors governing resistance to atovaquone will be 
covered in more detail later, but it is important to note that cheaper 
alternatives that overcome the resistance issues identified are desperately 
needed 42
1.3 The Cytochrome bc^ Protein Complex
At first it would seem that cytochrome is an unusual choice as a drug 
target as the protein complex exists in some form in all mitochondria, 
meaning that it is present in all respiring eurkaryotic cells, including those of 
humans. This target therefore presents a selectivity issue for the design of 
new therapeutic agents. However the determination that be, is the site of 
action for atovaquone has definitively validated this target for exploitation by 
a new generation of antimalarial therapies for use against P. falciparum35
1.3.1 General Structure of the bci Complex
Although it catalyses a chemical process cytochrome bc<\ should not be 
referred to as an enzyme as it is not a single protein. Instead it is, as its name
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suggests, a homodimeric complex each identical half of which is composed 
of ten interwoven polypeptide chains embedded with a number of haem 
units. The catalytic core of each consists of three separate subunits; 
cytochrome b, cytochrome Ci and the Rieske iron-sulphur protein (ISP).43 
The function of the other seven subunits is not well understood and they are 
currently presumed to be largely structural in nature44 anchoring the complex 
in the inner membrane of mitochondria.
The catalytic core contains two binding sites for the endogenous 
compounds involved in the catalytic processes through which the complex 
functions. These are termed alternatively Q0 or P on the outer, electropositive 
portion of the complex and Qj or N on the inner, electronegative portion. Q0 is 
the site of action for atovaquone and the target of this study. It is known in 
P. falciparum to consist of a hydrophobic channel roughly 15 A in length with 
a polar pocket at the end containing glutamic acid and histidine residues 
essential for its function 45,46
1.3.2 The Protonmotive Q-Cycle
Normal function of the complex requires the cofactors ubiquinol and 
ubiquinone; these cofactors interact with the Qj and Q0 sites on cytochrome b 
in a sequence of redox reactions to “pump” protons out of the inner matrix of 
mitochondria and into the intermembrane space (Figure 1.11). This 
generates a membrane potential that in turn provides the energy for a 
number of downstream processes including enzymes involved in ATP 
production and active transport processes.46, 47 This process has been 
studied in great detail over the years and is best described by Mitchell’s Q- 
cycle hypothesis (Figure 1.12).48
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Figure 1.11: Showing the structures of the endogenous be-, ligands, ubiquinol and 
ubiquinone and a ribbon model of cytochrome b subunit of the bc1 complex showing key 
binding regions and the 2Fe2S cluster of the Rieske (ISP) protein (IMS = intermembrane 
space, MIM = mitochondrial inner membrane)47
Figure 1.12: Showing a schematic of the protonmotive Q cycle across the inner membrane of 
the mitochondria.
The Qj and Q0 sites are both part of cytochrome b but are distinct in that 
they are on opposing sides of the mitochondrial inner membrane. The sites 
are connected by a transmembrane electron transport pathway formed by 
two haem groups, bi and bn (Figure 1.12)42 In each bifurcated reaction cycle 
a molecule of ubiquinol is oxidised at Q0 releasing two protons (H+) and 2 
electrons (e ). One of these electrons passes across the electron transport 
pathway to reduce one of the carbonyl groups of a molecule of ubiquinone 
bound at Qj, the other electron passes to the 2Fe-2S cluster of the ISP, 
reducing it. The reduction of the ISP causes a conformational change in the
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cytoplasmic region of the protein, which brings the 2Fe-2S cluster in close 
proximity to the haem group bound in cytochrome Ci, the electron then 
passes from the 2Fe-2S cluster to reduce the haem group. Reduced 
cytochrome Ci is reoxidised by soluble cytochrome c and from there the 
electron goes on to power cellular processes. In each complete cycle this 
process happens twice, therefore two molecules of ubiquinol are oxidised for 
every one molecule of ubiquinone reduced, a net translocation of four 
protons out of the mitochondrial matrix into the cytoplasm. This proton 
transfer results in a relative charge being maintained across the 
mitochondrial membrane and it is this charge that powers the cell.49"51
1.3.3 Inhibition of the Cytochrome bci Protein Complex
Although only recently validated as an antimalarial target by the studies 
on atovaquone’s mechanism of action, the bci protein complex has been 
known to be the site of action for a number of fungicides and antibiotics for 
several years, including the natural inhibitors stigmatellin, myxothiazol and 
antimycin Ai (Figure 1.13). There have been numerous studies carried out on 
the various inhibitors available for research by crystallography, spectroscopy 
and kinetic studies meaning that their mechanisms of action are generally 
well known with respect to their particular targets.45, 461 52, 53 Though the 
toxophores identified across the existing range of bci inhibitors show great 
variation (Figure 1.13), the compounds can be broadly classified according to 
their binding site and effect on the protein complex.
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Stigmatellin (Q0)
Myxothiazol (Q0)
—O
Antimycin A1 (Qj)
Figure 1.13: Showing the structures of a selection of natural bc1 inhibitors with their identified 
toxocophores highlighted in blue 46
Class I compounds are Q0 site inhibitors and historically have been 
further subdivided into 3 subclasses, la - Ic, according to their chemical 
characteristics. However recent literature has sought to reclassify the Q0 
inhibitors into just 2 subclasses according to their structural effects on the 
protein target and in particular their effect on ISP region mobility rather than 
by their chemical class.54
Class la compounds include myxothiazol (Figure 1.13) and are 
characterised as those that bind at the Q0 site and are believed to hinder 
electron transfer from the endogenous quinol to the ISP.46 The new Xia 
classification identifies these compounds as Pm type; P indicating positive 
region, i.e. Q0 binders, and ‘m’ indicating that the ISP remains mobile while 
the inhibitors are bound.54 As their toxocophore these compounds typically 
contain an E-(3-methoxyacrylate moiety or close structural relative. Synthetic 
examples of the class include commercial fungicides azoxystrobin, kresoxim- 
methyl and the new potential antimalarials in development by Ridley et al. 
(Figure 1.14) 55
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o o
Azoxystrobin (Syngenta)45 Kresoxim-methyl (BASF)'
O
Ridley Compound 15j'
Figure 1.14: Class Pm bc1 inhibitors with their toxocophores highlighted in blue.
Class lb and Ic inhibitors under the traditional system were considered to 
be separate due to their differing core structures. Class lb structures possess 
a chromone ring system like stigmatellin (Figure 1.13) whereas Ic inhibitors 
are generally 2-hydroxy quinone analogues such as UHDBT (Figure 1.15). 
However the DuPont agrochemical famoxadone (Figure 1.15) is structurally 
different to both classes but has been shown to work in the same way.46 
Under the new system famoxadone and compounds from both lb and Ic 
classes are all considered to be Pf inhibitors; P again indicating Q0 binding 
and T indicating that when bound these compounds fix the ISP region in a 
set position.54
Figure 1.15: Class Pf be-, inhibitors with their toxocophores highlighted in blue.
Finally there are the class II inhibitors; these are compounds that bind at 
the alternative Qj site. In terms of resistance Qj is a more desirable target 
than Q0 in that it suffers less from the point mutation issues that can present 
a problem for Q0 binders.56 However the fact that it is situated on the inner 
face of the inner mitochondrial membrane makes it relatively inaccessible
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and to date only antimycin Ai (Figure 1.13) and its analogues are known to 
be Q, specific. The amino acid sequence of the Qj active site is also well 
conserved between species potentially making selectivity a challenge 46
1.3.4 Inhibition by Atovaquone
Atovaquone is a class lb inhibitor, like stigmatellin it binds reversibly at Q0 
competitively interfering with ubiquinol oxidation and temporarily locking the 
ISP region in place. A number of studies have been carried out to ascertain 
the exact binding position of atovaquone to try and better understand the 
factors controlling its selectivity and resistance mechanisms. To date the bci 
complex of P. falciparum has not been successfully isolated and crystallised 
for analysis therefore these studies have been carried out in bacterial35 and 
yeast based systems.43,57,58 Of particular note are the studies by Trumpower 
et al. using the crystal structure coordinates of stigmatellin-bound 
Sacchanomyces cerevisiae yeast in combination with biological and 
spectroscopic data to model the interactions of atovaquone with the Q0 
pocket (Figure 1.16).58
Electron paramagnetic resonance (ERR) spectroscopy indicates that like 
stigmatellin and UHDBT, atovaquone binds tightly with the Q0 pocket when 
the water-soluble mobile region of the ISP is closest to cytochrome b allowing 
the compound to interact directly with both protein chains. It was observed 
that the inter-atomic distances in the head group of atovaquone (Figure 1.10) 
were a match with those of UHDBT (Figure 1.15) and that the hydroxyl 
groups in the two compounds have the same pKa.58 Studies using optical 
spectra have shown that the hydroxyl group of UHDBT is ionised when 
bound with b^ resulting in the formation of a hydrogen bond between the 
His181 residue and the ionised oxygen.59 Crystallisation studies using 
UHDBT have shown that a second, water mediated hydrogen bond is formed 
between the Glu272 residues of cytochrome b and the carbonyl group of the
• ■ 59quinone ring.
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Figure 1.16: In silico docking results from the Trumpower study. Cytochrome b is shown as 
cyan ribbons and a section of the ISP is shown in orange. The [2Fe-2S] Rieske cluster is 
shown as yellow and purple balls; docked atovaquone is shown in green. Key amino acids 
His181, Glu272 and Leu275 are highlighted58
The Trumpower study uses this as a guide to manually dock atovaquone 
overlaid on the ring structure of stigmatellin, orientated such that the carbonyl 
and hydroxyl groups form hydrogen bond interactions analogous to those of 
UHDBT.58 The manually docked structure was then energy minimised in 
silico to predict the precise binding position of atovaquone in Q0 (Figure 
1.16). The results indicate that this orientation would promote strong binding 
between atovaquone and both cytochrome b and the ISP accounting for the 
observed fixture of the mobile protein region during binding.58
The study also used comparison of the protein sequence between 
protozoan and mammalian b^ to explain the selectivity of atovaquone. In 
the mammalian sequence the leucine at 275 found in yeast is replaced by 
phenylalanine. Modelling of this change showed that it directly effects the 
region of the hydrophobic channel leading to Q0 that is occupied by the 
chlorine substituted aromatic ring of atovaquone. In the yeast protein the 
channel is relatively open at this point, where as in mammalian bci the 
increased van der Waals radius of the phenylalanine residue results in a 
bulge in the wall of the channel giving rise to unfavourable steric interactions
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(Figure 1.17). This alteration is responsible for the reduced sensitivity of 
mammalian bci proteins to atovaquone compared to protozoan proteins. Site 
directed mutagenesis of yeast bci to create L275F mutants have confirmed 
this with the mutated proteins showing similar levels of insensitivity to 
atovaquone.58
Figure 1.17: Left atovaquone docked in yeast bc1 with the region occupied by Leu275 
highlighted in cyan. Right atovaquone docked in bovine bd with the region occupied by 
Phe275 highlighted in purple 58
1.3.5 Atovaquone Resistance
In sensitive parasites atovaquone is highly potent, with an average IC50 of 
~6 nM, and has a reasonable therapeutic index; the parasite protein is 
inhibited at concentrations ~200-fold lower than those required to have any 
noticeable affect on human bci.35 However single point mutations in the 
gene’s coding for the Q0 binding site have been shown to confer up to a 760- 
fold drop in potency, rendering the drug effectively inactive at safe 
therapeutic doses.60
The majority of resistance-conferring mutations cause alterations in the 
amino acids forming the hydrophobic channel leading to Q0 rather than 
altering the structure of Q0 itself as alterations here tend to render the protein 
complex inactive themselves 40, 41 ’ 57, 60-62 The most common mutation in 
parasite isolates leading to Malarone® treatment failure are those that alter 
the amino acid at position 268 in the cytochrome b structure, usually a 
tyrosine (Y268) this residue is often exchanged for serine in resistant strains
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(Y268S).63,64 Indeed site directed mutagenesis studies mimicking this single 
alteration at the equivalent residue (Y279S) in yeast dci have shown drops in 
atovaquone sensitivity from 60 nM in the parent strain, to >4000 nM in the 
mutated strains.65 Research appears to indicate that this residue is involved 
in a hydrophobic stabilising interaction with ubiquinol and it is likely that the 
mutation results in a significant respiratory penalty for the parasite.58
Other mutations have been identified and as with the Y268 mutation most 
appear to significantly alter the structure of the hydrophobic region of the Q0 
site. A side-effect of this is that atovaquone resistance tends to confer cross 
resistance to other Q0 inhibitors. For example in strains of P.yoelli in which 
atovaquone resistance was induced by sub-optimal dosing, myxothiazol 
resistance was also observed in all the mutated strains although at lower 
levels than that towards atovaquone.40 This cross resistance highlights a 
critical drug design challenge for the development of novel bci inhibitors that 
we hope to overcome.
1.4 Antimalarials in Development Targeting the Cytochrome Protein 
Complex
While atovaquone is the first inhibitor to be licensed for the treatment of 
malaria, other compounds acting at the same site in organisms such as fungi 
and some insects, have been in existence for the best part of five decades. 
Since the elucidation of atovaquone’s mode of action led to the validation of 
the bci complex as an antimalarial target, work on bci inhibition as a therapy 
for malaria has intensified. The p-methoxyacrylate compounds in 
development by Ridley et al. (Figure 1.14) have already been briefly 
discussed but these are in their infancy.55 The more established areas of 
antimalarial bci inhibition research tend to be based on aromatic ring 
systems and can be broadly divided into four classes based on their core 
chemical structure.
1.4.1 Atovaquone analogues-1,4-Naphthoquinones
This class of compounds have the same basic core as atovaquone 
(Figure 1.18) but seek to improve on atovaquone’s relatively poor 
bioavailability66 and other pharmaceutical properties. The structurally related
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1,2-naphthoquinones have also been investigated but were not confirmed to 
be bci inhibitors 67
Figure 1.18: Core structures of the naphthoquinone class of compounds
The antimalarial activity of 1,4-naphthoquinones was identified in the 
1940’s when a study at Harvard in conjunction with Abbott Laboratories 
recognised hydrolapachol (Figure 1.19) as a potential antimalarial and 
developed a number of synthetic derivatives with high levels of potency in 
bird models.68 The majority of the compounds identified during the course of 
this work possessed long aliphatic or cycloalkane-based side-chains (Figure 
1.19) and suffered from rapid metabolic degradation. One compound from 
the study, termed M-2350 (Figure 1.19) did reach early stage clinical trials in 
man, but was found to be poorly absorbed when administered orally or 
intramuscularly.69
Hydrolapachol
M-285 M-1916
M-2350
Figure 1.19: Structures of naphthoquinone antimalarials identified by Fieseret al in 1948 68
-31 -
In recent years the Trumpower group of Dartmouth Medical School have 
revisited this work focusing on analogues of M-285 (Figure 1.19), specifically 
the S-enantiomer (S-10576) which they have determined is significantly more 
parasite selective than the corresponding R-enantiomer.70 The group sought 
to increase the compound’s metabolic stability through the use of 
perflourinated side-chains and substitution at the 8-position of the 
naphthoquinone head group (Figure J\.20).70'72
o
S-10576: R = H, R' = CH3 
NQ1: R = H, R'= CF3 
NQ2: R = CH3, R' = CH3 
NQ3: R = CH3, R' = CF3
Figure 1.20: The general structure of 2-hydroxy-naphthoquinones developed and 
investigated by the Trumpower group.
While these alterations did indeed improve the metabolic profile of the 
compounds, their species selectivity was dramatically reduced compared to 
the parent compound71 and the inclusion of a methyl group at the 8-position 
significantly reduced potency (Table 1.1).72
Table 1.1: Activity of naphthoquinone compounds against liver stage P. berg he i
sporozoites in vitro.72
Inhibitor Compound IC5o versus P.berghei (nM)
Atovaquone 19.7
S-10576 96.2
NQ1 17.1
NQ2 246.5
NQ3 4451.8
In summary 1,4-naphthoquinone-based compounds continue to show 
promise as bci inhibitors, however the continuing need for chiral purity to 
ensure good levels of parasite selectivity is an issue and the current leads 
require considerable further development to increase their drug-like 
character.
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1.4.2 Pyridones
Clopidol (Figure 1.21) has been known as a potent antimalarial since the 
1960’s and recent collaborative efforts by GlaxoSmithKline and various 
research groups have produced a number of pyridone based compounds 
(Figure 1.21).73
Clopidol GW844520
GSK932121
Figure 1.21: Showing the structures of clopidol and recently developed pyridone based 
antimalarials.
Many of these compounds exhibit impressive antimalarial potency, 
GW844520 (Figure 1.21) has a recorded IC5o of 2 nM, and importantly they 
maintain activity against atovaquone resistant strains of parasite.42 The 
solubility issues so often encountered with these compounds have been 
overcome by the introduction of a hydroxyl moiety as in GSK932121 (Figure 
1.21), allowing the formulation of the compounds as phosphate prodrugs.74 A 
selection of lead compounds of this type reached early stage clinical trials but 
were withdrawn after toxicity issues were identified that have yet to be 
resolved.75
1.4.3 Acridinediones and Acridones
These classes have very similar core structures and so are discussed 
together here (Figure 1.22). Acridinediones are well known in the antimalarial 
literature as they are established haem binders, one of the best known being 
the experimental drug floxacrine (Figure 1.22). Floxacrine was developed
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during the late 1970’s and initially showed promise for use as a prophylactic 
agent but limited solubility, rapid resistance development and unacceptable 
side-effects led to its development being temporarily abandoned.76
o o o
Acridinedione Acridone
Floxacrine
Figure 1.22: The structures of acridinedione and acridone ring systems and of floxacrine, an 
acridinedione based antimalarial first developed in the 1970’s.
More recently acridinediones have garnered increased attention following 
the discovery that they can have a dual mode of action. Developed in 2001 in 
an attempt to overcome the drawbacks of floxacrine, WR 243251 (Figure 
1.23) is an inhibitor of hematin polymerisation with comparable haem binding 
to that of chloroquine. However WR 243251 has higher overall potency 
against P.falciparum than chloroquine and maintains activity against 
chloroquine resistant parasite strains, indicating that a second mechanism of 
action may be present.76 This hypothesis is supported by the fact that the 
ketone hydrolysis product WR 243246 (Figure 1.23) has a similar level of 
potency against P.falciparum as its parent compound, but does not inhibit 
hematin polymerisation to any appreciable level.76
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O O
WR 243246
Figure 1.23: Structures of some recently developed floxacrine derivatives.
It was observed that acridinediones similar to WR 243251 and WR 
243246 (Figure 1.23) exhibited cross resistance with atovaquone resistant 
parasite strains77 and further investigation led to the discovery that these 
compounds are potent and highly parasite selective £>Ci inhibitors; in 
particular WR 249685, the S-enantiomer of WR 243246 (Figure 1.23), is 
more than 4600 times more potent against P.falciparum bci protein than it is 
against the mammalian protein.78 Interestingly, despite being structurally very 
similar to the active derivatives, floxacrine (Figure 1.22) has only negligible 
activity against bci with no measurable degree of selectivity.42, 78 This 
suggests that while the acridinedione core clearly has some exciting 
properties the further development of analogues for clinical use could be 
hampered by restricted substitution options.
The structurally related acridones benefit over the acridinediones by being 
fully aromatic and therefore avoiding the issue of chiral isomers that can arise 
from substitution of the alkyl C ring of acridinediones (Figure 1.22). Interest in 
the acridones arose following the observation by the Riscoe group that an 
intermediate in their work on haem binding acridones (Figure 1.24) was 
active as an antimalarial at 45 nM against P.falciparum, but did not interfere 
with hematin polymerisation.79
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Development of their initial hit allowed the group to develop a small 
library of highly potent compounds, with their lead compound having activity 
of around 1 pM against P.falciparum in vitro (Figure 1.24).
o
F
3-chloro-6-((S,6,6,6-tetrafluoro-5-(trifluoromethyl)hexyl)oxy)acridin-9(10H)-one 
Figure 1.24: The structure of the intermediate indentified by Riscoe et al. during their work on 
haem binders (top) and the lead compound that developed from it (bottom)79
The group found that activity was increased if substitution was moved 
from the 2-position to the 3-position on the C ring and that perfluorinated alkyl 
chains comprising at least one CF3 group gave the highest levels of potency. 
While it has not yet been proven that these compounds are bci inhibitors 
their structural similarity to compounds that are, observed cross-resistance 
with atovaquone80 and other evidence from outside the field of antimalarial 
research would certainly seem to support this hypothesis.79 A potential 
concern with the acridone structures currently published is that the flexibility 
of the side-chains currently utilised may result in issues with selectivity 
although no toxicity problems were reported following in vivo tests.79 At 
present, little further development appears to have been carried out on these 
compounds with the majority of work on acridones instead focusing on the 
nitrogen substituted haem binding variants that have been demonstrated to 
reverse chloroquine resistance.81,82
1.4.4 Quinolone based compounds
In the late 1940’s work at Bayer resulted in the synthesis of endochin 
(Figure 1.25).83 The compound was extremely active in bird models both as a 
prophylactic agent and as a treatment, however in mammal models activity 
all but disappeared and the compound was dropped.
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oEndochin
Figure 1.25: The structure of the Bayer compound endochin with the quinolone core 
structure highlighted83
The quinolone core (Figure 1.25) however has continued to reappear in 
antimalarial studies. In the late 1960’s during a combined study by ICI and 
the Liverpool School of Tropical Medicine searching for anticoccididial 
compounds it was noted that a number of the quinolone esters (Figure 1.26) 
developed were active against malaria in rodent and monkey models.84 The 
compounds showed high potency, up to 50 times that of chloroquine against 
P.berghei, and were successful both as treatments and as prophylactics. Of 
particular interest was the observation that the compounds appear to have 
been effective against all stages of the parasite life cycle and chloroquine 
resistant strains, suggesting that they were probably inhibiting a respiratory 
target such as bci.84 However there were issues with the development of 
resistance in rodent models and there appears to have been little further 
development of the compounds.
o o
ICI 56780
o o
ICI 60128
Figure 1.26: Quinolone esters identified by ICI as potent antimalarials in animal models.84
Fluoroquinolone antibiotics, such as ciprofloxacin (Figure 1.27), were 
shown to have antimalarial activity during the 1980’s85 and during the drive 
for new antimalarials in the 1990’s fluoroquinolones were studied extensively 
as potential replacements for the failing aminoquinolines despite being
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markedly less potent.86'94 However, severe side effects,9597 resistance 
issues88,89 and the advent of artemisinin eventually caused enthusiasm for 
the compounds to wane.
More recently the observation that some fluoroquinolones, including 
grepafloxacin and trovafloxacin (Figure 1.27), have limited activity against 
hepatic stage parasites as well as the erythrocytic stage resulted in interest 
being rekindled for a time with the belief that a dual mode of action could be 
established.98,99 However activities against P.falciparum were still too low for 
the compounds to be considered promising drug leads, even against 
chloroquine resistant parasite strains.98 More potent fluoroquinolones have 
been recently developed in Japan by substitution at the quinolone nitrogen 
with side-chains containing pyridyl rings but these compounds have yet to be 
investigated beyond a simple initial screening.100
Grepafloxacin
Figure 1.27: Fluoroquinolone-based antibacterials with multi-stage activity against 
P.falciparum malaria 98
Recent work by R. K. Guy et al. on quinolone 3-esters substituted at the 
2-position with short aromatic side-chains (Figure 1.28) have shown promise 
with a lead compound achieving a 50% parasite clearance of both 
chloroquine-sensitive and chloroquine-resistant strains of P.falciparum at 
around 100 nM in vitro. Whether or not these compounds target parasite bc<\ 
has yet to be determined, but evidence from the study certainly suggests that 
it is a possibility.101
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ethyl 7-methoxy-2-(3-methoxyphenyl)-4-oxo*1,4- 
dihydroquinoline-3-carboxylate
Figure 1.28: Structure of the lead compound identified by R. K. Guy et al.101
The most promising studies on antimalarial quinolones in recent years 
have been on endochin-type structures.80,102,103 Endochin (Figure 1.25) was 
developed by Bayer in the 1940’s and showed promise in avian models but is 
rapidly metabolised in mammals leading to poor bioavailability.83 Cross­
resistance of endochin-based compounds with atovaquone has been noted 
on a number of occasions in recent years and indicates that agents of this 
structure are almost certainly targeting the bci protein complex.80,102
In 2008 a study was published by Riscoe and Winter in which they 
applied findings from their work on antimalarial acridones79 to a quinolone 
core structure by substitution with perfluorinated alkyl chains (Figure 1.29).80 
They found that by extending the 3-heptyl chain of endochin to an undecyl 
chain (11 carbons) and terminating with a trifluoromethyl moiety activity 
against P.falciparum was doubled in vitro, (IC5o = 1.4 nM versus 2.8 nM for 
endochin against chloroquine resistant parasite strains) and cross-resistance 
in atovaquone resistant parasite strains was significantly diminished (IC5o = 
4.7 nM versus 17.4 nM for endochin against multidrug resistant parasite 
strains). A synergistic relationship with clopidol (Figure 1.21) was also 
determined, but the solubility of the lead compounds was very poor.80
ELQ-103
Figure 1.29: The structure of the lead compound identified by Riscoe et al in 2008 80
In a continuation of this study published in 2011 the group sought to 
optimise the structure of their initial hit, ELQ-103 (Figure 1.29) by changing 
the substitution pattern of the quinolone ring, introducing novel functionality in 
an effort to increase solubility and reduce metabolic instability. Their resulting
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library of around 30 compounds established a new lead in the form of ELQ- 
121 (Figure 1.30) which exhibited 10-fold higher potency than ELQ-103 
against 4-aminoquinoline resistant parasite strains. While ELQ-121 does 
exhibit marginally increased cross-resistance with atovaquone compared to 
ELQ-103, more importantly in vitro metabolic studies showed that ELQ-121 
exhibits enhanced metabolic stability.103 Solubility of the compounds was still 
an issue for in vivo use but the successful synthesis of a poly(ethylene) glycol 
prodrug, ELQ-125 (Figure 1.30) has improved on this, with successful cure 
achieved in mouse models infected with multi-drug resistant parasites.103
Figure 1.30: The lead compound, ELQ-121, and related prodrug, ELQ-125, from the most 
recent study by Riscoe et al.103
In parallel to the Riscoe et al studies the Manetsch group of the University 
of South Florida in partnership with the Medicines for Malaria Venture 
designed and synthesised a library of over 60 endochin-type quinolones in an 
effort to establish a comprehensive structure-activity relationship for this 
class of compounds against P.falciparum parasites.102
As with the Riscoe studies they found that altering the alkyl chain length 
at the 3-position modulated activity and that the carbonyl at the 4-position, as 
well as the lack of substitution at N-1 are key factors for this chemotype. It 
was also established that only limited changes to the 5, 6, 7 and 8 positions 
are well tolerated but the presence of a halogen atom, particularly chlorine, at 
the 6-position does enhance activity and reduces cross-resistance. 
Increasing solubility by shortening the 3-alkyl chain length resulted in a 
dramatic reduction in parasite selectivity and attempts to increase solubility
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utilising various alkenyl side chains were found to severely hamper activity 
against both sensitive and multidrug resistant parasite strains. While 3-aryl 
substituted analogues also exhibited a drop in potency it was less severe and 
both solubility and metabolic stability versus human liver microsomes were 
much improved.102
In summary it was determined that the most potent endochin derivatives 
had structures in which there was an alkyl chain of at least 7 carbons in 
length at the 3-position, positions 5 and 8 were unsubstituted, there was a 
methoxy group at the 7-position and a chlorine atom at the 6-position (Figure 
1.31). However it was suggested that, while less potent, an aryl group at the 
3-position offers better scope for further development.102
Compound 49 Compound 67
Compound 55
Figure 1.31: Examples from the Manetsch et al. study of endochin derivatives including their 
most potent analogue, compound 55, and their suggested scaffold for further development, 
compound 49.102
1.5 Project Aims
For this project we decided to focus on a quinolone core similar to those 
identified by ICI in the 1960’s (Figure 1.26). We hope that by varying the 
functional groups at the 3 and 7-positions of the quinolone ring we will be 
able to design analogues with high levels of potency against the P.falciparum
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bci protein and achieve good levels of selectivity over mammalian proteins. It 
is also hoped that through the use of in silico modelling of the compounds 
synthesised we will be able to determine the factors governing atovaquone 
cross-resistance for this class of compounds and so develop antimalarial 
agents that maintain activity against multidrug resistant parasite strains.
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Results and Discussion 1: Building a 
Structure-Activity Relationship for 
4-Quinoione based Inhibitors of the 
P.falciparum bc1 Complex
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2. Results and Discussion 1: Building a Structure-Activity Relationship 
for the P.falciparum bci Complex
2.1 Quinolone Synthesis
As noted in the introduction, we have selected the 4-quinolone ring 
system as the core of our target compounds. In the literature, 4-quinolones 
are commonly presented as their tautomers, 4-hydroxyquinolines (Figure 
2.1). However, studies have demonstrated that for the majority of examples, 
the preferred tautomer both in solution and the solid state is the 4- 
quinolone.104 This finding has also been borne out by our own analysis, 
which will be shown later. Therefore, compounds will be presented as their 4- 
quinolone tautomer for the remainder of this discussion.
The quinolone system has found use in a range of pharmaceutical 
applications and forms the core of a well established class of antibiotics. 
Consequently, many different synthetic pathways have been developed for 
their formation from a variety of starting points.
Figure 2.1: Showing the numbering system used for 4-quinolone/4-hydroxyquinoline
based ring substitutions.
There are a number of notable named examples for the synthesis of 
quinolones. The Conrad-Limpach synthesis can be used to synthesise 4- 
quinolones substituted at the C2 and C3 positions from anilines and (3- 
ketoesters (Scheme 2.1).105
Scheme 2.1: The Conrad-Limpach Synthesis
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The Camps cyclisation is a base-catalysed method which, dependent on 
choice of conditions and starting material, can be used to give either C2 
substituted 4-quinolones or 2-hydroxyquinolines from ortho- 
acylaminoacetophenones (Scheme 2.2).106
Scheme 2.2: The Camps Cyclisation
The Niementowski quinoline synthesis uses anthranilic acid derivatives 
and ketones or aldehydes to yield 4-hydroxyquinolines disubstituted at both 
C2 and C3 positions, or monosubstituted at C3, respectively (Scheme 2.3).107
o
Scheme 2.3: The Niementowski Quinoline Synthesis
For the development of our initial library, we chose to utilise the Gould- 
Jacobs reaction. First published in 1939 by R. Gordon Gould and Walter A. 
Jacobs, this method is a two stage process which proceeds via the reaction 
of an a,p-unsaturated ester (usually a malonate derivative) with an aniline. 
This is followed by a thermally driven cyclisation in which the phenyl ring of 
the aniline acts as a nucleophile, attacking the carbon of the ester carbonyl 
group (Scheme 2.4).108 This allows functionalities such as esters and nitriles 
to be easily incorporated at the 3-position, which we believe should interact 
favourably with the hydrophilic amino acid residues in the Q0 target site.52,53,
109
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Scheme 2.4: The mechanism by which the Gould-Jacobs Quinolone Synthesis proceeds.
2.2 Validating the Template - Synthesis of 1st Generation Inhibitors
Choosing to utilise the Gould-Jacobs methodology for the synthesis of our 
quinolone targets ensured that we could use commercially available anilines 
to rapidly synthesise a small number of compounds to test the validity of our 
design.
The particular process followed was that used by Stern et al. in 2006 to 
develop a series of CB2 cannabinoid agonists with similar core structures to 
our targets,110 but there is little variation across the literature.110*114 The first 
stage of the reaction is solvent free, with an aniline dissolved directly in one 
equivalent of malonic ester. This is then heated to 100 °C overnight, before 
cooling to give the enamine intermediate as a crude solid (Figure 2.4). The
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crude enamine is then added directly to refluxing Dowtherm A (Fluka) at 240 
°C and further heated for 1 - 2 hours, followed by cooling and precipitation of 
the product using hexane. Following reprecipitation from a suitable solvent 
(usually dimethylformamide), the products are obtained in moderate to good 
yields as off-white powders. To obtain our first two targets, this was 
accomplished by reaction of diethyl 2-(ethoxymethylene) malonate 1 with 3- 
phenoxyaniline 2 and 3-benzyloxyaniline 3, to give compounds 4 (Scheme 
2.5) and 5 (Scheme 2.6) respectively.
(I) 100 ’C, 24 h
(li) Dowtherm A, 240 0C, 1 h
Scheme 2.6: Synthesis of compound 5
2.2.1 Synthesis of ethyl 7-(4-(trifluoromethoxy)phenoxy)-quinolin-4-one-3- 
carboxylate
Following the work of Riscoe et al. on the effect of perfluorinated side- 
chains on the antimalarial activity of acridones,79 we also wanted to include 
an analogue with a trifluoromethoxy moiety on the aryl ring. As no 
commercially affordable anilines were available with this structure, it was 
necessary to synthesise this intermediate.
The most common method for the synthesis of diphenyl ethers is the 
Ullmann coupling process, which can be either palladium-115 or copper- 
catalysed.116, 117 In terms of affordability, the copper-catalysed options were 
more desirable to us. After experimenting with a number of methods, a 
glycine mediated process developed by Ma and Cai in 2003 was selected.116 
The Ullmann reaction cannot be carried out using anilines as this would 
result in a side reaction at the nitrogen, in addition to the desired coupling
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through oxygen. Therefore, 3-nitrophenol 7 was used as the starting material 
and reacted with 4-(trifluoromethoxy)iodobenzene 8 to give 1-nitro-3-(4- 
(trifluoromethoxy)phenoxy)benzene 9 (Scheme 2.7) in yields of 
approximately 60% following purification by chromatography.
Scheme 2.7: Ullmann coupling reaction to synthesise 8
The mirror reaction of 4-(trifluoromethoxy)phenol and 3-iodonitrobenzene 
was also attempted, in the hope that yields could be increased. However, it 
was quickly discovered that the Rf of 4-(trifluoromethoxy)phenol was 
essentially identical to that of 9, making efficient purification of the product 
impractical.
Synthesis of 9 was followed by reduction of the nitro group to the primary 
amine, giving 3-(4-(trifluoromethoxy)phenoxy)aniline 10, by a zinc-mediated 
process used previously in the group for the same transformation (Scheme 
2.8).118 The process consistently gives greater than 90% yields after 
purification, and while not being the most elegant method available, it 
benefits from not requiring the use of hydrogen gas as palladium-catalysed 
alternatives would.
9
JO-
Zn powder FjC
CaCI2, EtOH 
N02 100 °C
10
NH2
Scheme 2 8:
Zinc mediated reduction of 8 to 9
Reaction of 10 with 1 via the Gould-Jacobs protocol gave ethyl 7-(4- 
(trifluoromethoxy)phenoxy)-quinolin-4-one-3-carboxylate 6 in good yield 
(Scheme 2.9). The first three compounds synthesised in this manner were 
submitted for biological testing.
(i) 100 °C, 24 h
(ii) Dowtherm A, 240 'C, 1 h
Scheme 2.9: Synthesis of compound 6.
-48-
2.2.2 Initial Test Results
Pure samples of 4, 5 and 6 were assessed in vitro in a growth inhibition 
assay against erythrocytic stage, “wild-type” P. falciparum 3D7 strain parasite 
cultures. The results (Table 2.1) indicated two things; our chosen template 
was certainly active against P.falciparum. Also, solubility was an inherent 
problem, with compound 5 proving impossible to test biologically.
Table 2.1: Results for the 1st generation compounds
Code
IC5o versus 3D7
parasites (nM)a
Isolated Yield (%)
CLogP by ALog
PS2.1C
4 19.3 61.7 3.07 ± 0.40
5 No Data6 66.7 3.02 ± 0.45
6 5.3 79.8 4.07 ± 0.84
a Average value from at least 3 independent experiments. 0Insufficient solubility for testing. 
c http://www.vcclab.org/lab/alogps/
While the inability to test compound 5 was disappointing, the potency of 
compounds 4 and 6 was very exciting, compound 6 in particular as it 
demonstrated similar potency to atovaquone.
2.3 Improving Solubility - Synthesis of 2nd Generation Inhibitors
While the in vitro results for 4 and 6 clearly demonstrated that the 3,7- 
substituted quinolone template is active against P.falciparum, the poor 
solubility exhibited by all three compounds (particularly 5) indicated that 
absorption in vivo was likely to be a problem. As the Medicines for Malaria 
Venture profile for the development of novel antimalarials specifies that new 
candidates must be orally bioavailable, this was a problem of some 
urgency.119 Our first attempt at tackling this issue was to lower the CLogP of 
the compounds by replacement of the 3-ester group of the lead compounds 
with a variety of amides.
This was achieved by heating the ester in an excess of the appropriate 
amine for 1 hour at 120 °C using Dowtherm A as a solvent (Scheme 2.10). 
The resulting amides were then purified by column chromatography to 
remove any residual ester compound before submission for biological 
screening. This method of synthesis was not compatible with all the amines
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attempted. Morpholine, for example, evaporated from the reaction mixture 
faster than it reacted. However, a number of amides were successfully 
produced and tested (Table 2.2).
O Eto
7-11
Scheme 2.10: Synthetic route to the amide series.
Table 2.2: Results for the amide series compounds
Code Structure
Isolated
Yield (%)
IC50 versus 3D7
parasites (nM)a
CLogP by
ALog
PS2.1b
7 A0 45.1 Not Tested 4.14 ±0.68
8 o / 55.4 2728 3.08 ± 0.79
9 Ao^ 87.8 3511 3.57 ± 0.87
10 39.5 350 3.70 ± 0.79
11
° ix 30.0C 1120 4.21 ± 0.78
a Average value from at least 3 independent experiments. 
bhttp://www. vcclab. org/lab/alogps/. c Synthesised from 4
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Although not reflected in the CLogP values calculated for the 
compounds (Table 2.2), the solubility of the amide series was an 
improvement over the original esters. However when tested in vitro they 
demonstrated vastly reduced activity, with the most potent amide 10 over 60- 
fold less potent than compound 6 (Table 2.2). This observation implied that 
the nature of the functional group at the 3-position was critical for good 
activity against P. falciparum. The electron distribution pattern for esters and 
amides differs significantly, (Figure 2.2) leading to speculation that this has 
an effect on the binding of the compounds with the target protein. In esters, 
the electronegative ether oxygen draws electron density away from the 
carbon atom of the carbonyl group, in turn drawing electron density away 
from the carbonyl oxygen making it less available for hydrogen bond 
formation. In amides, donation of the nitrogen lone pair into the carbonyl 
carbon ensures that the reverse occurs with the carbonyl oxygen 
consequently relatively electron rich.
This is offset, however, by the resulting partial double bond character 
of the carbon nitrogen bond (Figure 2.2) reducing amide flexibility. This may 
compromise the ability of the group to orientate itself for optimal binding 
within a target protein.120
O
R" RM
Amides
Figure 2.2: Displaying the difference in electron distribution between esters and amides
In order to further our understanding of the structure-activity relationship, 
it was decided to test the tolerances of the 3-position by synthesising a 
number of analogues based on compound 4.
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2.4 Exploring the 3-position: Synthesis of 3rd Generation Inhibitors
In order to test the importance of the group at the 3-position, the obvious 
first step was to remove the functionality from that point on the ring 
altogether. A procedure was found in the literature to hydrolyse the ethyl 
ester of 4, followed by decarboxylation of the resulting carboxylic acid to give 
12 (Scheme 2.11).114 This method worked well, generating the target 
compound in a greater than 85% yield following purification by 
chromatography.
i) NaOH 
MeOH 
Reflux
Dowtherm A
Reflux
Scheme 2.11: Reduction and decarboxylation of 4 to remove functionality from the 3- 
position.114
2.4.1 Synthesis of a 3-Nitrile Analogue
It was postulated that simply by exchanging diethyl 
ethoxymethylenemalonate 1 with ethyl(ethoxymethylene)cyanoacetate 13 in 
the Gould-Jacobs procedure, a 3-nitrile analogue could be easily produced. 
This proved to be less simple in practice, with 13 being much slower to react 
with 3-phenoxyaniline 2 and giving a far less clean reaction than had 
previously been observed for the solvent free reactions carried out during the 
synthesis of the esters. A search of the literature and a certain amount of trial 
and error eventually led to the discovery that using a small amount of ethanol 
(~1 mL/mmol) to dissolve the reactants, rather than carrying out the reaction 
solvent free, and using a slightly elevated reaction temperature (120 °C 
versus 100 °C) gave the ethyl 2-cyano-3-((3-phenoxyphenyl)amino)acrylate 
product 14 (Scheme 2.12) in near quantitative yields as a mixture of E and Z
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isomers (Figure 2.3).112 Unlike the previous analogues, it was not possible to 
take the intermediate through to the thermal cyclization step crude; instead it 
was properly isolated, washed and dried.
Scheme 2.12: Synthesis of ethyl 2-cyano-3-((3-phenoxyphenyl)amino)acrylate 14.
cri r-
m rsi
od od
t I Os ✓p"
c (BZ)
Figure 2.3 - 1H NMR expansion of 14 showing E/Z isomerism of the enamine proton a and 
the ethyl ester protons b and c
Cyclisation of 14 also proved more difficult compared with the previous 
ester syntheses. Rather than the 1-2 hour reaction times found to be 
adequate for the ester analogues, it was necessary to maintain temperatures 
of 240 °C overnight to obtain reasonable yields of the desired product. This 
reduced reaction rate is presumably due to the requirement of the E-isomer 
of 14 to rearrange before it can successfully ring close to give 15 (Scheme 
2.13). Attempts to increase the reaction rate by further elevating the 
temperature resulted in the formation of degradation products.
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^ ^ Dowtherm A
J 240 *C, 12 h
"N^ ^ "O"
H
14 15
Scheme 2.13: Cyclisation to give 4-oxo-7-phenoxy-1,4-dihyclroquinoline-3-carbonitrile 15.
2.4.2 Pyrazoloquinolinone Derivative
The discovery of a paper by A. Carotti et al. while investigating potential 
bioisosteres, inspired the synthesis of a tricyclic derivative, 7-phenoxy-2H- 
pyrazolo[4,3-c]quinolin-3(5H)-one 16.121 Bioisosteres are defined as chemical 
groups that maintain or enhance the biological properties of a compound, 
such as their metabolic profile, without making significant changes to the 
physiochemical properties.122 A classic example is the replacement of 
hydrogen with fluorine on aromatic rings to reduce metabolism by 
cytochrome P450 enzymes.
n—-nh
16
The pyrazoloquinolone structure was of interest because the pyrazole ring 
is a bioisostere of the (3-ketoester structure of the initial hit molecules. The 
pyrazole introduces an additional hydrogen bond donor without much 
increase in steric bulk. We were also interested to see the effect of the 
extension of the conjugation system and the reduced flexibility at the 3- 
position. 16 Was synthesised from 4 in two straightforward steps.121 Reflux 
conditions in phosphoryl chloride displaced the carbonyl oxygen of the 
quinolone to give ethyl 4-chloro-7-phenoxy-1,4-dihydroquinoline-3- 
carboxylate 17 in high yields (Scheme 2.14).
Scheme 2.14: Reaction of 4 with phosphoryl chloride to give ethyl 4-ch!oro-7-phenoxy-1,4- 
dihydroquinoline-3-carboxylate 17.
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The 4-chloro compound 17 was then reacted with hydrazine, which 
displaces the chloride before attacking the ester to ring close forming a 
pyrazolone ring (Scheme 2.15). Provided the reaction conditions were kept 
reasonably anhydrous, using dry solvents and an N2 atmosphere, both 
reaction steps were almost quantitative, with yields of 91.6% and 97.4% 
respectively.
Scheme 2.15: Reaction of 17 with hydrazine to give the thcyclic target 16 in high yield.121 
2.4.3 Transesterification
In addition to generating new functionalities at the 3-position, we also 
experimented with different esters to determine whether steric bulk at the 3- 
position was of significance in the binding conformation. Using a titanium (IV) 
isopropoxide catalysed transesterification procedure found in the literature, a 
number different alcohols were reacted with 4, with varying degrees of 
success.123 Isopropanol, cyclopentanol and cyclohexanol were all used 
successfully to give compounds 18 to 20 respectively (Scheme 2.16). 
However, yields for the synthesis of compound 18 were reduced by the 
difficulty inherent in distinguishing it from the starting material 4 when 
purifying by column chromatography.
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Scheme 2.16: Successful transesterification reactions of 4 with secondary alcohols.123
Attempts to carry out the same reaction with a number of other alcohols 
were less successful. In particular, the reaction of 4 with 2-(pyrrolidin-1- 
yl)ethanol, (intended to give an ester analogue of the most potent amide 10), 
proved unsuccessful despite a number of attempts with various reaction 
conditions. We postulate that this was due to destruction of the product by 
the titanium derived Lewis acid present in the reaction mixture through an 
elimination pathway (Scheme 2.17), but have no evidence to support this 
hypothesis beyond the continued failure to obtain the desired product.
Scheme 2.17: The proposed Lewis acid promoted elimination pathway leading to the failure 
to isolate the desired 2-(pyrrolidin-1-yl)ethyl target.
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2.4.4 Analysing the 3rd Generation Inhibitors
Once synthesised, a selection of the novel quinolones were tested in vitro 
against 3D7 P.falciparum parasites for comparison with the original hits 
(Table 2.3).
Table 2.3: Results for the 3™ generation compounds
Compound
4
6
12
15
16 
18
19
20
IC5o versus 3D7 
parasites (nM)a 
19.3 
5^30
6725
8103
No activity at 1 pM 
8.45
Not Tested45
29l5
Isolated Yield
88.4 
87.9
97.4
32.4 
68.6 
3T3
CLogP by ALog 
PS2.1C 
3.07 ± 0.40 
4.07 ± 0.84 
2.72 ± 0.42
2.84 ± 0.80
2.85 ± 0.73 
3.42 ± 0.45 
3.77 ± 0.62 
4.36 ± 0.67
a Average value from at least 3 independent experiments. 0 Purity of isolated compound 
insufficient for biological testing. c http://www. vcclab. org/lab/alogps/
The results from the 3rd generation of compounds support the observation
that esters are the superior group in the 3-position, with both the
decarboxylated compound 12 and nitrile analogue 15 demonstrating much 
reduced potency in vitro. Perhaps more significantly, the result for 18 reveals 
that a slight increase in the size of the ester group (ethyl to isopropyl) 
increases biological activity. Further increases in size are not well tolerated,
with a drop in potency observed for the cyclohexyl ester 20. However, this 
compound maintains higher potency than any of the amides of similar size, 
suggesting that the other properties of the functional group are also 
important.
2.5 Exploring the 7-position - Modifying the Linker
Having established that the preferred group in the 3-position is an ethyl or 
isopropyl ester, we turned our attention to the “tail” section of the compounds 
at the 7-position on the quinolone ring. As the channel leading to the Q0 
active site is known to be lined with hydrophobic residues, we surmised that 
substitution of the phenoxy linker with a methylene group to give the 
corresponding benzyl compounds might improve activity. 3-Benzylaniline 21
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is commercially available and reacted easily with diethyl 
ethoxymethylenemalonate 1 to give ethyl 7-benzyl-4-oxo-1,4- 
dihydroquinoline-3-carboxylate 22 in good yield.
(I) 100 'C, 24 h 
(if) Dowtherm A, 240 “C, 1 h
Scheme2.18: Synthesis of 22 by the Gould-Jacobs method.
2.5.1 Revisiting the Benzyloxy Linker
It had been observed during the biological testing that compound 6 is 
marginally more soluble than 4, suggesting that in addition to increasing 
potency, the trifluoromethoxy group also improved solubility, despite raising 
the the ClogP of the compound. Therefore, an analogue of 5 with a 
trifluoromethoxy moiety on the aryl ring was synthesised in order to test the 
potency of the benzyloxy linker system. As with the synthesis of 6, the 
desired aniline starting material was not commercially available. This 
compound was synthesised from 3-nitrophenol 7, which was reacted with 4- 
trifluoromethoxy benzyl bromide 23 in the presence of base to yield 1-nitro-3- 
((4-(trifluoromethoxy)benzyl)oxy)benzene 24 (Scheme 2.19).
Scheme 2.19: Synthesis of intermediate 24 from 3-nitrophenol 7
The nitro group was then reduced to the primary amine using the same
zinc-mediated method previously employed to give aniline compound 25 
(Scheme 2.20).118
Zn powder
100 °C
Scheme 2.20: Zinc mediated reduction of nitro compound 24 to prepare aniline 25
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Reaction of 25 with 1 via the Gould-Jacobs protocol to give the desired 
product 26 (Scheme 2.21) was found to be lower yielding than for the earlier 
analogues, but gave a sufficient quantity of product for in vitro testing. 
Consequently, no further attempts were made at optimising the reaction.
(I) 100 °C. 24 h
(li) Dowtherm A. 240 “C, 1 h
Scheme 2.21: Gould-Jacobs reaction of 1 with 25 to give ethyl 4-oxo-7-((4- 
(trifluoromethoxy)benzyl)oxy)-1,4-dihydroquinoline-3-carboxylate 26
2.5.2 Incorporating Heterocycles
Following the disappointing results from attempts to increase solubility via 
the use of amides at the 3-position, it was decided to try and increase 
solubility by incorporation of heterocycles into the “tail” portion of the 
compounds, allowing us to formulate salts. Unfortunately, this proved 
problematic and only two of the analogues attempted survived the harsh 
conditions of the Gould-Jacobs thermal cyclisation. The first analogue that 
was successfully produced was a piperazine containing compound, ethyl 7- 
(4-benzylpiperazin-1 -yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 27.
27
Synthesis began with reaction of 3-fluoronitrobenzene 28 with N- 
benzylpiperazine 29 in the presence of base, displacing fluoride to give 1- 
benzyl-4-(3-nitrophenyl)piperazine 30 (Scheme 2.22).124
no2
NH KjCOj
DM SO 
90 *C
NOz
Scheme 2.22: Reaction of 28 and 29 to give 1-benzyl-4-(3-nitrophenyl)piperazine 30
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This was followed by tin (II) chloride mediated reduction of the nitro group 
to the amine 31 (Scheme 2.23).125 The tin procedure was utilised following 
the discovery that the zinc mediated method (employed in the synthesis of 
earlier analogues) was resulting in a partial cleavage of the benzyl group 
from the piperazine ring, resulting in a reduced yield and a difficult 
purification.
NOz
SnCt2. H20
EtOAc
A
NH2
Scheme 2.23: Tin (II) chloride mediated reduction of nitro compound 30 to yield aniline 
intermediate 31.
Reaction of 31 with diethyl ethoxymethylenemalonate 1 via the Gould- 
Jacobs procedure generated 27 in a moderate yield (Scheme 2.24). It was 
surprising to find that the solubility of the product was quite poor, and we 
were unable to successfully formulate either hydrochloride or citric acid salts 
of the compound that was stable in solution.
(i) 100 *C, 24 h
240 *C, 1 h
Scheme 2.24: Using the Gould-Jacobs reaction of 1 with 31 to give quinolone target 27.
An analogue with a chlorine at the 4-position of the terminal phenyl ring 
was also attempted but decomposed during cyclisation. Resynthesis was not 
attempted as having found that incorporating heterocycles directly into the 
“tail” part of the compounds did not improve solubility, we instead targeted 
analogues with terminal heterocycles on flexible alkyl linkers, such as ethyl 7- 
(4-(2-morpholinoethoxy)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 
(Figure 2.3).
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Figure 2.3: Terminal heterocyclic target ethyl 7-(4-(2-morpholinoethoxy)phenyl)-4-oxo-1,4- 
dihyclroquinoline-3-carboxylate.
However, we were only partially successful in this aim, as the thermal 
cyclisation conditions again proved to be problematic. Instead of obtaining 
the desired 3-ethyl ester, only 7-(4-(2-morpholinoethoxy)phenyl)quinoline- 
4(1H)-one 32 was recovered in sufficient quantities for biological evaluation.
A key step in the synthesis was the Suzuki coupling of 3- 
bromonitrobenzene 33 with 4-methoxybenzene boronic acid 34,126 followed 
by boron tribromide demethylation of the methoxy group to give 3'-nitro-[1,1'- 
biphenyl]-4-ol 35 (Scheme 2.25).127
Scheme 2.25: Synthesis of biphenyl intermediate 35
Reaction of 35 with A/-(2-chloroethyl)morpholine hydrochloride 36 gave 4- 
(2-((3'-nitro-[1,1'-biphenyl]-4-yl)oxy)ethyl)morpholine 37. The nitro group was 
then successfully reduced by the tin (II) chloride-mediated procedure 
employed previously, to give the desired aniline compound 4'-(2- 
morpholinoethoxyHTI'-biphenylJ-S-amine 38 (Scheme 2.26).
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Scheme 2.26: Synthesis of 38 from 35
The Gould-Jacobs reaction of this compound with 1 failed to yield the 
desired ethyl ester in isolatable quantities over several attempts, although 
HPLC purification of the product mixture from one attempt did yield sufficient 
quantity of compound 32 for an in vitro test. It would appear that the target 
ester is unstable under the Gould-Jacobs conditions and the bulk of the 
isolated product had undergone decarboxylation. Additional analogues 
incorporating A/-methyl and /V-ethyl substituted piperazine in place of 
morpholine were attempted but repeatedly decomposed during the 
cyclisation step and so were abandoned.
2.5.3 Evaluation of 4th Generation Inhibitors
The four new compounds were submitted for testing and evaluated 
according to their performance in vitro compared to the initial hit compound 
(Table 2.4).
Table 2.4: Results for the 4in generation compounds;
Compound
IC5o versus 3D7
Isolated Yield (%)
CLogP by ALog
parasites (nM)a PS2.1C
22 4.57 57.4 3.36 ± 0.43
26 5.00 16.0 4.05 ± 0.82
27 No Data b 36.1 3.14 ±0.77
32 1368 3.9 2.69 ± 0.75
a Average value from at least 3 independent experiments 0 Insufficient solubility for testing 
c http://www.vcclab.org/lab/alogps/
Interestingly, the switch from an oxygen to a methylene linker between 
the aromatic rings of the “tail” (22 versus 4) resulted in a 4-fold increase in 
potency, presumably as a result of more favourable interactions between the
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hydrophobic regions of the target protein and the carbon than for the more 
polar oxygen linker.
With the trifluoromethoxy group present, the benzyloxy linked compound 
26 displayed similar levels of potency to the corresponding phenoxy 
compound 6. However, solubility was still extremely poor, and the additional 
difficulty involved in the synthesis of compound 26 led us to discard this 
particular chemotype.
As mentioned previously, piperazine compound 27 proved surprisingly 
insoluble. In a similar manner to compound 5, it was unable to be tested in 
vitro. Although salts were formulated, they were unstable and often 
precipitated out of solution unpredictably.
Compound 32 was more active than anticipated, considering it lacked the 
all important ester group functionality at the 3-position, suggesting that if a 
more reliable route to the intended target had been developed, the 
compound may have had potential.
2.6 Identification of the Lead?
From the initial synthesis of the hit compounds through the development 
of the subsequent generations, two observations stood out. The inclusion of 
a trifluoromethoxy moiety on the aryl “tail" resulted in an approximate 4-fold 
increase in potency (compound 4 versus 6); and the switch from an oxygen 
linker to a methylene linker produced a similar 4-fold increase in potency 
(compound 4 versus 22). The question therefore was, were these effects 
additive? If both these modifications were included in a single compound, 
ethyl 4-oxo-7-(4-(trifluoromethoxy)benzyl)-1,4-dihydroquinoline-3-carboxylate 
39, would we get a molecule with an even better profile?
o o
39
2.6.1 Synthesis of 3-(4-(trifluoromethoxy)benzyl)aniline
Synthesising 3-(4-(trifluoromethoxy)benzyl)aniline 40 was a relatively 
simple process, involving the palladium tetrakis(triphenylphosphine)-
-63-
catalysed Suzuki coupling of 4-(trifluoromethoxy) benzyl bromide 41 with 3- 
nitrophenylboronic acid 42. This consistently gave 1-nitro-3-(4- 
(trifluoromethoxy)benzyl)benzene 43 in 76 - 89 % yields, following 
purification by column chromatography.(Scheme 2.27).
F,
F
41
HOv
'B
I
OH
Pd(PPh,U
NOj KjCOj (aq) 
THF 
95-C
F,C/0
43
NOj
Scheme 2.27: Suzuki coupling synthesis of 1-nitro-3-(4-(trifluoromethoxy)benzyl)benzene 43
The nitro compound 43 was then reduced to give the desired aniline 
intermediate 40 in high yields( > 96%), using the same tin (II) chloride- 
mediated procedure previously used in the synthesis of the heterocycle 
containing compounds 27 and 32 (Scheme 2.28).
Scheme 2.28: Tin (II) chloride-mediated reduction of 43 to key aniline intermediate 40.
2.6.2 Lead Compound Synthesis
For reasons that we have been unable to satisfactorily explain, difficulties 
became apparent in the latter stages of the synthesis. While the aniline 
compound 40 had been synthesised with relative ease, using it in the Gould- 
Jacobs quinolone synthesis proved surprisingly problematic. In the first 
attempt at carrying out the synthesis of 39, the enamine intermediate 44 was 
taken through to the cyclisation step without purification, following 
evaporation of the volatile by-products (as had been done for most previous 
instances of this reaction step). However, instead of the solid product 
expected, the thermal cyclisation reaction of 44 returned a dark brown oil, 
which was comprised of an inseparable mixture of multiple components.
F,C'
OEt
44
At the second attempt, diethyl 2-(((3-(4-(trifluoromethoxy) 
benzyl)phenyl)amino)methylene)malonate 44 was isolated and purified.
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However, after the usual solvent free, overnight reaction, just 8% of the 
desired compound was isolated from the reaction mixture. Eventually, after 
small scale optimisation of various conditions, including longer reaction 
times, higher temperatures, dilution and a variety of work-up procedures, a 
method was found that consistently gave satisfactory yields. Dilution of the 
aniline 40 in ethanol, followed by overnight reaction at 100 °C and isolation of 
the product by reduced pressure removal of the volatile components rather 
than the precipitation from non-polar solvents employed previously, 
generated 44 in yields of up to 97%.
Further problems were encountered when the first attempt at cyclising the 
isolated, pure intermediate 44, gave just a 6% yield of 39. However, this was 
a sufficient quantity for an in vitro test, which gave promising results (Table 
2.5). In subsequent synthetic runs, the yield of ethyl 4-oxo-7-(4- 
(trifluoromethoxy)benzyl)-1,4-dihydroquinoline-3-carboxylate 39 has been 
improved to just over 50% by careful monitoring of the reaction temperature. 
It has been found that while earlier analogues could tolerate a certain amount 
of variation in temperature between 240 - 250 °C with little consequence, 39 
has a much smaller margin for error, degrading rapidly if reaction 
temperatures rose much above 240 °C.
Table 2.5: In vitro results for compound 39 and the previous analogues contributing to its
design.
Compound IC5o versus 3D7 parasites (nM)a CLogP byALog PS2.1b
4 19.3 3.07 ± 0.40
6 5.30 4.07 ± 0.84
22 4.57 3.36 ± 0.43
39 0.46 4.41 ± 0.79
a Average value from at least 3 independent experiments. D 
http://www. vcclab.org/lab/alogps/
2.7 Further Development of the Lead - Prodrugs
At 0.46 nM, compound 39 is the most potent quinolone antimalarial 
developed by the O’Neill group to date. However, despite its in vitro potency 
when the compound was tested orally, in vivo testing using mouse models 
infected with P.berghei revealed that the compound was much less active, 
with only a slight reduction of parasitaemia observed. This was attributed to
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its poor solubility, leading to low absorption and consequently insufficient 
bioavailability to exert a curative effect on the parasites.
As our previous attempts to increase the solubility of these compounds by 
modification of the functional groups had led to the loss of biological activity, 
an alternative approach was attempted, namely the synthesis of prodrugs. 
Prodrugs are compounds which have additional functionality designed to 
increase the solubility of the active species, promoting increased absorption 
of the compound. Once absorbed, they can be easily metabolised to 
generate the active species in sufficient concentration to exert the desired 
effect.
Esterases are one of the most common enzyme classes and work by 
hydrolysing ester bonds to give an alcohol and a carboxylic acid.6 It was 
surmised that the substitution of the quinolone carbonyl with a group that 
would be metabolised to give the 4-hydroxyquinoline (in turn tautomerising to 
give the active compound 39), (Scheme 2.28), would increase in vivo activity.
Our initial attempts to synthesise a simple ethyl carbonate prodrug by 
reaction of 39 with ethyl chloroformate (following deprotonation with 
potassium f-butoxide) were frustrated by poor yields. Examination of the 
literature revealed a possible explanation; in 2007, while working on 
quinolone based antibacterial agents, Hammerschmidt et al. observed that at 
room temperature, ethyl and f-buty! carbonates of quinolone A/-oxides would 
rearrange to their A/-substituted isomers.128 While our compounds are not N- 
oxides, and so are unable to rearrange in this fashion, this does suggest that 
the prodrug targets we were aiming for could be unstable enough to 
hydrolyse rapidly back to the starting material during isolation explaining the 
apparent lack of reaction we were observing. During the same study in which 
they observed the rearrangement of carbonate quinolones, Hammerschmidt 
et al. also noted that the related carbamates were more stable, and did not 
rearrange in this fashion.128
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Scheme 2.28: Esterase activation of a compound 39 based prodrug.
Therefore, compounds 6 and 39 were reacted with A/-morpholine carbonyl 
chloride 45 according to the literature conditions to yield prodrugs 46 and 47 
respectively, in modest but adequate yields (Scheme 2.29). In vivo testing of 
both prodrugs has given very promising results for further development, with 
a parasite clearance of 45.8% at 30 mg/kg oral dose for 46 and 47 achieving 
a rate of 57.7% from a daily 20 mg/kg oral dose.
46 X = O 42.1%
47 X = CHZ 36.8%
Scheme 2.29: Synthesis of N-morpholine carbamate prodrugs of compounds 6 and 39.
2.8 Confirmation of bci Activity: Cross-Resistance and Selectivity Testing
In addition to testing against 3D7 “wild-type” parasite strains of 
P.falcipanim, which are not resistant to any current antimalarial agents, a 
number of the synthesised compounds were also tested in vitro against the 
atovaquone-resistant TM90C2B parasite strain to assess the compounds for 
the presence of any cross resistance (Table 2.6).42
-67-
Table 2.6: Atovaquone cross resistance results for a cross section of the synthesised 
library.
Compound
6
10
15
18
20
26
1Cso versus 3D7 parasites (nM)
5.30
350
8103
8.45
29.6
5.00
IC5o versus TM90C2B 
parasites (nM)a 
488 
442
No activity at 1 pM 
No activity at 1 pM 
No activity at 1 pM 
No activity at 1 pM
a Average value from at least 3 independent experiments.
While these results were discouraging in that the tested compounds
clearly have not avoided the issues that result in atovaquone resistance, the
very fact that the library demonstrates cross resistance with atovaquone
indicates that the compounds produced are indeed inhibitors. The result
for the trifluoromethoxy substituted ethyl ester compound 6 is encouraging. 
Although a 92 fold drop in potency is observed, this is a distinct improvement 
over the 6000-fold drop in potency observed for atovaquone in the same 
parasite strain. The result for compound 10, the ethyl-A/-pyrollidine amide is 
unusual and may indicate that this compound has a mode of action other
than the intended bc^ inhibition.
To further confirm that the compounds were indeed targeting the intended 
active site, a selected group of compounds were tested against isolated 
samples of P.falciparum bc^ protein in enzyme inhibition studies (in addition 
to the whole cell parasite growth inhibition assays used to generate the in 
vitro test data for all the synthesised compounds) (Table 2.7).
Table 2.7: Enzyme inhibition results confirming bc-t activity.
Code IC50 versus 3D7 parasites (nM)a EC5o versus parasite bc^ isolates (nM)a
6 5.30 141
22 4.57 227
39 0.46 1.3
a Average value from at least 3 independent experiments.
These results clearly show that we have been successful in designing bci 
inhibitors with good activity against the desired target. Having confirmed this, 
it was important to establish that the developed compounds were selective
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for parasite Jbci over the equivalent mammalian protein. The standard check 
for 6ci selectivity is testing against jbci protein isolated from bovine cardiac 
tissue. Although it differs very slightly from human bci protein, the amino acid 
sequence for the Q0 binding region of both cytochrome b and the ISP 
segment are near identical.78 Therefore, a selection of analogues with the 
highest in vitro potencies were tested against isolated bovine bci protein 
samples (Table 2.8).
Table 2.8: Results of selectivity testing against bovine bCi for the most potent analogues 
versus P.falciparum in vitro.
Compound
EC5o versus 3D7
isolates (nM)a
EC5o versus bovine bc^
isolates (nM)a
Selectivity
Factor
6 141 200 1.4
22 227 483 2.1
39 1.3 17.7 13.6
3 Average value from at least 3 independent experiments.
Unfortunately, as the results show, the compounds demonstrate only a 
low degree of selectivity for the parasite protein over mammalian bci. The 
lead compound 39 demonstrated the highest selectivity of the tested 
compounds with a selectivity factor of over 10-fold, however this level of 
selectivity is nearly half that of atovaquone, which has a therapeutic index of 
24-fold.78
In addition to the test results shown above, two other analogues were 
tested in vitro against bovine bci protein isolates but not against the parasite 
protein as the P.falciparum protein is difficult to isolate and its availability 
consequently highly limited.
Table 2.9: Results of testing against bovine be-, protein isolates in vitro.
Compound
EC5o versus bovine bci isolates IC50 versus 3D7 parasites
(nM)a (nM)a
18 3220 8.45
26 6470 5.00
3 Average value from at least 3 independent experiments.
EC5o and IC5o values are not strictly comparable due to the different ways 
in which they are recorded; EC50 values are tested for against isolated 
proteins where as IC50 data indicates activity against whole cell parasites. 
However when it is considered that they are structurally very similar and have
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comparable IC5o values to compound 6, the high EC5o values versus 
mammalian bci recorded for compounds 18 and 26 are significant and may 
indicate an increase in parasite selectivity. The result for the benzyloxy 
derivative 26 was of limited interest, as we had previously discounted this 
structure for further development due to its very poor solubility. The result for 
the isopropyl ester 18 was of much more interest however, as it appears to 
indicate that a very slight change in the ester group at the 3-position may be 
sufficient to significantly increase selectivity.
2.9 Increasing the Selectivity of the Lead
Following the result for compound 18 an additional analogue was 
designed. Using the same titanium (IV) isopropoxide mediated method as 
employed previously for the synthesis of esters 18, 19, and 20, a small 
quantity of the lead compound 39 was reacted with isopropanol to give the 
isopropyl ester analogue 48 (Scheme 2.30).123
39 48
Scheme 2.30: Lewis acid-catalysed transesterification of 39 to yield 48
At the time of writing, selectivity analysis has not been carried out for 
compound 48, however preliminary in vitro results versus 3D7 parasites 
appear promising, with an IC5o reported at 0.98 nM.
2.10 Summary
A small but significant library of quinolone-based compounds have been 
developed and demonstrated to have activity at the bci protein of 
P.falciparum malaria parasites.129 It has been shown that while the most 
active compounds are compromised by poor solubility, it is possible to 
formulate carbamate prodrugs with good activity in vivo. While selectivity 
over mammalian bci is currently relatively low, progress has been made 
towards potentially increasing selectivity for the parasite target. At present 
the problem of atovaquone cross resistance has not been completely 
resolved, but resistance is reduced relative to atovaquone itself.
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In order to better understand the observed structure-activity relationships, 
and to guide any further development of these compounds, the synthesised 
library has been modelled by in silico docking with the crystal structure of 
yeast bci.
2.11 Experimental
Commercially available starting materials were sourced from Sigma- 
Aldrich, Alfa Aesar, Acros Organics or Apollo Scientific Ltd. and used without 
additional purification. Solvents were obtained from either Fisher Scientific or 
VWR and used without purification unless otherwise stated.
Flash column chromatography purification was carried out using silica gel 
(particle size 40-63 pm) sourced from Sigma-Aldrich and thin layer 
chromatography (TLC) was carried out using Merck aluminium backed 
sheets 20 x 20 cm Silica gel 60 F254. TLC plates were visualised using an 
ultraviolet lamp (254 nm).
Analysis
1H NMR spectra were recorded using a Bruker Avance 400 (400 MHz) 
machine; 13C spectra were recorded on the same machine (100 MHz). 
Chemical shifts (5) are recorded in ppm relative to an internal 
tetramethylsilane standard. Deuterated solvents were supplied by Sigma- 
Aldrich and Cambridge Isotope Laboratories and were used without 
additional purification. 1H spectra multiplicities are recorded as singlet (s), 
broad singlet (bs), doublet (d), triplet (t), quartet (q), doublet of doublets (dd), 
doublet of triplets (dt) or multiplet (m), coupling constant J values are given in 
Hz where appropriate.
High resolution mass spectroscopy (HRMS) was carried out by Dr. A. 
Mills and Miss M. McCarron via electrospray ionisation (El) using a 
Micromass LCT Mass Spectrometer. Samples were injected as methanol 
solutions using a direct infusion syringe pump.
Elemental analysis (CHN) was performed by Mr. S. Apter and Mrs. J. Ellis 
of this department. Melting points and decomposition temperatures, where 
reported, were identified using a Gallenkamp melting point apparatus and are 
reported uncorrected in °C.
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General Method A: Synthesis of enamine intermediates
The appropriate aniline (1 eq.) was dissolved in diethyl 
ethoxymethylenemalonate 1 (1 eq.). The mixture was heated to 100 °C and 
stirred overnight. The still warm solution was poured into petroleum ether (50 
mL) and cooled in an ice/acetone bath resulting in a precipitate that was 
collected by filtration, washed with cold petroleum ether and dried under 
vacuum.
Diethyl 2-(((3-phenoxyphenyl)amino)methylene)malonate
Synthesised according to general method A to give an off-white solid.
(4.82 g, yield 99.0%)
Melting point: 50 - 53 °C
’H NMR (MeOH-d4) 6 8.48 (s, 1H), 7.39 - 7.33 (m, 3H), 7.18 - 7.14 (m, 1H), 
7.06 - 7.03 (m, 2H), 6.99 - 6.97 (dd, 1H, J = 8.1, 2.1), 6.88 -6.87 (t, 1H, J = 
2.2), 6.77 - 6.74 (dd, 1H, J = 8.2, 2.2), 4.30 - 4.25 (q, OCH2CH3, J = 7.1), 
4.22 - 4.17 (q, OCH2CH3, J = 7.0), 1.34 - 1.30 (t, OCH2CH3, J = 7.0), 1.32 - 
1.28(1, OCH2CH3, J = 7.1);
,3C NMR 5 170 (C=0), 168 (C=0), 161, 158, 153, 143, 133, 131 (2C), 125, 
121 (2C), 116, 113, 109, 95, 62 (2C), 15 (2C);
HRMS: [M+H]* C20H22NO5 requires 356.15 found 356.15;
CHN for C20H21NO5 requires C 67.59 H 5.96 N 3.94 found C 67.68 H 5.99 N 
3.88
Diethyl 2-(((3-(benzyloxy)phenyl)amino)methylene)malonate
Synthesised according to general method A to give an off-white solid. 
(4.39 g, yield 92.2%)
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1H NMR (MeOH-d4) 6 8.50 (s, 1H), 7.46 - 7.27 (m, 5H), 6.86 - 6.85 (t, 1H, J 
= 2.2), 6.83 - 6.79 (m, 2H), 4.88 (s, 2H), 4.31 - 4.25 (q, OCHsChh, J = 7.1), 
4.23-4.18 (q, OCK2CH3, J = 7.1), 1.36- 1.32 (t, OCH2CH3, J = 7.1), 1.35- 
1.31 (t, OCH2CH3, J = 7.1);
HRMS: [M+H]+ C21H24NO5 requires 369.16 found 440.13;
CHN for C21H23NO5 requires C 68.28 H 6.28 N 3.79 found C 56.05 H 4.62 N 
3.14.
General Method B: Thermal cyclisation of quinolones
The appropriate diethyl malonate enamine intermediate (10 mmol) was 
added to boiling Dowtherm A® (50 ml) and refluxed for 1 hour. The solution 
was cooled to room temperature and diluted with n-hexane (20 ml). The 
resulting precipitate was collected by filtration, washed with ethyl acetate and 
pulled dry. Reprecipitation from dimethylformamide using n-hexane gave the 
final compounds.
Ethyl 4-oxo-7-phenoxy-1,4-dihydroquinoline-3-carboxylate (4)
Synthesised according to general method B to yield a cream powder.
(2.61 g, yield 61.7%)
Melting point: > 250 °C
1H NMR (DMSO-d6) 6 8.50 (s, 1H), 8.15 - 8.13 (d, 1H, J = 8.9), 7.51 - 7.48 
(appt, 2H), 7.31 - 7.27 (t, 1H, J = 7.4), 7.21 - 7.19 (d, 2H, J = 7.7), 7.08 - 
7.05 (dd, 1H, J = 8.9, 2.4), 6.97 (d, 1H, J = 2.4), 4.22 - 4.17 (q, OCH2CH3, J 
= 7.0), 1.29 - 1.25 (t, OCH2CH3, J = 7.0);
13C NMR 5 168 (C=0), 160 (C=0), 154, 145, 140, 136, 131 (2C), 128, 
125,123, 121 (2C), 116, 104, 60, 15;
HRMS: [M+Hf C^HieNCU requires 310.10 found 310.11;
CHN for C18H15NO4 requires C 69.89 H 4.89 N 4.53 found C 69.74 H 4.75 N 
4.44.
Ethyl 7-(benzyloxy)-4-oxo-1,4-dihydroquinoline-3-carboxylate (5)
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Synthesised according to general method B to yield a white solid.
(2.56 g, yield 66.7%)
Melting point: > 250 °C
1H and 13C NMR data not obtained due to insolubility of compound in all 
available solvents;
HRMS [M+Hf Ci9H18N04 requires 324.1236, found 324.1238;
CHN for C19H17F3NO4 requires C 70.58 H 5.30 N 4.33 found C 70.34 H 5.35 
N 4.29.
Synthesis of 1-nitro-3-(4-(thfluoromethoxy)phenoxy)benzene (9)
o
3-Nitrophenol 7 (1.393 g, 10.01 mmol), caesium carbonate (1.639 g, 5.03 
mmol) and A/,/\/-dimethylglycine (308 mg, 2.99 mmol) were dissolved in 1,4- 
dioxane (4 mL). Copper (I) iodide (208 mg, 1.09 mmol) and 4- 
(trifluoromethoxy)iodobenzene 8 (0.31 mL, 2.0 mmol) were added and the 
reaction mixture heated to ~100 °C with vigorous stirring under nitrogen. 
When no iodobenzene was visible by TLC (10% ethyl acetate/n-hexane) the 
reaction mixture was cooled and poured into aqueous sodium hydroxide (2 
M, 25 mL). The aqueous mixture extracted with dichloromethane (3 x 25 mL) 
and ethyl acetate (2 x 30 mL). The combined organic extracts were dried 
over sodium sulphate and concentrated under reduced pressure. Purification 
by flash column chromatography (Silica gel, 2% Ethyl acetate/petroleum 
ether) gave 9 as a yellow oil.
(348 mg, yield 58.1%)
1H NMR (Acetone-d6) 6 8.05 - 8.03 (dd, 1H, J = 7.7, 1.6), 7.83 - 7.82 (t, 1H, 
J = 2.3), 7.74 - 7.70 (t, 1H, J = 8.2), 7.53 - 7.50 (dd, 1H, J = 8.2, 2.4), 7.46 - 
7.43 (m, 2H), 7.29 - 7.26 (dt, 2H, J = 9.1, 2.4);
13C NMR 6 159, 156, 151, 147, 132, 126, 124, 123, 122, 121, 119, 118, 114;
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HRMS: [M+Naf CiaHaFaNC^Na requires 322.03 found 322.03;
CHN for C13H8F3NO4 requires C 52.19 H 2.70 N 4.68 found C 52.06 H 2.69 N 
4.71.
Synthesis of 3-(4-(trifluoromethoxy)phenoxy)aniline (10)
9 (2.80 g, 9.36 mmol) and zinc powder (20.2 g, 0.3 mol) were suspended 
in ethanol (50 ml_). A solution of calcium chloride (760 mg, 6.85 mmol) in 
water (1.0 mL) was added and the mixture heated to reflux with vigorous 
stirring. When TLC (10% ethyl acetate/petroleum ether) showed complete 
conversion the reaction mixture was cooled and filtered to remove the zinc. 
Solvents were evaporated and the residue purified by flash column 
chromatography (2% ethyl acetate/petroleum ether) to give 10 as an orange 
oil.
(2.31 g, yield 91.8%)
1H NMR (Acetone-d6) 6 7.32 - 7.31 (m, 2H), 7.09 - 7.05 (m, 3H), 6.50 - 
6.47 (m, 1H), 6.36 - 6.34 (t, 1H, J = 2.3), 6.26 - 6.23 (m, 1H). 4.87 (bs, NH2); 
13C NMR 6 159, 158, 151, 145, 132 (2C), 124 (2C), 121 (2C), 112, 110, 107; 
HRMS: [M+Hf C^HnFaNC^ requires 270.07 found 270.07;
CHN for Ci3H1oF3N02 requires C 58.00 H 3.74 N 5.20 found C 58.05 H 3.76 
N 5.18.
Diethyl 2-(((3-(4-(trifluoromethoxy)phenoxy)phenyl)amino)methylene)
malonate
Synthesised from 10 according to general method A to yield off-white 
crystals.
(4.79 g, yield 89.9%)
1H NMR (MeOH-d4) 6 8.47 (s, 1H), 7.41 - 7.37 (t, 1H, J = 8.2), 7.31 - 7.28 
(m, 2H), 7.13 - 7.10 (dt, 2H, J = 9.1, 2.2), 7.04 - 7.01 (dd, 1H, J = 8.0, 2.2), 
6.95 - 6.94 (t, 1H, J = 2.2), 6.80 - 6.77 (dd, 1H, J = 8.2, 2.2), 4.30 - 4.24 (q,
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OCH2CH3, J = 7.2), 4.23 - 4.17 (q, OCH2CH3, J = 7.1), 1.34 - 1.30 (t, 
OCH2CH3, J = 7.1), 1.32 - 1.28 (t, OCH2CH3, J = 7.2);
13C NMR 5 170 (C=0), 168 (C=0), 160, 157, 153, 143, 133, 124 (2C), 122 
(2C), 116, 114, 109, 101, 95, 62 (2C), 15 (2C);
HRMS: [M+H]+ C21H21F3NO6 requires 440.13 found 440.13;
CHN for C21H20F3NO6 requires C 57.40 H 4.59 N 3.19 found C 56.05 H 4.62 
N 3.14.
Ethyl 4-oxo-7-(4-(trifluoromethoxy)phenoxy)-1 A-dihydroquinoHne-3-
carboxylate (6)
Synthesised according to general method B to yield a beige solid.
(3.39 g, yield 79.8%)
Melting point: > 250 °C
1H NMR (DMSO-d6) 6 12.13 (bs, NH), 8.73 (s, 1H), 8.36 (d, 1H, J = 8.9), 
7.72 - 7.69 (d, 2H, J = 8.8), 7.57 - 7.52 (dt, 2H, J = 9.0, 3.6), 7.35 - 7.31 (dd, 
1H, J = 8.9, 2.4), 7.22 (d, 1H, J = 2.3), 4.45 - 4.36 (q, OCH2CH3, J = 7.1), 
1.50-1.38 (t, OCH2CH3, J = 7.1);
,3C NMR 6 176 (C=0), 164, 151, 147, 145, 142, 137, 133 (2C), 129, 
127,122, 119 (2C), 113, 107,64, 13;
HRMS: [M+H]+ C19H15F3NO5 requires 394.09 found 394.09;
CHN for C19H14F3NO5 requires C 58.02 H 3.59 N 3.56 found C 58.29 H 3.69 
N 3.34.
General Method C: Amide Synthesis
Dowtherm A® (25 ml_) was heated to boiling point. 6 (1 g, 2.5 mmol) was 
added followed by the appropriate amine (5 mmol). The temperature was 
reduced to ~ 120 °C and the reaction mixture left for 1 hour. Cooling to room 
temperature and dilution with n-hexane (20 mL) resulted in a precipitate that 
was collected by filtration. Purification by column chromatography 
(methanol/dichloromethane) gave the pure amides in moderate yields.
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3-(Piperidine-1-carbonyl)-7-(4-(trifluoromethoxy)phenoxy)quinolin-4(1H)-one
(7)
Synthesised according to general method C to yield an off-white powder. 
Melting point: > 250 °C 
(100 mg, yield 45.1%)
'H NMR (DMSO-d6) 8 8.16 (d, 1H, J = 8.9), 8.04 (s, 1H), 7.51 - 7.49 (d, 2H, 
J = 8.8), 7.33-7.31 (dt, 2H, J = 9.0, 2.3), 7.11 -7.08 (dd, 1H, 8.9, 2.4),
7.02 (d, 1H, J = 2.4), 3.56 (bs, 2H), 3.23 (bs, 2H), 1.60 (bs, 2H), 1.50 (bs, 
4H);
,3C NMR 6 172 (C=0), 165, 160, 154, 141, 140, 128, 123 (2C), 122 (2C), 
119, 115, 105, 48 (2C), 42 (2C), 26, 25, 24;
HRMS: [M+Na]* C22H,9F3N204Na requires 455.1195, found 455.1196;
CHN for C22H19F3N2O4 requires C 61.11 H 4.43 N 6.48 found C 60.64 H 4.22 
N 6.21.
3-(4-Methylpiperazine-1-carbonyl)-7-(4-(trifluoromethoxy)phenoxy) quinolin- 
4(1 H)-one (8)
F,
F
O O
Synthesised according to general method C to yield a.
(309 mg, yield 55.4%)
Melting point: > 250 °C
1H NMR (MeOH-d4) 6 8.27 (d, 1H, J = 9.0), 8.05 (s, 1H), 7.41 - 7.38 (d, 2H, 
J = 8.7), 7.27 - 7.24 (dt, 2H, J = 9.0, 2.1), 7.17 - 7.14 (dd, 1H, J = 9.0, 2.3), 
6.97 (d, 1H, J = 2.3), 3.78 (bs, Chb), 3.44 (bs, CH2), 2.54 (bs, Chh), 2.49 (bs, 
CH2), 2.32 (s, NCH3);
13C NMR 6 176, 169, 163, 156, 147, 143, 142, 130, 125 (2H), 123 (2H), 119, 
118 (2H), 106 (2H), 101, 57, 55, 46;
HRMS: [M+H]+ C22H21F3N3O4 requires 448.1484, found 448.1474;
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CHN for C22H20F3N3O4 requires C 59.06 H 4.51 N 9.34 found C 58.81 H 4.45 
N 9.35.
3-(4-Ethylpiperazine-1-carbonyl)-7-(4-(trifluoromethoxy)phenoxy) quinolin- 
4(1 H)-one (9)
Synthesised according to general method C to yield a beige powder.
(201 mg, yield 87.8%)
Melting point: 246 - 248 °C (decomp.)
1H NMR (DMSO-d6) 5 8.27 (d, 1H, J = 9.0), 8.05 (s, 1H), 7.40 - 7.38 (d, 2H, 
J = 8.8), 7.26 - 7.24 (dt, 2H, J = 9.1, 2.3), 7.17 - 7.14 (dd, 1H, J = 9.1, 2.3), 
6.97 (d, 1H, J = 2.3), 3.79 (bs, CHa). 3.45 (bs, Chh), 2.58 (bs, Chh), 2.53 (bs, 
Chb), 2.51-2.46 (q, NCH2CH3, J = 7.2), 1.14-1.10 (t, NCH2CH3, J = 7.2); 
13C NMR 6 221, 176, 168, 163, 156, 142, 129, 125 (2C), 123 (2C), 119, 118, 
106, 54, 53, 12;
HRMS: [M+Na]+ C23H22F3N304Na requires 484.1460 found 484.1472;
CHN for C23H22F3N3O4 requires C 59.87 H 4.81 N 9.11 found C 59.70 H 4.84
N 9.14.
4-Oxo-N-(2-(pyrrolidin-1-yl)ethyl)-7-(4-(trifluoromethoxy)phenoxy)-1,4- 
dihydroquinoline-3-carboxamide (10)
Synthesised according to general method C to yield a pale yellow solid. 
(460 mg, yield 39.5%)
Melting point: 188 - 192 °C
'H NMR (DMSO-d6) 8 8.69 (s, 1H), 8.34 (d, 1H, J = 9.0), 7.39 (d, 2H, J = 
8.5), 7.38 - 7.25 (m, 2H), 7.19 - 7.17 (dd, 1H, J = 9.0, 2.4), 6.99 (d, 1H, J = 
2.3), 3.64 - 3.61 (t, CHaCHa, J = 6.7), 2.82 - 2.79 (t, CHaCHa, J = 6.7), 2.73 - 
2.69 (t, 4H, J = 6.6), 1.87 - 1.83 (m, 4H);
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13C NMR 6 175, 146, 133, 130, 125 (2C), 123 (2C), 118, 106, 101 (2C), 57, 
55 (2C), 39, 24 (2C);
HRMS: [M+Hf C23H23F3N304 requires 462.1641 found 462.1656;
CHN for C23H22F3N3O4 requires C 59.87 H 4.81 N 9.11 found C 59.69 H 4.87 
N 9.07.
Synthesis of N-( 5-(diethylamino)pentan-2-yl)-4-oxo- 7-phenoxy-1,4-
dihydroquinoline-3-carboxamide (11)
4 (252 mg, 0.82 mmol) was suspended in Dowtherm A (10 mL). 4-amino- 
1-diethylaminopentane (0.8 mL, 4.1 mmol) was added and the mixture 
heated to 200 °C for 2 hours. Resulting orange solution concentrated under 
reduced pressure to give an orange oil. Residue taken up in dichloromethane 
(30 mL) and extracted with aqueous HCI (2N, 2 x 40 mL). Aqueous extracts 
neutralised with saturated aqueous NaOH and extracted with ethyl acetate (2 
x 70 mL). Organic extracts dried over magnesium sulphate and concentrated. 
Purification by flash column chromatography (1% methanol/dichloromethane) 
gave a hygroscopic yellow waxy solid.
(103 mg, yield 30.0%)
1H NMR (CDCIs) 6 10.24 - 10.22 (d, NH, J = 8.4), 8.66 (s, 1H), 8.29 - 8.27 
(d, 1H, J = 9.0), 7.41 - 7.37 (<w,t, 2H), 7.22 - 7.18 (t, 1H, J = 7.5), 7.12 - 
7.10 (d, 2H, J = 8.3), 7.07 - 7.05 (dd, 1H, J = 9.0, 2.2), 6.92 - 6.91 (d, 1H, J 
= 2.1), 4.20 - 4.07 (m, NCHCH3), 2.55 - 2.50 (q, 2 NCH2CH3, J = 6.9), 2.45 - 
2.36 (m, 2H), 1.52 (bs, 4H), 1.22 - 1.20 (d, NCHCH3, J = 6.6), 0.98 - 0.95 (t, 
2 NCH2CH3, J = 7.1);
13C NMR 5 177 (C=0), 165, 162 (C=0), 155, 144, 141, 130 (2C), 129, 125, 
122, 121 (2C), 117, 112, 105, 53, 47 (2C), 45, 35, 32, 22, 11 (2C);
HRMS: [M+H]* C25H32N3O3 requires 422.2444, found 422.2442;
CHN for C25H31N3O3 requires C 71.23 H 7.41 N 9.97, found C 68.67 H 7.38 N 
8.17 (5% H20 present).
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Synthesis of 7-phenoxyquinolin-4(1 H)-one (12)
4 (299 mg, 0.97 mmol) was suspended in methanol (5 mL). NaOH soln. 
(10% aq., 7.5 mL) was added and the mixture heated at 100 °C for 1 hour. 
The resulting solution was cooled to room temperature and acidified by 
addition of HCI soln. (10% aq.) until a precipitate was observed. The solid 
was collected by filtration, washed with chloroform (30 mL) and methanol (10 
mL) and pulled dry to yield crude 4-oxo-7-phenoxy-1,4-dihydroquinoline-3- 
carboxylic acid (260 mg).
The crude carboxylic acid was added to boiling Dowtherm A (20 mL) and 
reflux was maintained for 1 hour. The reaction mixture was cooled to room 
temperature and purified by flash column chromatography (Silica gel, 3% 
methanol/chloroform) to yield 12 as a cream powder.
(203 mg, yield 88.4%)
Melting point: 178-181 °C
1H NMR (MeOD-d4) 6 8.23 - 8.20 (d, 1H, J = 9.1), 7.87 - 7.85 (d, 1H, J = 
7.3), 7.48 - 7.44 (t, 2H, J = 7.8), 7.28 - 7.24 (^t, 2H), 7.15 - 7.13 (d, 2H, J 
= 7.7), 7.11 - 7.08 (dd, 1H, J = 9.1,2.3), 6.90 (d, 1H, J = 2.3), 6.27 - 6.25 (d, 
1H, J = 7.3);
13C NMR 5 180 (C=0), 164, 157, 144, 142, 132 (2C), 129, 127, 123, 122 
(2C), 117, 110, 105;
HRMS: [M+H]* C^H^NCb requires 238.0868, found 238.0872;
CHN for C15H11N02 requires C 75.94 H 4.67 N 5.90, found C 75.74 H 4.64 N 
5.88.
Synthesis of ethyl 2-cyano-3-((3-phenoxypheny!)amino)acrylate (14)
3-phenoxyaniline 2 (2.05 g, 11.05 mmol) and
ethyl(ethoxymethylene)cyanoacetate 13 (1.87 g, 11.05 mmol) were mixed in
-80-
ethanol (10 mL) and heated to 100 °C overnight. The resulting brown soln. 
was cooled and the product precipitated by addition of petroleum ether (40 
mL). The solid was recovered by filtration, pulled dry and dried in a vacuum 
desiccator for 24 hours to yield ethyl 2-cyano-3-((3- 
phenoxyphenyl)amino)acrylate 14 as a mixture of E and Z isomers, as a pale 
brown solid.
(3.23 g, yield 94.6%)
’H NMR (MeOD-d4) 5 8.39 (s. 1H, £), 8.27 (s, 1H. Z), 7.4 - 7.35 (m, 3H), 
7.17-7.14 (t, 1H, J = 7.3), 7.04-7.02 (m, 3H), 6.98-6.93 (dt, 1H, J= 13.5, 
2.2), 6.78-6.74 (m, 1H), 4.30-4.25 (q, CH2CH3, E, J = 7.1), 4.26-4.21 (q, 
OCH2CH3, Z,J = 7.1), 1.34 - 1.30 (t, OCH2CH3, E,J = 7.1), 1.32 - 1.29 (t, 
CH2CH3,Z, J = 7.1);
13C 5 169/167 (E/Z C=0), 161, 158, 154/153 (E/Z), 143/142 (£/Z), 134, 132 
(2C), 125, 121 (2C), 119, 117, 116, 113, 110, 109, 77, 59/58 (BZ), 15;
HRMS: [M+NH4r C18H20N3O3 requires 326.1505, found 326.1509;
CHN for CiaHieNjOs requires C 70.12 H 5.23 N 9.09, found C 70.05 H 5.23 N 
9.06.
Synthesis of 4-oxo- 7-phenoxy-1,4-dihydroquinoline-3-carbonitrile (15)
Ethyl 2-cyano-3-((3-phenoxyphenyl)amino)acrylate 14 (320 mg, 1.04 
mmol) was dissolved in hot Dowtherm A (5 mL) and heated to reflux 
overnight. The resulting solution was cooled to room temperature and poured 
into n-hexane (50 mL) resulting in a brown precipitate. Solid recovered by 
vacuum filtration, washed with n-hexane and dried under suction to yield 15 
as a dark tan solid.
(239 mg, yield 87.9%)
Melting point: 171 -175 °C (decomp.)
'H NMR (DMSO-d6) 5 12.61 (bs, NH), 8.67 (s, 1H), 8.14 - 8.12 (d, 1H, J = 
8.8), 7.53 - 7.49 (‘"*'1, 2H), 7.33 - 7.29 (t, 1H, J = 7.1), 7.22 - 7.20 (d, 2H, J 
= 8.3), 7.17 - 7.14 (dd, 1H, J= 8.8, 2.3), 6.98 (d, 1H, J = 2.3);
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13C NMR 5 174.1 (C=0), 161.7, 154.8, 147.3, 141.3, 130.9 (2C), 128.0, 
125.7, 120.9 (2C), 117.2, 116.7, 105.0, 99.5, 94.0;
HRMS: [M+H]* C16HHN2O2 requires 263.0821, found 263.0817;
CHN for C16H10N2O2 requires C 73.27 H 3.84 N 10.68, found C 73.00 H 3.79 
N 10.58.
Synthesis of ethyl 4-chloro-7-phenoxyquinoline-3-carboxylate (17)
Cl o
4 (0.76 g, 2.5 mmol) was dissolved in phosphoryl chloride (5 mL) under a 
nitrogen atmosphere. The resulting yellow solution was heated to reflux for 
V/2 hours before being poured onto ice (200 ml) and being left to stir 
overnight. The resulting aqueous solution was extracted with 
dichloromethane (2 x 250 mL) and the organic extracts dried over 
magnesium sulphate before evaporation to give 17 as a yellow solid.
(0.74 g, yield 91.6%)
Melting point: 105 - 108 °C (decomp.)
'H NMR (CDCb) 6 9.15 (s, 1H), 8.41 - 8.39 (d, 1H, J = 9.3), 7.51 - 7.43 (m, 
4H), 7.28 - 7.24 (m, 1H), 7.17-7.15 (d, 2H, J = 7.8), 4.51 - 4.46 (q, 2H, J = 
7.1), 1.46-1.44 (t,3H,J = 7.1);
13C NMR 6 165 (C=0), 162, 155, 151, 127 (2C), 126, 123, 122, 121 (2C), 
113,62, 15;
HRMS: [M+H]* Ci8Hi535CIN03 requires 328.0740, found 328.0724;
CHN for CieH1435CIN03 requires C 65.96 H 4.31 N 4.27, found C 65.37 H 
4.32 N 5.10.
Synthesis of 7-phenoxy-2H-pyrazolo[4,3-c]quinolin-3(5H)-one (16)
17 (0.50 g, 1.5 mmol) was dissolved in dry 1,4-dioxane (5 mL) under a 
nitrogen atmosphere. Hydrazine hydrate (0.50 mL, 3.1 mmol) was added 
slowly and the resulting solution heated to 80 °C. After - 30 minutes a yellow
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precipitate was observed. Solid recovered by filtration, washed with 
petroleum ether and water and dried in a vacuum desiccator for 48 hours to 
yield a bright yellow powder.
(0.41 g, yield 97.4%)
Melting point: > 250 °C
1H NMR (DMSO-d6) 5 12.29 (s, NH), 11.32 (s, NH), 8.48 - 8.47 (d, 1H, J = 
5.9), 8.07 - 8.05 (d, 1H, J = 8.7), 7.50 - 7.46 (appt, 2H), 7.27 - 7.24 (t, 1H, J 
= 7.4), 7.18-7.13 (m,4H);
13C NMR 6 169.5, 163.4, 158.2, 141.5, 138.7, 136.9, 130.7 (2C), 124.9, 
124.1, 120.1 (2C), 117.3, 112.3, 106.7, 94.7;
HRMS: [M+H]* CieH^NsOj requires 278.0930, found 278.0916;
CHN for C16HHN3O2 requires C 69.31 H 4.00 N 15.15, found C 64.81 H 4.39 
N 14.19.
General Method D: Transesterification of 4
4 (0.2 g, 0.65 mmol) was dissolved in an appropriate alcohol (10 mL). A 
catalytic quantity of titanium (IV) isopropoxide was added and the solution 
heated to reflux for 24 hours. Reaction mixture preabsorbed onto silica and 
purified by column chromatography eluting with ethanol in chloroform. The 
solid product was then washed with ethanol and dried in a desiccator.
Isopropyl 4-oxo- 7-phenoxy-1.4-dihydroquinoline-3-carboxylate (18)
Synthesised from 4 according to general method D to yield a white solid. 
(64.4 mg, yield 32.4%)
Melting point: > 250 °C
'H NMR (DMSO-d6) 6 12.09 (bs, NH), 8.45 (s, 1H), 8.13 (d, 1H, J = 8.9), 
7.52 - 7.48 (appt, 2H), 7.31 - 7.28 (appt, 1H), 7.22 - 7.19 (d, 2H, J = 8.1), 
7.10 - 7.08 (dd, 1H, J = 8.9, 2.0), 6.97 (d, 1H, J = 1.9), 5.08 - 4.99 (m, 
CH(CH3)2, J = 6.2), 1.27 (d, CH(CH3)2, J = 6.2);
,3C NMR 5 173 (C=0), 164, 161, 155, 145, 141, 131 (2C), 128, 125, 123, 
121 (2C), 116, 110, 104, 67, 38, 22;
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HRMS: [M+H]+ C19H18NO4 requires 324.1236, found 324.1232;
CHN for Ci9H17N04 requires C 70.58 H 5.30 N 4.33 found C 69.79 H 5.20 N 
4.17.
Cyclopentyl 4-oxo- 7-phenoxy-1,4-dihydroquinoline-3-carboxylate (19)
Synthesised from 4 according to general method D to yield a cream solid. 
(116 mg, yield 68.6%)
Melting point: > 250 °C
1H NMR (DMSO-d6) 6 12.12 (bs, NH), 8.49 (s, 1H), 8.19 (d, 1H, J = 8.9), 
7.58 - 7.54 (appt, 2H), 7.37 - 7.33 (appt, 1H), 7.27 - 7.25 (d, 2H, J = 8.2), 
7.15 - 7.12 (dd, 1H, J = 8.9, 2.2), 7.03 (d, 1H, J = 2.2), 5.28 - 5.25 (m, 
OCH), 1.94-1.63 (m, 8H);
13C NMR 5 172, 161, 155, 145, 131 (2C), 128, 125, 122, 121 (2C), 116, 110, 
105, 76, 32 (2C), 24 (2C);
HRMS: [M+Hf C21H20NO4 requires 350.1392 found 350.1400;
CHN for C21H19NO4 requires C 72.19 H 5.48 N 4.01 found C 70.05 H 5.35 N 
3.59.
Cyclohexyl 4-oxo- 7-phenoxy-1,4-dihydroquinoline-3-carboxylate (20)
Synthesised from 4 according to general method D to yield a white 
powder.
(115 mg, yield 31.3%)
Melting point: > 250 °C
1H NMR (DMSO-d6) 5 12.06 (bs, NH), 8.46 (s, 1H), 8.14 (d, 1H, J = 8.9), 
7.52 - 7.48 (t, 2H, J = 7.9), 7.31 - 7.27 (t, 1H, J = 7.4), 7.21 - 7.19 (d, 2H, J 
= 7.9), 7.10 - 7.07 (dd, 1H, J = 8.9, 2.4), 6.97 (d, 1H, 2.4), 4.86 - 4.81 (m, 
OCH), 1.82 (bs, 2H), 1.74 (bs, 2H), 1.52 - 1.45 (m, 3H), 1.41 - 1.28 (m, 3H);
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13C NMR 6 207 (C=0), 173 (C=0), 161, 155, 145, 131 (2C), 128, 125, 123, 
121 (2C), 116, 111, 104, 71, 31 (4C), 25, 23;
HRMS: [M+Naf C22H2iN04Na requires 386.1368, found 386.1362;
CNN for C22H21NO4 requires C 72.71 H 5.82 N 3.85 found C 72.29 H 5.77 N 
3.75.
Synthesis of ethyl 7-benzyl-4-oxo-1,4-dihydroquinoline-3-carboxylate (22)
3-benzylaniline 21 (275 mg, 1.5 mmol) was stirred gently in diethyl 
ethoxymethylenemalonate 1 (0.30 mL, 1.5 mmol) and heated to 100 °C 
overnight. Dilution with petroleum ether (5 mL) and cooling in an ice/acetone 
bath resulted in a cream solid, recovered by filtration and pulled dry.
Crude diethyl 2-(((3-benzylphenyl)amino)methylene)malonate (519 mg) 
was added to boiling Dowtherm A (5 mL) and refluxed for 2.5 hours. The 
resulting solution was cooled to room temperature and poured in to n-hexane 
(25 mL). Solid collected by filtration, washed with diethyl ether, pulled dry and 
dried in a vacuum desiccator to yield 22 as a white powder.
(247 mg, yield 57.4 %)
Melting point: 242 - 246 °C (decomp.)
’H NMR (DMSO-d6) 6 12.22 (bs, NH), 8.48 (s, 1H), 8.08 - 8.06 (d, 1H, J = 
8.3), 7.37 - 7.21 (m, 7H), 4.22 - 4.17 (q, OCH2CH3, J = 7.0), 4.09 (s, 
ArCHjAr), 1.29 - 1.25 (t, OCH2CH3, J = 7.1);
13C NMR 5 178 (C=0), 174 (C=0), 165, 146, 145, 140, 139, 129 (2C), 128 
(2C), 127, 126 (2C), 125, 118, 60, 41, 15;
HRMS: [M+Na]+ CigHirNOsNa requires 330.1106 found 330.1111;
CHN for C19H17NO3 requires C 74.25 H 5.58 N 4.56 found C 74.24 H 5.60 N 
4.61.
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Synthesis of 1-nitro-3-((4-(trifluoromethoxy)benzyl)oxy)benzene (24)
3-Nitrophenol 7 (4.09 g, 29.4 mmol) and cesium carbonate (9.84 g, 30.2 
mmol) were dissolved in acetonitrile (25 mL). 4-(trifluoromethoxy)benzyl 
bromide 23 (2.0 ml, 12.5 mmol) was added and the mixture heated to reflux. 
Thin layer chromatography showed complete reaction after 2 hours. The 
reaction mixture was cooled to room temperature and the resulting inorganic 
precipitate screened off by filtration. The organic filtrate was concentrated 
directly onto silica gel and purified by column chromatography (0.5% 
methanol/3% ethyl acetate/96.5% petroleum ether). Product 24 was obtained 
as a yellow liquid.
(3.34 g, yield 85.9%)
'H NMR (Acetone-d6) 5 7.88 - 7.83 (m, 2H), 7.71 - 7.37 (m, 6H), 5.3 (s, 
OCH2Ar);
HRMS: [M+Na]+ C^HioFaNC^Na requires 336.0460, found 336.0476.
Synthesis of 3-((4-(trifluoromethoxy)benzyl)oxy)aniline (25)
24 (3.32 g, 10.6 mmol) and zinc powder (21.53 g, 0.3 mol) were 
suspended in ethanol (50 mL). Calcium chloride (0.83 g, 7.48 mmol) and 
water (2 mL) were added and the mixture heated to reflux (90 °C) overnight. 
The cooled reaction mixture was filtered to remove inorganic solids and the 
filtrate concentrated under reduced pressure to yield an off-white solid with 
brown impurities. Recrystallisation from hot ethyl acetate gave 25 as beige 
flakes.
(2.72 g, yield 91.2%)
1H NMR (Acetone-d6) 6 7.64 - 7.59 (m, 2H), 7.38 - 7.35 (m, 2H), 6.98 - 6.94 
(t, 1H, J = 8.0), 6.37 - 6.36 (t, 1H, J = 2.2), 6.31 - 6.26 (m, 2H), 5.08 (s, 
OCHUAr);
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13C NMR5 161, 151, 139, 131 (2C), 130 (2C), 122, 113, 109, 107, 104, 102, 
69;
HRMS: [M+H]+ C14H13F3NO2 requires 284.0898, found 284.0906;
CHN for Ci4H12F3N02 requires C 59.37 H 4.27 N 4.95, found C 55.98 H 4.21 
N 4.35.
Synthesis of ethyl 4-oxo-7-((4-(trifluoromethoxy)benzyl)oxy)-1,4-
dihydroquinoline-3-carboxylate (26)
25 (2.65 g, 9.4 mmol) was dissolved in diethyl ethoxymethylenemalonate 
1 (1.90 mL, 9.5 mmol) and ethanol (3 mL). The solution was heated to reflux 
overnight with vigorous stirring. Addition of the cooled solution to n-hexane 
(20 mL) resulted in an off-white precipitate, recovered by filtration and pulled 
dry to give crude diethyl 2-(((3-((4-(trifluoromethoxy)benzyl)oxy)phenyl) 
amino)methylene)malonate.
Crude intermediate was added to boiling Dowtherm A (15 mL) and 
refluxed for 2 hours. The resulting solution was cooled and poured into n- 
hexane (50 mL) to yield a fine brown powder. Recrystallisation from hot 
acetone gave 26 as fine beige crystals.
(0.609 g, yield 16.0%)
Melting point: > 250 °C
1H NMR (DMSO-d6) 6 11.57 - 11.55 (bs, NH), 8.81 (s, 1H), 8.25 - 8.23 (d, 
1H, J = 8.8), 7.29 - 7.21 (m, 3H), 7.00 - 6.99 (m, 2H), 6.76 - 6.74 (d, 1H, J = 
7.1), 5.26 (s, 2H), 4.23 - 4.17 (q, OCH2CH3, J = 7.0), 1.29 - 1.25 (t, 
OCH2CH3, J = 7.1);
13C NMR not obtained due to poor product solubility;
HRMS: [M+H]* C20H17F3NO5 requires 408.1059 found 408.1079;
CHN for C20H16F3NO5 requires C 58.97 H 3.96 N 3.44 found C 58.68 H 3.86 
N 3.37.
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Synthesis of 1-benzyl-4-(3-nitrophenyl)piperazine (30)
o
n-1+
A/-benzylpiperazine 29 (6.5 mL, 37.6 mmol) was added to a stirring 
mixture of 3-fluoronitrobenzene 28 (2.0 mL, 18.8 mmol) and potassium 
carbonate (3.94 g, 28.2 mmol) in dimethylsulphoxide under a nitrogen 
atmosphere. The mixture was heated to 90 °C and the reaction followed by 
TLC. After ~ 40 hours starting material was still evident however the reaction 
was quenched by cooling to room temperature and pouring in to ethyl acetate 
(50 ml). The resulting solution was washed with water (2 x 75 mL) and brine 
(75 mL) before being dried over sodium sulphate and being concentrated to 
give a viscous orange liquid. Column chromatography (10 %
methanol/dichloromethane) gave the pure product 30 as an orange oil.
(3.49 g, yield 62.5%)
1H NMR (Acetone-d6) 6 7.71 - 7.25 (m, 9H), 3.58 (s, NChhAr), 3.36 - 3.33 (t, 
4H, J = 5.0), 2.62 - 2.60 (t, 4H, J = 5.1);
,3C NMR 6 153.5, 150, 139.8 131.2, 130.2 (2C), 129.5 (2C), 128.3, 122.3, 
114.0, 110.1, 63.8, 53.9 (2C), 49.4 (2C);
HRMS: [M+H]* CizhfeoNsOa requires 298.1556, found 298.1555;
CHN for C17H-19N3O2 requires C 68.67 H 6.44 N 14.13, found C 68.66 H 6.48 
N 14.18.
Synthesis of 3-(4-benzylpiperazin-1-yl)aniline (31)
30 (3.30 g, 11.2 mmol) was dissolved in ethyl acetate (110 mL). Tin (II) 
chloride dihydrate (12.6 g, 55.8 mmol) was added and the resulting lemon 
yellow solution heated to 80 °C for 2 hours. Reaction mixture was then 
poured into water (200 mL) and basified with saturated NaHCC>3(aq ) solution 
to pH 8. Inorganic precipitate removed by filtration and the aqueous filtrate 
extracted with ethyl acetate (4 x 50 mL). The combined organic layers were
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dried over sodium sulphate and the solvents evaporated to yield the product 
as an off-white solid.
(1.92 g, yield 64.1%)
Melting point: 150 - 154 °C
1H NMR (Acetone-d6) 6 7.38 - 7.25 (m, 5H), 6.91 -6.87 (t, 1H, J=8.0), 6.28 
- 6.27 (t, 1H, J = 2.2), 6.22 - 6.19 (m, 2H), 4.4 (bs, NH2), 3.53 (s, ArCfcbN), 
3.11 - 3.09 (t, 4H, J = 4.9), 2.54 - 2.52 (t, 4H, J = 5.0);
13C NMR 6 154.5, 150.2, 139.8, 130.5, 130.2 (2C), 129.4 (2C), 128.2, 107.4, 
106.4, 103.4, 63.9, 54.4 (2C), 50.3 (2C);
HRMS: [M+H]+ C17H22N3 requires 268.1814, found 268.1804;
CHN for C17H21N3 requires C 76.37 H 7.92 N 15.72, found C 76.03 H 7.88 N 
15.26.
Synthesis of ethyl 7-(4-benzylpiperazin-1 -yl)-4-oxo-1,4-dihydroquinoline-3- 
carboxylate (27)
31 (1.09 g, 4.1 mmol) was dissolved in diethyl ethoxymethylenemalonate 
1 (0.82 mL, 4.1 mmol) and ethanol (2.5 mL) and the solution was stirred at 90 
°C overnight. Evaporation of the volatile components gave crude diethyl 2- 
(((3-(4-benzylpiperazin-1-yl)phenyl)amino)methylene)malonate as a brown 
oil. This was added Dowtherm A (7.5 mL) and heated to reflux for 30 minutes 
after which the temperature was reduced to 200 °C for 1 hour. The cooled 
reaction mixture formed a semi-solid brown gel. Filtration and extensive 
washing of the gel with diethyl ether yielded a beige powder.
(0.58 g, yield 36.1%)
Melting point: > 250 °C
1H NMR (DMSO-d6) 6 11.86 (bs, NH), 8.40 (s, 1H), 7.94 - 7.92 (d, 1H, J = 
9.1), 7.36 - 7.28 (m, 5H), 7.11 - 7.09 (d, 1H, J = 9.1), 6.80 (s, 1H), 4.21 - 
4.16 (q, OCH2CH3, J = 7.1), 3.54 (s, NCthAr), 3.31 (bs, 4H), 2.51 (bs, 4H), 
1.28 - 1.25 (t, OCH2CH3, J = 7.1);
,3C NMR not obtained due to poor product solubility;
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HRMS: [M+Na]+ C23H25N303Na requires 414.1794, found 414.1807;
CHN for C23H25N3O3 requires C 70.57 H 6.44 N 10.73, found C 70.73 H 6.43 
N 10.68.
Synthesis of 3'-nitro-[1,1 '-biphenyl]-4-ol (35)
Palladium bis(dicyclohexylamine)diacetate (0.78 g, 0.13 mmol) was 
dissolved in ethanol (45 mL). Potassium phosphate (2.76 g, 13.0 mmol) was 
added followed by 1-bromo-3-nitrobenzene 33 (1.38 g, 6.83 mmol) and 4- 
methoxybenzeneboronic acid 34 (1.21 g, 7.96 mmol). Reaction mixture 
refluxed with vigorous stirring for 4 hours. Diluted with ethyl acetate (250 mL), 
washed with brine (2 x 100 mL) and dried over sodium sulphate. Column 
chromatography (5% ethyl acetate/petroleum ether) gave 4'-methoxy-3-nitro- 
1,1'-biphenyl (1.29 g, 82.1%). Dissolved in dry dichloromethane (45 mL) and 
saturated with N2 gas at -78 °C. Tribromoboron solution (5 mL, 1M in 
dichloromethane) was added dropwise by syringe over the course of 5 
minutes. Temperature maintained at -78 °C for 3 hours, before warming to 
room temperature and stirring overnight. Diluted with dichloromethane (30 
mL) and washed with water (3 x 50 mL). Organic phase dried over 
magnesium sulphate and absorbed on to silica gel. Column chromatography 
(2 < 20% ethyl acetate/petroleum ether) furnished the product 35 as a 
crystalline yellow solid.
(1.04 g, yield 86.7%)
'H NMR (Acetone-d6) 5 8.71 (s, 1H), 8.41 - 8.40 (t, 1H, J = 2.0), 8.17 - 8.14 
(dd, 1H, J = 8.2, 2.2), 8.06 - 8.04 (d, 1H, J = 7.9), 7.74 - 7.70 (t, 1H, J = 8.0), 
7.67 - 7.63 (m, 2H), 7.02 - 6.99 (m, 2H);
13C NMR 6 159.5, 150.2, 143.9, 133.7, 131.4, 131.0, 129.6 (2C), 122.3, 
121.8, 117.3 (2C);
HRMS: [M+Na]* C^HgNOsNa requires 238.0480, found 238.0474;
CHN for C12H9NO3 requires C 66.97 H 4.22 N 6.51, found C 66.92 H4.20 N 
6.49.
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Synthesis of 4-(2-((3'-nitro-[1,1'-biphenyl]-4-yl)oxy)ethyl)morpholine (37)
35 (0.28 g, 1.3 mmol) dissolved in anhydrous acetonitrile. Powdered 
sodium hydroxide (0.21 g, 5.2 mmol) and tetrabutylammonium hydrogen 
sulphate (0.92 g, 0.27 mmol) were added and the resulting orange mixture 
stirred at room temperature for 30 minutes during which time sodium chloride 
is observed to precipitate from the solution. /V-(2-chloroethyl)morpholine 
(0.49 g, 2.6 mmol) added and the solution heated to 60 °C overnight. Filtered 
to remove inorganic precipitate, solid washed with dichloromethane (50 mL), 
washings combined with filtrate and concentrated under reduced pressure. 
Residue dissolved in ethyl acetate (50 mL) and washed with water (25 mL) 
and brine (25 mL) before drying over magnesium sulphate. Solvents 
removed and product crystallised under high vacuum to yield orange crystals. 
(0.37 g, yield 86.1%)
1H NMR (Acetone-d6) 5 8.43 - 8.42 (t, 1H, J = 2.0), 8.19 - 8.16 (dd, 1H, J = 
8.2, 2.2), 8.10 - 8.08 (d, 1H, J = 7.8), 7.76 - 7.72 (m, 3H), 7.13 - 7.09 (m, 
2H), 4.23 - 4.20 (t, 2H, J = 5.8), 3.64 - 3.61 (app t, 4H), 2.80 - 2.77 (t, 2H, J = 
5.8), 2.56-2.53 (appt,4H);
13C NMR 5 150.2, 133.8, 132.3, 132.1, 131.4, 129.6 (2C), 122.5, 122.0, 
116.5 (2C), 100.9, 67.9 (2C), 67.4, 58.7, 55.4 (2C);
HRMS: [M+H]+ C18H21N2O4 requires 329.1501, found 329.1516.
Synthesis of 4'-(2-morpholinoethoxy)-[1,1 '-biphenyl]-3-amine (38)
37 (0.59 g, 1.8 mmol) dissolved in ethyl acetate (18 mL). Tin (II) chloride 
dihydrate (2.1 g) added and the reaction mixture heated to reflux overnight. 
Diluted with water (50 mL) and saturated sodium hydrogencarbonate added 
until - pH 8. Inorganic precipitate filtered out and washed with ethyl acetate 
(100 mL), the aqueous filtrate extracted with ethyl acetate (2 x 50 mL).
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Organic extracts and washings combined and washed with brine (50 ml_) 
before drying over sodium sulphate. Solvents removed to yield 38 as a yellow 
oil.
(0.39 g, 72.0%)
1H NMR (Acetone-d6) 5 7.52 - 7.50 (m, 2H), 7.12 - 7.08 (t, 1H, J = 7.8), 7.01
- 6.98 (m, 2H), 6.91 - 6.90 (t, 1H, J = 2.0), 6.83 - 6.81(d,1H,J = 7.7), 6.62
-6.60 (dd, 1H, J= 7.9, 2.1), 4.68 (bs, NHj), 4.17-4.14 (t, 2H, 5.8), 3.63
- 3.61 (app t, 4H), 2.78 - 2.75 (t, 2H, J = 5.8), 2.55 - 2.54 (m, 4H);
13C NMR 6 154.5, 151.9, 150.2, 132.5, 130.6, 128.9 (2C), 116.3, 115.9 (2C), 
114.1, 113.7, 67.9 (2C), 67.2, 58.8, 55.4 (2C);
HRMS: [M+H]* C18H23N2O2 requires 299.1760, found 299.1758;
CHN for C18H22N2O2 requires C 72.46 H 7.43 N 9.39, found C 70.38 H 7.37 N 
10.25.
Synthesis and isolation of 7-(4-(2-morpholinoethoxy)phenyl)quinolin-4(1H)- 
one (32)
38 (0.39 g, 1.3 mmol) was dissolved in ethanol (1 ml_) and diethyl 
ethoxymethylenemalonate 1 0.26 mL, 1.3 mmol) added. Mixture heated to 
100 °C overnight. Volatiles removed under reduced pressure to give diethyl 
2-(((4'-(2-morpholinoethoxy)-[111 '-biphenyll-O-yOaminoJmethyleneJmalonate 
as an orange oil. Dissolved in Dowtherm A (1 mL) and heated to 200 °C for 2 
hours. Taken up in ethyl acetate and absorbed onto silica gel. Column 
chromatography (2% methanol/dichloromethane) gave a yellow oil. Reverse 
phase HPLC in acetonitrile gave pure 32 as a white solid.
(30.1 mg)
HPLC (100% MeCN) Retention time = 20.02 min;
1H NMR (Acetone-d6) 6 10.98-10.94 (d, NH, J = 13.6), 8.63-8.60 (d, 1H, J 
= 13.7), 7.68 - 7.65 (dt, 2H, J = 9.7, 2.9), 7.58 (s, 1H), 7.49 - 7.41 (m, 2H), 
7.30 - 7.28 (d, 1H, J = 7.6), 7.06 - 7.03 (dt, 2H, J = 9.7, 2.9), 4.20 - 4.15 (m, 
4H), 3.63 - 3.61 (m, 4H), 2.78 - 2.75 (t, 2H, J = 5.8), 2.54 (m, 2H);
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,3C NMR 5 169.7 (C=0), 160.3, 152.8, 152.5, 143.6, 141.5, 133.7, 131.5,
129.4 (2C), 124.0, 116.2 (2C), 67.9 (2C), 67.2, 58.8, 55.4 (2C); 
HRMS: [M+Hf C21H23N2O3 requires 351.1709, found 351.1690.
Synthesis of 1-nitro-3-(4-(trifluoromethoxy)benzyl)benzene (43)
o
3-Nitrophenylboronic acid 42 (1.80 g, 10.8 mmol) and palladium 
tetrakistriphenyl-phosphine (0.27 g, 0.2 mmol) were stirred in degassed, 
anhydrous tetrahydrofuran (35 mL) under a nitrogen atmosphere. K2CO3 
solution (15 mL, 2M aq.) was added followed by 4-(trifluoromethoxy)benzyl 
bromide 41 (2.09 g, 8.1 mmol). The resulting orange solution was heated to 
95 °C overnight. TLC confirmed consumption of benzyl bromide 41, the 
reaction was then quenched by cautious addition of aqueous HCI (50 mL, 
2N). Mixture extracted with ethyl acetate (2 x 100 mL) and the combined 
organic extracts dried over magnesium sulphate. Preabsorbed onto silica gel 
and purified by column chromatography (4% ethyl acetate/petroleum ether) 
to give 43 as a yellow oil.
(1.99 g, yield 82.5%)
’H NMR (CDCI3) 6 8.11 -8.06 (m, 2H), 7.52-7.46 (m, 2H), 7.22-7.11 (m, 
4H), 4.09 (s, ArChbAr);
13C NMR 6 148.9, 148.4, 142.8, 138.5, 135.4, 130.6 (2C), 129.9, 124.1, 
122.0, 121.8 (2C), 121.4, 41.2.
Synthesis of 3-(4-(trifluoromethoxy)benzyl)aniline (40)
43 (1.99 g, 6.7 mmol) was dissolved in ethyl acetate (50 mL). Tin (II) 
chloride dihydrate (6.1 g, 27.0 mmol) was added and the resulting mixture 
heated to 90 °C overnight. TLC confirmed complete reaction. Diluted with 
water (75 mL) and basified to ~pH 8 using saturated aqueous NaHC03. 
Inorganic solid removed by filtration and washed with ethyl acetate (2 x 100 
mL). Aqueous solution extracted with ethyl acetate (2 x 100 mL) and
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combined organic extracts and washes were dried over magnesium sulphate. 
Evaporation gave the product as a yellow oil.
(1.50 g, yield 84.0%)
1H NMR (CDC!3) 5 7.21 - 7.19 (m, 2H), 7.13 - 7.07 (m, 3H), 6.60 - 6.58 (d. 
1H, J = 7.6), 6.56 - 6.54 (dd, 1H, J = 7.9, 2.3), 6.48 (s, 1H), 3.88 (s, 
ArCHsAr), 3.65 (bs, NH2);
13C 6 147.0, 142.1, 140.3, 130.5, 129.9, 121.4, 119.7, 115.9, 113.6, 41.6; 
HRMS: [M+H]* C14H13F3NO requires 268.0949, found 268.0947.
Synthesis of diethyl 2-(((3-(4-(trifluoromethoxy)benzyl)phenyl)amino) 
methylenejmalonate (44)
40 was dissolved in ethanol (15 mUg) and diethyl 
ethoxymetylenemalonate 1 (1 eq.) was added. Reaction mixture was heated 
to 100 °C overnight. Once consumption of aniline 40 was confirmed by TLC 
volatile components were removed by at reduced pressure using a rotary 
evaporator to yield a red oil. Cooling under vacuum gave the desired product 
as an off-white crystalline solid.
(2.38 g, yield 97.4%)
1H NMR (CDCI3) 5 10.99 - 10.96 (d, NH, J = 13.7), 8.51 - 8.48 (d, 1H, J = 
13.7), 7.33 - 7.29 (t, 1H, J = 7.8), 7.21 - 7.14 (m, 4H), 7.02 - 6.96 (m, 2H), 
6.92 (s, 1H), 4.32 - 4.27 (q, OCH2CH3, J = 7.1), 4.27 - 4.21 (q, OCH2CH3, J 
= 7.1), 3.98 (s, ArCHzAr), 1.39 - 1.36 (t, OCH2CH3, J = 7.1), 1.34 - 1.30 (t, 
OCH2CH3, J = 7.1);
13C NMR 6 169.5 (C=0), 166.2 (C=0), 152.2, 142.9, 139.9, 139.4, 130.5, 
130.4, 125.9, 121.6, 118.2, 115.4, 94.0, 60.8, 60.5, 41.4, 14.8, 14.7;
HRMS: [M+Na]+ C22H22F3N05Na requires 460.1348, found 460.1333.
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Synthesis of ethyl 4-oxo-7-(4-(trifluoromethoxy)benzyl)-1,4-dihydroquinoline- 
3-carboxylate (39)
Synthesised from 44 according to general method B to yield a cream 
solid.
(1.18 g, yield 53.5%)
Melting point: > 250 °C
1H NMR (DMSO-d6) 8 12.23 (s, NH), 8.49 (s, 1H), 8.09 - 8.07 (d, 1H, J = 
8.6), 7.41 - 7.29 (m, 6H), 4.23 - 4.17 (q, OCH2CH3, J = 7.1), 4.14 (s, 
ArChhAr), 1.29 - 1.25 (t, OCH2CH3, J = 7.1);
13C NMR 8 171.9 (0=0), 164.6 (C=0), 158.6, 150.5, 145.6, 144.7, 139.5, 
139.0, 130.6 (2C), 130.2, 125.9, 125.7, 121.1 (2C), 117.9, 109.7, 59.4, 40.0, 
14.2;
HRMS: [M+Na]+ C2oHi6F3N04Na requires 414.0929, found 414.0919;
CHN for C20H16F3NO4 requires C 61.38 H 4.12 N 3.58, found C 61.46 H 4.11 
N 3.56.
Synthesis of 3-(ethoxycarbonyl)-7-(4-(trifluoromethoxy)benzyl)quinolin-4-yl 
morpholine-4-carboxylate, Prodrug (46)
6 (0.18 g, 0.4 mmol) was suspended in freshly distilled anhydrous
tetrahydrofuran (10 mL). Potassium f-butoxide (0.06 g, 0.6 mmol) was added 
and the mixture stirred at room temperature under nitrogen for 1 hour. N- 
morpholinecarbonyl chloride (0.10 mL, 0.9 mmol) was added by syringe and 
the resulting solution stirred at room temperature for 2 hours. N- 
morpholinecarbonyl chloride (0.10 mL, 0.9 mmol) was again added by 
syringe and the solution stirred for a further hour. Quenched with water (5
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mL) and extracted with dichloromethane (3 x 10 mL). Organic extracts 
washed with water (10 mL) and brine (10 mL) before drying over magnesium 
sulphate and absorbing onto silica gel. Column chromatography (1% 
methanol/dichloromethane) gave a sticky yellow solid. Trituration with diethyl 
ether and drying under suction gave 46 as an off-white crystalline solid.
(0.094 g, yield 42.1%)
Melting Point: 168-172 °C
1H NMR (DMSO-d6) 6 8.73 (s, 1H), 8.26 - 8.23 (d, 1H, J = 8.9), 7.52 - 7.50 
(d, 2H, J = 8.3), 7.36 - 7.32 (dt, 2H, J = 9.1, 3.0), 7.21 - 7.18 (dd, 1H, J = 
8.9, 2.3), 6.88 (d, 1H, J = 2.3), 4.27 - 4.21 (q, OCH2CH3, J = 7.0), 3.57 - 
3.54 (t, 4H, J = 4.8), 3.15-3.12 (t, 4H, J = 4.8), 1.31 - 1.27 (t, OCH2CH3, J = 
7.1);
13C NMR 5 164.2 (C=0), 161.3 156.8, 153.9, 150.9 (C=0), 145.1, 138.8, 
134.7, 129.6, 123.8 (2C), 122.9, 122.4 (2C), 116.6, 112.2, 104.2, 66.3 (2C), 
60.5, 47.2 (2C), 14.6;
HRMS: [M+H]* C24H22N2O7F3 requires 507.1379, found 507.1371.
3-(ethoxycarbonyl)-7-(4-(trifluoromethoxy)benzyl)quinolin-4-yl morpholine-4- 
carboxylate, Prodrug (47)
Synthesised from 39 according to the method used for 46.
(0.18 g, yield 36.8%)
Melting Point: 175 - 178 °C
1H NMR (DMSO-d6) 6 8.72 (s, 1H), 8.17 - 8.15 (d, 1H, J = 8.2), 7.44 - 7.31 
(m, 6H), 4.26 - 4.20 (q, OCH2CH3, J = 6.4), 4.20 (s, ArCh^Ar), 3.79 - 3.00 
(m, 8H), 1.30-1.27 (t, OCH2CH3, J = 7.1);
13C NMR 6 173.1 (C=0), 164.3 (C=0), 151.0, 147.4, 144.9, 140.0, 137.5, 
131.2 (2C), 127.2, 127.0, 125.6, 121.6 (2C), 116.6, 115.7, 111.8, 60.5 (2C), 
55.08, 50.72, 47.2, 40.7, 14.6;
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HRMS: [M+Na]+ C25H23N205F3Na requires 527.1406, found 527.1425.
Synthesis of isopropyl 4-oxo-7-(4-(trifluoromethoxy)benzyl)-1,4-
dihydroquinoline-3-carboxylate (48)
Synthesised from 39 according to general method D.
(0.11 g, yield 55.8%)
Melting point: > 250 °C
1H NMR (DMSO-d6) 6 12.18 (s, NH), 8.44 (s, 1H), 8.08 - 8.06 (d, 1H, J = 8.2 
Hz), 7.42 - 7.29 (m, 6H), 5.09 - 4.99 (sept, 1H, J = 6.3 Hz), 4.14 (s, 2H), 
1.28-1.26 (d, 6H, J = 6.3 Hz);
13C NMR 6 171.7 (C=0), 164.1(0=0), 151.3, 145.5, 144.5, 139.9, 139.6, 
130.7 (2C), 125.9, 125.8, 125.6, 121.1 (2C), 120.6, 115.0, 110.5, 40.13, 
30.59, 21.7 (2C);
HRMS: [M+Na]+ C2iH18F3N04Na requires 428.1086, found 428.1086.
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3. Results and Discussion 2: Docking Simulation
3.1 A Brief Introduction to Protein Ligand Docking Software
As computers have become increasingly powerful, computational 
chemistry has gained increased significance and computer-aided ligand 
docking is now a standard method for ascertaining the way in which small 
molecules bind with the active sites of proteins. The ability to predict the way 
in which a compound is likely to interact with a given target protein has two 
generic uses; either it can be used as a method to determine those 
compounds most likely to give good results when synthesised, referred to as 
virtual screening, or it is used to rationalise the observed results for 
compounds previously made and so inform further development, as in this 
study.
There are a number of different, highly regarded pieces of docking 
software including Glide,130,131 AutoDock132 and GOLD133'135 to name just a 
few, each of which evaluates ligands in a slightly different way and 
consequently have their own strengths and weaknesses. For the purposes of 
this study we have elected to use GOLD (Genetic Optimization for Ligand 
Docking)136 as it has been shown by a number of comparative reviews to 
give the best results for buried, hydrophobic binding sites such as the Q0 site 
of the bci complex.133,137,138
GOLD performs molecular docking using a genetic algorithm in which the 
molecules to be docked are modelled using molecular mechanics and the 
strength of binding is predicted according to the non-covalent interactions 
observed between the ligand and the protein.134 The predicted pose is then 
scored according to factors such as hydrogen bonding and van der Waals 
energies, ligand strain and steric clashes to generate a figure termed the 
GoldScore.136
3.2 The Protein
An atomic structure for P. falciparum bci is not available and a homology 
model has yet to be published for use; due to the multi-subunit nature of the 
bci protein complex and the many degrees of freedom involved in building, 
developing a homology model would be a far from trivial undertaking and it
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was deemed impractical for this study, although work towards this is 
underway within the research group. Instead, in an effort to rationalise the 
observed biological trends the compounds were docked in silico using the 
high resolution (1.9 A) crystal structure of yeast bci protein from 
Saccharomyces cerevisiae (Protein Data Bank accession code 3CX5)43 
Although not identical to the parasite bci complex the amino acid sequence 
of the yeast protein shares 40% homology and the Q0 region is well 
conserved between the two proteins.78 The Q0 active site is the region of 
interest as this would appear to be the most probable site of action for the 
developed library; as evidenced by the cross-resistance with atovaquone 
resistant parasites discussed previously and the structural similarities with 
established Q0 binders.42
The yeast bci complex was co-crystallised with stigmatellin (Figure 3.1) 
bound in the Q0 site (Figure 3.2) 43 Using the GOLD 5.0.1 protein-ligand 
docking suite,136 stigmatellin can be removed and other compounds docked 
into the Q0 site.135,139
Figure 3.1: The structure of natural be-, Q0 inhibitor stigmatellin.
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Figure 3.2: High resolution (1.9 A) crystal structure of yeast bd protein from Saccharomyces 
cerevisiae (Protein Data Bank accession code 3CX5) displayed as a cartoon ribbon model 
(green) with cytochrome c (cyan) shown in the reduced position and the Q0 binding region 
indicated by a red circle.43
3.3 Docking Validation
In the docking simulation the receptor model of the protein is a rigid 
system with the amino acid fixed in the crystallised position. In a biological 
setting, however, a protein is a flexible structure that can adapt to it’s 
environment. GOLD can allow for amino acid side-chain residues to be made 
flexible but cannot capture larger scale motions such as backbone motions. 
Crystallographic studies of bovine bci co-crystallised with a variety of 
inhibitors, have shown the conformations of a number of Q0 site residues in 
cytochrome b to be particularly variable.54 To ensure the most realistic 
protein environment for our docking study we selected flexibility in the 
analogous yeast bci residues; Val146, Ile147 and Glu272. The water 
molecule HOH5607 is known to be involved in the binding of stigmatellin and 
the endogenous ligands140 and so was retained in our docking model and it 
had the ability to rotate about the oxygen atom and translate to a limited 
degree ensuring the optimal docking position.
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GOLD uses a molecular mechanics force field to evaluate the strength of 
non-covalent interactions between a given ligand, e.g. stigmatellin, and a 
designated active site, e.g. Q0, producing a numerical value referred to as 
GoldScore. The GoldScore is used to guide a genetic algorithm to search for 
the optimal ligand-protein pose and thus demonstrate the most probable 
docking pose for a given protein-ligand complex. The reported pose with the 
highest GoldScore is considered to be the more favourable pose for the 
results of that search.
In cases where co-crystals are available, as with stigmatellin, the docking 
results can be validated by direct comparison with the crystaliographically 
observed ligand pose using the root mean square deviation (RMSD) value. 
This value is generated by GOLD as a function of how different a given 
docking pose is compared to the original pose of the native ligand, with 
smaller RMSD values indicative of more similar docking poses, an RMSD 
value of 2 A or less is considered the standard for a successful docking.133,
134, 137, 141
Therefore, in order to validate our chosen protein configuration 
stigmatellin was docked into the Q0 active site and the predicted docking 
poses compared to those of the co-crystallised ligand (Table 3.1 / Figure 
3.2).
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Table 3.1: Protein Validation Results
Pose GoldScore RMSD (A)r
dockl 104.70 0.90
dock2 28.75 3.48
dock3 78.74 1.88
dock4 94.50 0.71
dock5 65.14 1.07
dock6 98.46 0.96
dock? 98.28 1.21
docks 83.78 1.39
dock9 93.35 1.12
dockl0 39.15 2.89
TRoot Mean Square Deviation.
The program was configured such that a single docking run would consist 
of ten attempts producing ten distinct poses for comparison. These results 
show that the highest scoring docking pose for stigmatellin, dockl (Table 
3.1), has an RMSD of less than 1 A compared to the observed pose from the 
PDB file and the average RMSD is 1.56 A, well within the 2 A standard for a 
successful docking.133,134,141 In fact only two of the docking poses, dock 2 
and dock 10, have RMSD values greater than 2 A. As the resolution of the 
crystal structure is only 1.9 A these results can be considered a validation of 
the protein configuration, meaning that any docking results produced for 
other ligands are likely to be accurate. The two outlying results can be 
attributed to the relatively large search space present in the docking 
simulation. As there is no reference crystal structure for the developed 
ligands, the number of attempts per docking run will be increased to twenty. 
This was to reduce the influence of any incongruous results when visually 
comparing the poses to establish if there was a relationship between 
GoldScore and observed interactions.
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Phe278
Tyr279
Glu272
^22
HOH5607
Val146
[2Fe-2S] Cluster
Figure 3.2: Image of the Q0 site with stigmatellin docked. Nitrogen atoms are shown in blue 
and oxygen atoms in red. The carbons of the key residues His181 and Glu272 are 
highlighted in pink and the residues forming the hydrophobic channel are shown in green. 
The [2Fe-2S] cluster of the ISP is shown as blue and yellow spacefilling atoms. The 
crystallographically observed ligand pose for stigmatellin is shown in cyan and the highest 
scoring result of the docking simulation (dockl) is displayed in orange with the predicted 
hydrogen bonding interactions indicated in black and labelled in A.
3.4 Docking Atovaquone
Atovaquone (Figure 3.3) was also docked into the Q0 site using GOLD136, 
142 for the purpose of comparison with the synthesised quinolones and their 
docking poses. Results obtained were consistent with the literature, further 
validating the protein configuration and the docking protocol employed.35,78 
The highest scoring poses (Table 3.2) consistently orientated atovaquone 
such that the polar hydroxynapthoquinone head group occupied the binding 
pocket, with the cyclohexane side chain lying in the hydrophobic channel. 
Differences in GoldScore mainly arose from the precise orientation of the tail 
relative to the hydrophobic residues. This orientation of the head group
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promotes the formation of hydrogen bond interactions between the 
atovaquone carbonyl groups and the -NH of His181 and the carboxylate 
group of Glu272 through water HOH5607 (Figure 3.4).
Figure 3.3: The structure of atovaquone, currently the only anti-malarial bc1 inhibitor. 
Table 3.2: Results from the docking of atovaquone in the Q0 site of yeast bc^
Docking
Pose
GoldScore
dockl 53.4704
dock2 59.138
dock3 59.8841
dock4 59.7348
dock5 59.6784
dock6 51.6164
dock7 59.2893
dock8 59.5806
dock9 59.6564
dockl0 50.3065
Docking
Pose
GoldScore
dockl1 59.6246
dockl2 59.7703
dockl3 59.9727
dockl4 51.2095
dockl5 50.2908
dock16 59.254
dockl7 59.024
dockl8 58.9632
dockl9 52.0205
dock20 58.8999
Average Gold Score = 57.0692 
Standard Deviation = 3.8115
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[2Fe-2S] Cluster
Figure 3.4: Image of the Q0 site with atovaquone docked. The key protein residues are 
highlighted and the [2Fe-2S] cluster is shown as blue and yellow spacefilling atoms. 
Atovaquone and water molecule HOH5607 are shown in their highest scoring orientation 
(dock 13) as orange and red capped sticks respectively. Key hydrogen bonding interactions 
between atovaquone and the protein residues are shown in black and labelled in A.
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3.5 Preparing the Quinolone Ligands
In the earlier results and discussion section it was noted that 4- 
quinolones can adopt an alternative tautomer, 4-hydroxyquinolines. Before 
modelling the synthesised library it was important to establish which 
tautomeric form the compounds would adopt in a biological system, or the 
results of the docking simulation would be fundamentally flawed by 
inaccurate hydrogen bonding. This is of particular importance for the 3-ester 
compounds as it could be suggested that the potential for an intramolecular 
hydrogen bond system, between the 4-hydroxy moiety and the carbonyl of 
the 3-ester group, would favour the 4-hydroxyquinoline form (Figure 3.5).
Figure 3.5: Showing the intramolecular hydrogen bond arrangement that could potentially 
favour the 4-hydroxyquinoline tautomer.
Close examination of the 1H NMR spectra obtained for the compounds 
does not support this hypothesis however. The hydrogen atom on C2 of the 
quinolone ring has a characteristic chemical shift, appearing between 8 and 
9 ppm, depending on the substitution at C3, allowing it to be easily identified. 
If the 4-hydroxyquinoline tautomer were the favoured configuration the peak 
corresponding to this hydrogen would be expected to be a singlet as the next 
nearest hydrogen atoms are 5 bonds distant, too far to result in the presence 
of any 2nd order splitting patterns (Figure 3.6).
Figure 3.6: Showing the closest hydrogens to C2 in the 4-hydroxyquinoline tautomer.
Instead what is observed at around 8 ppm is a doublet with a coupling 
constant in the order of 8 Hz, indicating coupling with a proton on an 
adjacent atom. For many of the compounds this is accompanied by the 
presence of a broad peak, also occasionally observed as a doublet, at
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approximately 12 ppm corresponding to a conjugated N-H, indicating that the 
compounds are present in the 4-quinolone configuration (Figure 3.7).
_____J = 8.3 Hz
Figure 3.7: Section of 1H NMR for lead compound 39, the presence of a doublet peak for 
enamine proton b indicating coupling to NH a, thereby confirming the quinolone conformer.
3.6 Docking the Quinolone Ligands
Having established that the compounds are in the 4-quinolone tautomer, 
3-dimensional representations for each of the seventeen synthesised 
quinolones tested in vitro (Table 3.3) were constructed and energy minimised 
using the Spartan ’08 molecular mechanics program.143,144 The files were 
then uploaded to the GOLD136 protein-ligand docking suite and docked into 
the Q0 active site using the protein configuration previously validated by 
successful redocking of stigmatellin and atovaquone. As with the docking of 
atovaquone, the program was configured such that each quinolone structure 
produced twenty distinct docking poses for visual comparison and analysis.
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Table 3.3: The structures and in vitro results for the synthesised quinolone inhibitors.
Compound Structure
IC5o versus 3D7 
(nM)3
4 axxy1^
H
19.3
5
u
No Datab
6
H
5.30
8 >rixobJxx
H
2728
9 ^uxxIAx
H
3511
10 :t'txo6a^0
H
350
11 cxoi^^0
H
1120
12 axx!)
H
6725.0
15 axiy
H
8102.5
a Average value from at least 3 independent experiments.b Insufficient solubility for testing.
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Table 3.3 continued: The structures and in vitro results for the synthesised quinolone 
inhibitors.
iC6o versus 3D7Compound Structure
No Data'
Average value from at least 3 independent experiments.0 Insufficient solubility for testing.
- 110-
3.6.1 Docking of the Lead Compound
Compound 39 had the highest in vitro activity of the synthesised series, 
and therefore can be considered of most importance with regard to modelling 
interpretation. The compound did not score highest in the GoldScore 
evaluation; however it must be remembered that this figure is purely a 
descriptor of the strength of interaction between the protein and compound 
for a given docking pose, and does not account for any of the biological 
conditions influencing the activity of the compounds, such as membrane 
permeability.
The docking results for 39 are surprisingly consistent given the number of 
degrees of freedom afforded to the simulation. The GoldScores across the 
20 distinct docking poses vary by less than 10 points (Table 3.4) and the key 
compound features are located in the same positions for each result, varying 
only in their precise alignment with the protein residues. As anticipated the 
compound is orientated such that the quinolone “head” occupies the Q0 
binding pocket in a manner similar to that of stigmatellin (Figure 3.8).
Table 4.4: Docking results for 39 in the Q0 site generated using GOLD 5.0.
Docking
Pose
GoldScore
dockl 65.42
dock2 64.4779
dock3 64.8018
dock4 64.8968
docks 57.8416
dock6 64.3078
dock? 62.1144
dock8 62.0518
dock9 62.2712
dockl0 64.4153
Docking
Pose
GoldScore
dockl1 60.8198
dockl2 61.6874
dockl3 63.0822
dock14 58.6105
dockl5 61.9741
dockl6 62.859
dockl7 60.4181
dockl8 62.6482
dockl9 62.013
dock20 62.9725
Average GoldScore = 62.4842 
Standard Deviation = 2.0090
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Figure 3.8: Left; An image of the Q0 site with compound 39 docked. The key protein residues 
are highlighted and the [2Fe-2S] cluster is shown as blue and yellow spacefilling atoms. 39 
and water molecule HOH5607 are shown in their highest scoring orientation (dockl) as blue 
and red capped sticks respectively. Key hydrogen bonding interactions between 39 and the 
protein residues are shown in black and labelled in A. Right; an overlay of 39 (blue) on 
stigmatellin in its crystallised position (orange) showing the similarities in their orientations.
The orientation of the quinolone promotes the formation of key hydrogen- 
bonds between the inhibitor compound and amino acid residues Glu272 and 
His181. The quinolone N1 hydrogen bonds through water HOH5607 to the 
glutamate while the C4 carbonyl and the alkoxy oxygen of the C3 ester group 
simultaneously interact with the protonated imidazole eN atom of the ISP 
bound histidine (Figure 3.9). This provision of both H-bond donor and 
acceptor sites mimics the semiquinone transition state of the endogenous 
ligands during the bci catalytic cycle47, 49, 51, 145 and goes someway to 
explaining the efficacy of these quinolones as inhibitors. Additionally, the 
consistency of the results for compound 39 implies that the orientation of the 
compound is very stable and consequently the turnover of the compound in 
the Q0 site could be relatively slow, explaining the observed levels of 
potency.
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3.6.2 The Effect of Different Linkers
Comparison of the docking results for 39 with those of 6 shows the 
influence of a phenoxy linker compared to the methylene linker of the lead 
compound. While the GoldScores again show only a small range (Table 3.5), 
the docking poses produced for 6 show much more variation. Fifteen of the 
produced poses, including dock 17 the highest scoring pose (Figure 3.9), 
have the same basic orientation as the docking poses produced for 39.
Figure 3.9: Image of the Q0 site showing the highest scoring docking pose for 6 (dockU). 
The key protein residues are highlighted and the [2Fe-2S] cluster is shown as blue and 
yellow spacefilling atoms. Compound 6 and water molecule HOH5607 are shown as cyan 
and red capped sticks respectively. Key hydrogen bonding interactions between 6 and the 
protein residues are shown in black and labelled in A.
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Table 3.5: Docking results for compound 6.
Docking
Pose
GoldScore
Docking
Pose
GoldScore
dockl 63.5541 dockl1 63.6103
dock2 61.673 dockl2 61.4812
docks 61.9207 dockl3 63.567
dock4 59.4241 dock14 60.084
docks 62.1515 dockl5 62.3768
docks 62.8965 dockl6 65.0524
dock7 58.9594 dockl7 65.5616
dock8 61.258 dockl8 60.375
dock9 63.2853 dockl9 59.8731
dockl0 59.8889 dock20 62.4021
Average GoldScore = 61.9698
Standard Deviation = 1.8401
While the orientation of the key chemical components may be the same, 
the position of the phenyl ring shows much more variation for 6 than was
observed for 39. This suggests that it is less well tolerated in the hydrophobic 
channel which would account for the observed drop in potency. A possible 
reason for this is visible in the modelled docking poses; when the inhibitors 
are docked with the quinolone head group in the active site, the bridging 
atoms are situated between leucine (Leu275), phenylalanine (Phe278) and 
tyrosine (Tyr279) residues in the hydrophobic channel (Figure 3.10). The 
methylene linker of 39 will be stable in this position; however, the proximity of 
these hydrophobic amino acid side-chains to the lone pairs of the phenoxy 
linker in compound 6 will have a destabilising effect on the binding of the 
inhibitor leading to reduced occupancy of the active site and consequently 
reduced potency compared to the lead compound.
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[2Fe-2S]
HOH5607
Tyr279
Figure 3.10: View of compound 6 from the cytosolic end of the hydrophobic channel with the 
key residues forming the walls of the channel labeled, highlighting the proximity (3.4 A) of 
the linker to Phe278.
The same relationship is observed for the benzyloxy linked analogue 26; 
in this case even more variation is seen in the docking poses and the 
GoldScores obtained cover a much wider range (Table 3.6).
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Table 3.6: Docking results for compound 26.
Docking
Pose
GoldScore
dockl 56.9194
dock2 54.9984
docks 55.6126
dock4 53.678
dock5 57.1042
dock6 63.1699
dock7 57.5033
docks 53.4713
dock9 57.2041
dockl0 59.8253
Average GoldScore = 57.2768 
Standard Deviation = 3.4388
Docking
Pose
GoldScore
dockl1 62.19
dock12 55.0078
dockl3 61.7178
dock14 64.4694
dockl5 56.7163
dockl6 51.7466
dockl7 57.5456
dockl8 57.6955
dockl9 54.8825
dock20 54.0776
The highest scoring poses maintain the same position as the lead with 
the quinolone ester groups forming hydrogen bonds with amino acid residues 
Glu272 and His181 (Figure 3.11). However, the orientation of the “tail" in the 
hydrophobic channel shows great variation as the additional atom in the 
linker increases the flexibility of the system as the docking simulation seeks 
to accommodate the lone pairs of the benzyloxy oxygen atom between the 
hydrophobic residues lining the channel (Figure 3.12).
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Figure 3.11: The highest scoring pose for compound 26 (dock 14) in the Q0 active site. The 
key protein residues are highlighted and the [2Fe-2S] cluster is shown as blue and yellow 
spacefilling atoms. Compound 26 and water molecule HOH5607 are shown as orange and 
red capped sticks respectively with key H-bond interactions indicated in black and labeled in
A.
Figure 3.12: Overlay of compound 26 dock 14 (orange) and dock 1 (cyan) showing variation 
in benzyloxy “tail” position arising from the increased linker flexibility.
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3.6.3 Heterocyclic “Tails”
While the piperazine containing compound 27 had proved too insoluble to 
test biologically, it was still interesting to dock the compound in silico in order 
to observe the interactions between the heterocyclic portion and the protein. 
As with the previous analogues the highest scoring docking pose positioned 
the quinolone head between His181 and Glu272. However, the curved shape 
of the hydrophobic channel and the relatively linear, inflexible structure of the 
compound, arising from the direct link between the quinolone C7 and the 
piperazine nitrogen, appears to force the quinolone head further into the 
active site than for the previously discussed compounds (Figure 3.13). This 
disrupts the hydrogen bonds with the amino acids, extending the distances 
and consequently weakening the interactions.
2 931 G,u272
Figure 3.13: The highest scoring pose for compound 27 (dock 6) in the Q0 active site. The 
key protein residues are highlighted and the [2Fe-2S] cluster is shown as blue and yellow 
spacefilling atoms. Compound 27 and water molecule HOH5607 are shown as purple and 
red capped sticks respectively with key H-bond interactions indicated in black and labeled in 
A. Note the twist of the piperazine ring resulting from the proximity to Phe278.
The piperazine ring also appears to be twisted out of the low energy boat 
conformer by the interactions with the hydrophobic residues forming the
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walls of the channel leading to the active site, in particular Phe278. This 
weakening of the H-bonding system, in combination with the unfavourable 
interactions observed in the hydrophobic channel suggests that had 27 
proved more soluble it is unlikely to have demonstrated potent activity.
The terminal morpholine compound 32 in contrast may well have proved 
a potent derivative had the desired ethyl ester been successfully isolated. 
Despite the lack of an ethyl ester group the highest scoring orientations for 
32 correspond well with those of 39, the lead. The quinolone head occupies 
the space between Glu272 and His181, although without the additional H- 
bond afforded by the ester group the position of 32 is much closer to Glu272 
than is observed for the other analogues and may be hydrogen bonded 
directly to the glutamic acid residue rather than through a water mediated 
bond. This position may also be due in part to the rigidity of the biphenyl type 
structure at the quinolone C7 (Figure 3.14).
Figure 3.14: The highest scoring pose for compound 32 (dock 11) in the Q0 active site. The 
key protein residues are highlighted and the [2Fe-2S] cluster is shown as blue and yellow 
spacefilling atoms. Compound 32 and water molecule HOH5607 are shown as pink and red 
capped sticks respectively with key H-bond interactions indicated in black and labeled in A.
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Unlike the piperazine “tail” of 27, the long flexible ethyloxy linker of 32 
extends the terminal morpholine beyond the narrowest section of the 
hydrophobic channel formed by Phe278, Tyr279 and Leu275 that was the 
root cause of the unfavourable interactions identified for both 27 and 
analogues 6 and 26 discussed earlier (Figure 3.15). This may mean that 
compounds similar to 32 are better tolerated than some of the other 
analogues discussed, suggesting that compounds of this type may be worth 
further investigation in the future.
Figure 3.15: Compound 32 viewed from the opening of the hydrophobic channel with the 
solvent accessible surface of the protein shown in order to highlight how the ethyloxy linker 
extends the morpholine tail beyond the hydrophobic region, the colours of the surface 
indicate the nature of the atom forming the surface at a given point, white indicates 
hydrogen, green = carbon, red = oxygen and blue = nitrogen.
3.6.4 Increasing Potency with the Trifuoromethoxy Group
While the effects of the linker on potency have been relatively simple to 
explain by visual comparison of the docking poses for each compound, the 
increase in potency afforded by the inclusion of a trifluoromethoxy moiety is
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harder to rationalise. This simple alteration leads to a 4-fold increase in 
potency for the phenoxy compounds 4 versus 6 and a 10-fold increase for 
the methylene linked compounds 22 versus 39 and yet the docking poses 
produced for the compounds by the simulation show only a slight variation in 
the position of the phenyl ring (Figure 3.16). The most logical explanation is 
that change in position brought about by the trifluoromethoxy group has a 
stabilising effect on the interactions between the phenyl ring and the residues 
of the hydrophobic channel leading to increased occupancy of the active site 
and consequently improved biological activity.
Figure 3.16: Left; An image of the Q0 site with compound 22 docked. The key protein 
residues are highlighted and the [2Fe-2S] cluster is shown as blue and yellow spacefilling 
atoms. 22 and water molecule FIOFI5607 are shown in their highest scoring orientation as 
pink and red capped sticks respectively. Key hydrogen bonding interactions between 22 and 
the protein residues are shown in black and labelled in A. Right; Comparing the highest 
scoring orientations for compounds 22 (pink) and 39 (blue), showing the change in the 
phenyl ring position arising from the presence of a trifluoromethoxy group.
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3.6.5 Explaining the Increased Parasite Activity of Isopropyl Esters
In addition to the ethyl ester of the lead compound and initial hits, a 
number of alternative esters were synthesised and two were tested 
biologically; an isopropyl ester 18 and a cyclohexyl ester 20. Both 
compounds showed reasonable potency in vitro with the isopropyl analogue 
18 showing a slight improvement in activity against 3D7, 8.45 nM, compared 
to the corresponding ethyl ester 4, 19.3 nM.
When modelled 18 adopts the same basic binding position as the ethyl 
ester compounds, forming hydrogen bonds with Glu272 and His181 (Figure 
3.17) and giving no immediate indication of why the activity should be any 
higher than that of compound 4.
Figure 3.17: Showing the predicted orientation of 18 in the Q0 active site. The key protein 
residues are highlighted and the [2Fe-2S] cluster is shown as blue and yellow spacefilling 
atoms. 18 and water molecule HOH5607 are shown in their highest scoring orientation as 
lime green and red capped sticks respectively. Key hydrogen bonding interactions between 
18 and the protein residues are shown in black and labelled in A.
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Showing the solvent accessible surface of the protein residues reveals a 
possible explanation however. With the surface visible it becomes clear that 
the isopropyl ester fits very neatly into the active site (Figure 3.18) holding 
the quinolone head equidistant from the key His181 and Glu272 residues, 
suggesting that the slight increase in activity may simply be the result of 
longer active site occupancy times.
The modelling also reveals why the isopropyl group may potentially 
increase selectivity for the parasite protein over the mammalian protein. 
While the valine and isoleucine residues that line that region of the Q0 pocket 
are conserved between the species, the residues close by in the sequence 
are not so well conserved, for example leucine (Leu 149) in the yeast and 
parasite protein becomes phenylalanine (Phe149) in bovine bci. These 
alterations make the pocket in the bovine protein slightly more restrictive 
meaning the isopropyl ester of 18 is no longer as well tolerated and giving 
rise to the observed selectivity.
Figure 3.18: Showing 18 docked in the Q0 active site: the shape of the Q0 region is indicated 
in grey using the solvent accessible surface of the constituent amino acids, revealing the 
tight fit of the inhibitor compound in the active site.
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3.6.6 Explaining the Poor Performance of the Amide Compounds
The GoldScores obtained for the amide compounds would, in isolation, 
suggest that the compounds were highly potent as several of them are 
considerably higher than the results for the lead (Table 3.7).
Table 3.7: GoldScores and in vitro results for compound 39 and the amide compounds.
Compound
IC5o versus 3D7
(nM)a
Highest GoldScore
Average
GoldScore
39 0.46 65.42 62.48
8 2728 66.22 60.81
9 3511 69.50 63.91
10 350 70.46 62.51
11 1120 70.74 64.89
a Average value from cit least 3 independent experiments.
However, GoldScore predicts the strength of binding, not how efficacious
a compound is.136 Examination of the binding poses revealed the reason for
the low activity compared to the ester compounds. The bulky amides 
synthesised are not accommodated in the restrictive Q0 site and so the 
highest scoring poses have the compounds docked in a reversed 
configuration compared to the esters in which the phenyl ring portion of the 
compounds occupies the active site and the amide group extends out along 
the hydrophobic channel (Figure 3.19).
These docking poses are not conducive to good activity for a number of 
reasons; only one hydrogen bond interaction with the amino acids in the 
active site is possible (Figure 3.19) and the polar amide groups will not be 
well tolerated by the hydrophobic residues lining the channel. These factors 
mean that the amide analogues would be rapidly turned over by the enzyme 
resulting in no significant inhibition of the Q cycle.
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Figure 3.19: Amide analogue 10 (teal) docked in the Q0 active site in its highest scoring pose 
with the potential hydrogen bond interaction between His181 and the phenoxy linker 
highlighted in black and labeled in A. The key protein residues are highlighted and the [2Fe- 
2S] cluster is shown as blue and yellow spacefilling atoms.
3.6.7 The Decarboxylated, Nitrile and Pyrazolo Analogues
The functionality of these three analogues, 12, 15 and 16, is very 
different, both to each other and the rest of the synthesised library. However, 
the results in terms of biological activity are similar.
In the docking simulation the decarboxylated compound 12 docks in a 
manner completely different to any of the poses observed for the rest of the 
library, as the lack of functionality at C3 allows the molecule to sit much 
deeper in the active site than any of the other analogues (Figure 3.20).
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Figure 3.20: The highest scoring docking pose for decarboxylated compound 12 in the Q0 
active site with the postulated hydrogen bonding interactions with His181 and Glu272 
indicated in black and labeled in A. The key protein residues are highlighted and the [2Fe- 
2S] cluster is shown as blue and yellow spacefilling atoms.
As a result of this increased penetration into the Q0 active site the 
compound appears to form a hydrogen bond interaction with His181 through 
the phenoxy linker oxygen while simultaneously interacting with Glu272 
through the quinolone NH. The reduced activity observed for this species is 
probably a result of these hydrogen bonds being relatively weak interactions.
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The 3-nitrile analogue 15 is predicted to dock in broadly the same manner 
as the more active ester species (Figure 3.21). In order for a hydrogen bond 
to form between the nitrile nitrogen and His181 however the quinolone head 
is moved away from Glu272 (4.4 A) such that a strong water mediated bond 
from the quinolone NH is no longer predicted.
[2Fe-2S] ^Val146
Figure 3.21: 3-Nitrile compound 15 in the Q0 active site with the postulated hydrogen 
bonding interactions with His181 indicated in black and labeled in A. The key protein 
residues are highlighted and the [2Fe-2S] cluster is shown as blue and yellow spacefilling 
atoms. The possible weak interaction with HOH5607 is indicated in red.
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The pyrazolo compound 16 also binds in a manner completely different to 
the docking poses observed for the rest of the synthesised compounds. The 
addition of the third ring in the head group appears to result in inversion of 
the quinolone head relative to the most active configurations (Figure 3.22).
Figure 3.22: Tricyclic derivative 16 in the Q0 active site with the postulated hydrogen bond 
interactions indicated in black and labeled in A. The key protein residues are highlighted and 
the [2Fe-2S] cluster is shown as blue and yellow spacefilling atoms.
This inversion appears to promote the formation of two hydrogen bonds 
to Glu272, a water mediated bong from the imine type nitrogen of the ring 
and a direct interaction between the amine nitrogen and the amino acid. This 
position results in the phenoxy linker being brought into close proximity to a 
hydrophobic tyrosine residue (Tyr279) however, and is unlikely to be well 
tolerated.
The reduced biological activity for all three of these compounds therefore 
appears to be the result of weakened interactions with the key residues in 
the active site in turn resulting in increased turnover of the compounds 
reducing their inhibitory affect.
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3.7 Modelling Related Series
In parallel to the discussed library of compounds, two additional libraries 
were synthesised by other members of the O’Neill research group for 
comparison with the synthesised 7-quinolones.129
3.7.1 Modelling of 6-Substituted Analogues
A library of ten compounds corresponding to ten of the previously 
discussed inhibitors was synthesised with the aromatic substituent and linker 
moved from the 7-position to the 6-position (Table 3.8). With the exception of 
the 3-unsubstituted analogue 12, when tested in vitro the 6-substituted 
compounds were all between 8-fold and 100-fold less active than they’re 
corresponding 7-substituted analogue. In the case of the lead compound 39, 
the associated 6-substituted 39-SL exhibited a greater than 300-fold drop in 
potency against 3D7 P.falciparum parasites.
Table 3.8: In vitro results for the 6-series and the equivalent 7-series compounds.
IC50 versus 3D7
Compound Structure
Average value from at least 3 independent experiments. 0 Insufficient solubility for testing.
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Table 3.8 continued: In vitro results for the 6-series and the equivalent 7-series compounds.
Compound Structure IC5o versus 3D7 (nM)1
229.8
6725.0
12-SL 4698.0
8102.5
15-SL > 10 pM
18-SL 183.9
20-SL 1820.4
Average value from at least 3 independent experiments.0 insufficient solubility for testing.
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Table 3,8 continued: In vitro results for the 6-series and the equivalent 7-series compounds.
Compound Structure IC5o versus 3D7 (nM)'
22-SL
26-SL 674.8
39-SL 141.5
Average value from at least 3 independent experiments.
The 6-series analogues were modelled in silico using the same method 
as previously discussed, using GOLD 5.0136,142 to run a docking simulation 
using the crystal structure of yeast bcf3 with flexibility introduced at the 
Val146, Ile147 and Glu272 residues.54 Examination of the docking poses in 
comparison to the 7-series compounds reveals that the observed drop in 
biological potency is due to an inversion of the quinolone ring in the active 
site.
For the majority of the 6-substituted compounds the polar quinolone 
“head” occupies the binding pocket between His 181 and Glu272 and the 
aromatic “tail” portion extends into the hydrophobic channel as was observed
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for the more potent 7-substituted compounds. However due to the curvature 
of the hydrophobic channel64, 65 and the relocation of the flexible linker 
groups, the quinolones of the 6-substituted compounds are now orientated 
such that the quinolone nitrogen is adjacent to His181 and the 4-carbonyl 
moiety is pointing towards Glu272 (Figure 3.23).
Figure 3.23: Left; an image of the Q0 site with compound 39-SL docked. The key protein 
residues are highlighted and the [2Fe-2S] cluster is shown as blue and yellow spacefilling 
atoms. 39-SL and water molecule HOH5607 are shown in their highest scoring orientation 
as silver and red capped sticks respectively. Key hydrogen bonding interactions between 39- 
SL and the protein residues are shown in black and labelled in A. Right; the highest scoring 
poses for 39 (blue) and 39-SL (silver) are overlapped showing the relative inversion of the 
quinolone head group.
The net result of this rotation within the active site is a reduced ability to 
hydrogen bond; where as the 7-substituted compounds can form three 
separate H-bonds to the key protein residues, the 6-substituted analogues 
can only form two such interactions through the carbonyl oxygens and water 
molecule HOH5607 (Figure 3.24).
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Figure 3.24: 6-SL in the Q0 active site with the potential, water mediated, hydrogen bonds 
between the carbonyls and Glu272 indicated in black and labeled in A. The key protein 
residues are highlighted and the [2Fe-2S] cluster is shown as blue and yellow spacefilling 
atoms. 6-SL and water molecule HOH5607 are shown in their highest scoring orientation as 
blue and red capped sticks respectively.
Interestingly the 6-series inhibitors exhibit a number of relationships that 
oppose those of the original 7-series library. For example inclusion of a 
trifluoromethoxy moiety on the aryl ring portion of the compound was 
observed to cause a significant drop in potency for the 6-series compounds 
as opposed to the equally significant increase in activity that resulted from 
the group’s inclusion in the 7-series. The analogues lacking the
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trifluoromethoxy moiety, compounds 4-SL and 22-SL are the only 
compounds not to exhibit the inverted quinolone head and are consequently 
the most potent inhibitors in the 6-series (Figure 3.25).
Figure 3.25: 22-SL docked in the Q0 active site with the potential hydrogen bond interactions 
with the protein residues indicated in black and labelled in A. The key protein residues are 
highlighted and the [2Fe-2S] cluster is shown as blue and yellow spacefilling atoms. 22-SL 
and water molecule HOH5607 are shown in their highest scoring orientation as gold and red 
capped sticks respectively.
The reduced size of the “tail” portion allows the compounds to dock such 
that hydrogen bonds can form between both His181 and Glu272. This 
stabilises the complex resulting in improved activity. Inclusion of the
-134-
trifluoromethoxy group prevents this docking pose however and the result is 
reduced biological activity.
Similarly, for the 7-substituted compounds the change from ethyl to 
isopropyl ester resulted in greater potency; however for the 6-substituted 
analogues the opposite relationship was observed, 18-SL being around 10% 
less potent than 4-SL (183.9 versus 164.0 nM) where as 18 is more than 2- 
fold more active than 4 (8.45 versus 19.3 nM). Comparison of the docking 
poses for 18 and 18-SL suggests that this is again the result of a change in 
the orientation of the quinolone ring (Figure 3.26).
Figure 3.26: Comparison of the highest scoring docking poses for isopropyl ester 
compounds 18 (green) and 18-SL (blue).
The isopropyl group of both compounds is situated in roughly the same 
position such that hydrogen bonds can form with His181. However in order to 
accommodate the phenyl “tail” of 18-SL in the hydrophobic channel, the
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quinolone “head” is rotated along its axis, twisting such that the quinolone 
NH and ester oxygens are no longer in the appropriate plane for interaction 
with Glu272 and His181 (Figure 3.26).
3.7.2 Biphenyl type derivatives
At the conclusion of the previous chapter it was noted that the synthetic 
routes to the compounds were largely linear and consequently relatively 
inefficient. In an effort to overcome this, some time was spent attempting to 
develop a route to the compounds that would allow derivitisation towards the 
end of the synthesis and so allow a number of compounds to be made 
rapidly from a single intermediate. To this end a route to ethyl 4-chloro-7- 
iodoquinoline-3-carboxylate 50 was devised (Scheme 3.1) in the hope that 
Suzuki couplings with a range of boronic acids would result in a more 
efficient route to the lead compound 39 and swift synthesis of novel 
compounds for testing. The 4-chloroquinoline was utilised as poor solubility 
of the analogous quinolone 49 was found to be an issue in subsequent 
reactions.
GouM-Jacobs
Scheme 3.1: Synthesis of 50 from 3-iodoaniline 51 and diethyl 2-(ethoxymethylene) 
malonate 1 via the 7-iodoquinolone intermediate 49
Unfortunately 39 was never successfully synthesised in this manner 
despite numerous attempts, however, this approach has since been utilised 
to synthesis a small library of compound with the general structure shown in 
figure 3.27.
Figure 3.27: General structure of the biphenyl type analogues.
These compounds were tested in vitro in the same manner as the original 
library and the related 6-series quinolones discussed previously and in a
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number of cases displayed reasonable activity against 3D7 P.falciparum 
(Table 3.9). In silico docking of the WM compounds in the yeast Q0 site 
model then allowed comparison of their docking poses with those of the lead 
compound 39 in order to rationalise the differences in their activities.
Table 3.9: In vitro test results for biphenyl type compounds.
Code Structure IC50 versus 3D7 parasites (nM)
WM-1
WM-2
WM-3
WM-4
WM-5
WM-6
WM-7
Average value from at least 3 independent experiments.
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It is clear from the predicted docking poses that the rigid, rod-like 
structure of these compounds is not well tolerated by the bci Q0 site. In order 
to avoid steric clashes with the curved hydrophobic channel all of the 
compounds are orientated such that the substituted aromatic portion of the 
molecules occupies the active site with the quinolone ring lies along the 
hydrophobic channel (Figure 3.28).
Figure 3.28: Highest scoring predicted docking pose for WL-1 in the Q0 active site. The key 
protein residues are highlighted and the [2Fe-2S] cluster is shown as blue and yellow 
spacefilling atoms. WL-1 and water molecule HOH5607 are shown in their highest scoring 
orientation as teal and red capped sticks respectively.
This orientation does not allow for the formation of any hydrogen bonds 
between the inhibitor and the key amino acids of the active site. There also 
appears to be no relationship between the substitution pattern of the 
compounds and the observed docking poses and it is likely that the
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differences in biological activity are affected significantly by the individual 
solubility profiles of the compounds.
3.8 Summary
Modelling of the synthesised library has revealed that compounds with 
structures that maximise hydrogen bonding interactions with His181 and 
Glu272 exhibit the highest potency with ethyl and isopropyl esters 
demonstrating the strongest binding. Interaction between the “tail” of the 
compound and the hydrophobic channel is also an important consideration 
as demonstrated by the stabilising effect of methylene as opposed to oxygen 
linkers and the inclusion of a trifluoromethoxy moiety. Comparison of the 
docking of the compounds against that of related molecule libraries has 
shown 7-substitution to be superior to 6-substitution and that there is a 
requirement for a certain amount of flexibility in the molecules to prevent 
unfavourable interactions with the curved hydrophobic channel.129 This 
information can now be used to inform the development of new bci inhibitors 
with the aim of maintaining high potency while increasing solubility.
3.9 Experimental
Docking simulations were carried out using the GOLD 5.0.1 Protein- 
ligand docking suite136 running in Hermes 1.4.1 on an IBM compatible PC 
running an Intel® Core™ 2 Duo CPU at 2.33 GHz. The protein file used was 
derived from the crystal structure of yeast bci protein from Saccharomyces 
cerevisiae (Protein Data Bank accession code 3CX5).43 Using a PDB editor 
all non-essential water molecules were deleted and amino acid residues 
greater than 20 A from the designated Q0 binding region were removed to 
reduce processing time. The resulting 40 A ball was used as the protein file 
for the docking simulation in GOLD.
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Docking Protocol Validation - Docking Stigmatellin
Using the GOLD protein docking wizard the prepared protein file 
described above was loaded into Hermes and implicit hydrogen atoms added 
to the crystal structure. Water molecule HOH5607 was extracted and 
reloaded with spin state set to translate and spin. Sidechain flexibility was 
introduced for residues Val146, Ile147 and Glu272, restricted to their library 
conformers and the protonation state of residue His181 was checked to 
ensure that the correct tautomer was present; the proton should extend into 
the Q0 site away from the Rieske [2Fe-2S] cluster.
The stigmatellin ligand, designation N, was then extracted from the Q0 
active site and saved as a separate .mol2 file and selected as the ligand for 
docking. The binding site was defined as the vacated ligand cavity and all 
atoms within 6 A, as defined by the solvent accessible surface according to 
the default settings. The extracted stigmatellin ligand file was loaded as the 
reference file for calculation of RMSD. The genetic algorithm was set to 
200% search efficiency and early termination was not allowed. All other 
options were maintained as their default settings.
Average RMSD 1.56 A (standard deviation = 0.92).
Docking Atovaquone and the Quinolone Ligands
Energy minimised (MMFF94) 3-dimensional representations of each of 
the inhibitors were constructed using Spartan ’08 V1 and saved as Sybyl 
Mol2 files.143 The gold.conf configuration file generated during the validation 
with stigmatellin was reloaded and the appropriate ligand files selected in 
place of stigmatellin. No reference file was loaded. The number of genetic 
algorithm runs was increased to 20 per ligand file and the options to allow 
ligand flexibility by flipping of amide bonds and pyramidal nitrogen atoms 
were selected. All other settings were maintained as in the validated 
protocol. The resulting docking poses were visualised and evaluated using 
PyMol.146
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Synthesis of ethyl 4-chloro-7-iodoquinoline-3-carboxylate (50)
Cl o
3-lodoaniline (1 eq.) was combined with diethyl 
ethoxymethylenemalonate (1 eq.) and heated to 100 °C, under a nitrogen 
atmosphere, for 24 hours. The volatile components were evaporated under 
reduced pressure and the resulting solid washed with cold petroleum ether. 
The dried solid was suspended in Dowtherm A (5 mL/g) and heated to 240 
°C for 1 hour, cooled to room temperature and precipitated from solution 
using n-hexane. The precipitated ethyl 7-iodo-4-oxo-1,4-dihydroquinoline-3- 
carboxylate 49 was washed with petroleum ether, dried and suspended in 
phosphoryl chloride (10 mL/g). The suspension was heated to reflux for 1 
hour. The hot yellow solution was poured onto ice (15 g/mL) and stirred 
overnight. The resulting aqueous solution was extracted with chloroform and 
the combined organic extracts dried over magnesium sulphate and 
evaporated. Purified by column chromatography (Silica gel, 5% ethyl 
acetate/petroleum ether) to yield 50 as a pale brown solid.
(0.47 g, 63.2%)
1H NMR (CDCI3) 5 9.19 (s, 1H), 8.58 (s, 1H), 8.12 - 8.09 (d, 1H, J = 8.9), 
7.98-7.95 (d, 1H, J = 8.9), 4.53-4.48 (q, OCH2CH3, J= 7.1), 1.49-1.45 
(t, OCH2CH3, J = 7.1);
13C NMR 6 164.6 (0=0), 151.4, 150.3, 144.2, 139.2, 137.6, 127.0, 125.9, 
123.7, 99.5, 62.7, 14.7;
HRMS: [M+H]+ Ci2HioN0235CI127l requires 361.9445, found 361.9434;
CHN for C12H9CIINO2 requires C 39.86 H 2.51 N 3.87, found C 39.59 H 2.55 
N 3.91.
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4. Results and Discussion 3: Computer Lead Design of a New 
Chemotype
4.1 Attempts to Predict Activity Using in silico Docking Results
As covered in the previous section, in silico protein-ligand docking studies 
were carried out on three related libraries of quinolone compounds 
developed in the group. The data from these docking studies allowed us to 
rationalise the observed biological activity of these compounds with their 
structural features. For example, it had been established by the biological 
results that small ester groups (ethyl or isopropyl) at the 3-position of the 
quinolone core demonstrated the highest activity. Modelling studies revealed 
that this was due to a restrictive active site domain, requiring a specific 
configuration of hydrogen bond donors and acceptors to optimise binding. 
We hoped to use the docking models to predict the biological activity of new 
analogue designs before synthesising them.
The analysis of the previous libraries had made two aspects of the 
structure-activity relationship apparent; at the “head” of the compound in the 
3-position, a small polar group such as an ethyl ester was optimal. For the 
“tail” region, flexible, hydrophobic groups performed best, while substitution 
at the 7-position gave better results than at the 6-position. As a result of 
these observations, a number of proposed structures were docked in the 
model system developed using the previously synthesised compounds. The 
structures which scored highest in these docking runs had the general 
structure shown below (Figure 4.1). In terms of their binding interactions 
(GoldScore), the structures scored higher than any of the earlier compounds, 
scoring similarly to the natural inhibitor stigmatellin.
X = direct, -CH2- or -OCH2-
R = -OCF3, -F, -Cl etc.
Figure 4.1: The general structure of the highest scoring proposed compounds in the in silico 
screening.
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These structures were attractive targets when docked in the bci Q0 site. 
The quinolone “head” adopted the same position as previously observed for 
the most potent analogues (Figure 4.2a), whereas the curvature of the 
triazole containing “tail” appeared to match the shape of the hydrophobic 
channel to the active site very closely (Figure 4.2b). The incorporation of the 
triazole itself also allowed us to reduce the CLogP of the compounds without 
introducing any particularly polar functionality into the hydrophobic region, 
suggesting that we could expect to improve on the poor solubility 
encountered with the current lead compounds. The structures also 
represented a completely novel chemotype, as no triazole containing 
quinolone based compounds of this particular substitution pattern exist in the 
literature.
Figure 4.2: (a) Comparing the proposed compounds with the docking of lead compound 39 
and (b) with the solvent accessible surface of the protein displayed, revealing how the 
predicted pose fits the curvature of the hydrophobic channel extending the terminal group 
out towards the cytosol.
4.2 Retrosynthesis
Having determined that the compounds of the chosen design (Figure 4.1) 
were viable targets, we devised a synthetic route. A frustrating aspect of the 
previously developed library was the linear synthetic routes taken to each 
compound. This did not allow for any common intermediates to be
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synthesised. Consequently, the development of each analogue was very 
time consuming, and if a particular synthetic step failed to progress as 
expected, the result was often a return to the very beginning of the total 
synthesis. Therefore, when considering the route to the new targets, a 
divergent synthesis that would allow for a single key intermediate to be 
synthesised in bulk and quickly differentiated, was desirable.
The formation of 1,4-triazoles by the copper catalysed Huisgen 1,3- 
dipolar cycloaddition of azides and alkynes (Scheme 4.1) is well documented 
and is the classic example of “click-chemistry”, as termed by K. B. Sharpless 
in 2001.147 As such, the triazole ring formation provided an ideal point on 
which to centre our divergent synthesis strategy. Using this reaction as the 
final derivatising step in the synthesis would allow the rapid development of a 
library by synthesis of a single quinolone intermediate with a terminal 
acetylene group at the 7-position. Reaction of this intermediate with a 
selection of azides would then provide our new library (Scheme 4.2).
Azide
Cu2*
Acetylene
1,4-Triazole
Scheme 4.1: A general example of the Huisgen 1,3-dipolar cycloaddition “click” formation of 
a 1,4-triazole from an azide and an acetylene.
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R
HO no2
Scheme 4.2: Retrosynthetic design of the route to the proposed targets.
4.3 Synthesis of the Common Intermediate
To begin, benzyloxy linked analogues were selected. This subset of 
compounds was chosen for a number of reasons: they had scored highest in 
the predictive model, the benzyloxy compounds synthesised in the earlier 
3,7-substituted quinolone library had demonstrated reasonable potency (26 = 
5 nM versus 3D7), and the intermediates were simple to synthesise at 
multigram scales from affordable starting materials.
4.3.1 Synthesis of the Required Aniline
As our intention was to synthesise the common intermediate compound 
by the Gould-Jacobs method with which we had already become familiar, it 
was necessary to first synthesise 3-(prop-2-yn-1-yloxy)aniline 51. This was 
achieved in two simple steps. The first of which was the reaction of propargyl 
bromide 52 with 3-nitrophenol 7. Initially, the conditions from Issei Iwai’s 
1963 study on napthyl propargyl ethers were employed to good effect,
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achieving quantitative yields (Scheme 4.3a).148 However while investigating 
conditions for the reduction step, we came across a patent filed by Avila 
Therapeutics Inc., in which the synthesis of our aniline target was covered.149 
The patent conditions (Figure 4.3b), whilst similar to those already utilised, 
allowed reaction times to be reduced from 24 hours to 2 < 4 hours 
(depending on scale) with no observed reduction in product yield.
52 HO NOj
a) KjCOj, Acetone, 50 °C, 24 h 
b) KjCOj, Acetonitrile, 90 aC, 2 < 4 h N02
Scheme 4.3: Synthesis of 51; a) by Issei Iwai’s conditions148 and b) by the conditions used in 
the Avila Therapeutics patent149
The Avila patent also provided the conditions for the reduction of nitro 
compound 51 to the desired aniline 53, employing an iron-mediated 
procedure (Scheme 4.4).149 This was particularly useful, as there was 
concern over the lability of the triple bond under reducing conditions following 
a small scale test run of the previously utilised zinc mediated conditions, 
which resulted in the generation of multiple by-products.
51
Fe powder, 
NH4CI
NOj 1:1 MeOH IH20
80 °C, 4 h
53
NH2
Scheme 4.4: Conditions for the iron-mediated reduction of nitro compound 51 to aniline
53 149
For unknown reasons, the 91% yield claimed in the original patent was 
never achieved, with our yields being consistently more modest at 43 - 56%, 
despite following the patent procedure as closely as possible. TLC analysis 
indicated no residual nitro compound in the reaction mixture and no 
significant quantity of any by-products. Our only explanation is that the 
aniline was not fully extracted from the aqueous residue.
4.3.2 Synthesis of Ethyl 4-oxo-7-(prop-2-yn-1-yloxy)-1,4-dihydroquinoline-3- 
carboxylate by the Gould-Jacobs Procedure
Aniline 53 was reacted with diethyl ethoxymethylenemalonate 1 via the 
original, solvent free conditions used previously, to give the enamine product 
in > 99% yield (Scheme 4.5).
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Scheme 4.5: Reaction of aniline 53 with deiethyl ethoxymethyelenmalonate 1 to give 
enamine intermediate 54.
Attempts to cyclise enamine 54 by the Gould-Jacobs method (Scheme 
4.6) proved less successful. A small quantity of the desired product 55 was 
obtained, but the reaction produced a number of by-products which were 
only removed by a sequence of recrystallisations.
OEt
Scheme 4.6: Gould-Jacobs cyclisation to give the target common intermediate quinolone 55.
Of greater concern was the poor solubility of the quinolone product, which 
suggested that it was likely to be a poor choice as a common intermediate 
for further reactions.
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4.3.3 Redesigning the Common Intermediate to Improve Solubility
During the synthesis of the pyrazolo tricyclic compound 16 for the original 
library, the 4-chloroquinoline intermediate (compound 17) had been 
synthesised by reaction of the parent quinolone 4 with phosphoryl chloride 
(Scheme 4.7).
Scheme 4.7: Chlorination of 4 with phosphoryl chloride to give ethyl 4-chloro-7-phenoxy-1,4- 
dihydroquinoline-3-carboxylate 17
Due to poor yields and difficulty purifying the quinolone 55, avoiding the 
cyclisation step prior to chlorination was desirable. A literature source 
provided the means to combine both steps into a single reaction (Scheme 
4.8).150 It was possible to simultaneously cyclise the enamine and chlorinate 
the 4-position by heating a solution of the enamine precursor 54 in 
phosphoryl chloride just below reflux temperature, under a nitrogen 
atmosphere, giving the 4-chloroquinoline target 56 in good levels of purity 
with consistent yields of around 84%.
o
n'^y^oe* POCIj
95 *C
cr ^"OEt
OEt
54 56
Scheme 4.8: Simultaneous cyclisation and chlorination of enamine intermediate 54 to give 
the 4-chloroquinoline intermediate 56
As expected, the 4-chloroquinoline 56 demonstrated much improved 
solubility over the corresponding quinolone 55. It could be synthesised in 
multi-gram quantities with relative ease, making it an ideal candidate for a 
common intermediate in a divergent synthesis.
4.4 Building the Series: Huisgen 1,3-dipolar Cycloaddition
The original Huisgen 1,3-dipolar cycloaddition, first published in 1963, 
was a thermally driven process between any alkene or alkyne and a suitable 
1,3-dipolar compound, such as a diazoalkane or, classically, an azide.151 As 
there was no catalyst present to influence regioselectivity, and alkynes are
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relatively poor dipole acceptors, the reaction frequently required sustained 
high temperatures that would generally result in a mixture of 1,4 and 1,5 
substituted heterocyclic products (Figure 4.3).
r
R’
J v_
Figure 4,3: The original Huisgen 1,3~dipolar addition shown for the reaction of either a 
diazomethane or an azide, with a terminal alkyne, to give diazole or triazole products 
respectively.
In 2002, it was independently discovered by the groups of Meldal152 and 
Sharpless153 that the presence of copper (I) in the reaction between azides 
and terminal alkynes allowed temperatures to be considerably reduced, and 
that only the 1,4-substituted regioisomers were obtained. The mechanism for 
this transformation is not fully understood, but DFT studies by Sharpless et 
a/, have gone some way to explaining a viable route, involving an unusual 
copper (III) metallocycle intermediate (Figure 4.4).154
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Figure 4.4: The proposed mechanism for the copper catalysed Huisgen 1,3-dipolar addition 
of an azide to a terminal alkyne; (1) Displacement of a ligand from copper gives the copper 
acetylide; (2) Displacement of a second ligand by the azide gives the reactive copper 
complex, with the groups orientated such that the acetylene and azide groups are in close 
proximity; (3) Attack of the azide terminal nitrogen on acetylide C-2 gives the unusual 6- 
membered Cu(lll) complex; (4) Rearrangement of the intermediate gives the more stable 
Cu(ll) species and forms the triazole; (5) Acidic cleavage of the copper carbon bond 
realeases the triazole product and allows the original Cu(l) catalyst to reform.154
- 151 -
4.4.1 Problems Clicking
Numerous conditions exist for carrying out the eponymous “click” reaction 
in a variety of different solvents. For the first attempt we selected a method 
that had been used in the group previously with great success. This method 
had the advantage of generating the required benzyl azide reactant in situ 
using sodium azide and the corresponding benzyl bromide (Scheme 4.9).155 
This method was beneficial in that the potentially explosive organic azide 
intermediate would not require isolation, avoiding a potential safety issue.
Cl o
56
NaNj 
L-proline 
Ascorbic Acid 
X NajCOj
C11SO4.5H2O 
9:1 DMSOI HzO
Scheme 4.9: The conditions trialled for the unsuccessful one-pot “click’’ synthesis.
Although this procedure had worked well for us in previous projects, the 
added complexity of the quinoline appeared to be a problem, as no reaction 
was observed beyond the gradual hydrolysis of the 4-chloroquinoline 56. 
Therefore, the desired benzyl azides 59a-f were synthesised and isolated by 
direct displacement of the appropriate benzyl bromide 57a-f with sodium 
azide in dimethylformamide (Scheme 4.10).156
X
Br NaN3
DMF
X
N3
57a X = H 
57b X ■ 4-OCF3 
57c X = 4-CI 
57d X = 4-F 
57e X = 3-F 
57f X = 2,4-F
59a X = H 
59b X * 4-OCF3 
59c X = 4-CI 
59d X = 4-F 
59e X = 3-F 
59f X = 2,4-F
Scheme 4.10: Synthesis of the benzyl azides 59a-f for reaction with 56.
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Once the azides 59a-f had been synthesised, they were subjected to the 
same “click” conditions used previously. This time a successful reaction was 
observed. It had been assumed that the product of the “click” reaction would 
be the 4-chloroquinoline precursor to the targeted quinolone, which would 
then require hydrolysis in an additional step. This did not appear to be the 
case, however, as the isolated product showed no trace of chlorine when 
analysed by mass spectrometry (a quinolone N-H was also visible in the 
proton NMR spectrum). Unfortunately, the hydrolysis of the 4- 
chloroacetylene starting material appeared to be a competing process, with 
the isolated solid consisting of an approximate 1:1 mix of hydrolysed product 
and hydrolysed starting material (Scheme 4.11).
Cl o
'OEt
60a
Scheme 4.11: The two reaction pathways observed when 56 was subjected to the displayed 
"click’’ conditions with 60a.
It appears that even in the 9:1 dimethylsulphoxide / water solvent system 
used for the reaction, the quinolone acetylide is not sufficiently soluble to 
react once formed.
To avoid the necessity of a difficult column chromatography purification of 
the hydrolysed compound mixture it was decided to determine whether the 
hydrolysis could be prevented in the first place. The reaction to hydrolyse the 
4-chloroquinoline “click” products once formed was going to use mild acid. 
On that basis it was suggested that the ascorbic acid present in the reaction 
mixture may be sufficient to induce the hydrolytic cleavage of the carbon 
chlorine bond. Consequently, the reaction conditions were altered to use 
sodium ascorbate as opposed to ascorbic acid. It was indeed observed that
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the reaction now gave the desired 4-chloroquinoline product precursors in 
modest but acceptable yields (Scheme 4.12).
L-proline
Sodium Ascorbate 
NajCOj 
CuS04.5H20
58b X = OCFj 35%
Scheme 4.12: Successful “click” coupling of 56 with a variety of azides under basic 
conditions.
Further research in the literature led to the discovery of a set of superior 
reaction conditions. A review of the effects of different bases on the outcome 
of Huisgen reactions by Burgess et al. found that the use of ammonium 
carbonate as the base promoted faster reaction and a reduction in unwanted 
by-product formation (Scheme 4.13).157
58c X = 4-CI 46%
58e X = 3-F
58f X = 2,4-F 38%
59c X - 4-CI 
59d X = 4-F 
59e X = 3-F 
59f X = 2,4-F
Scheme 4.13: “Click” coupling of 56 with benzyl azides according to the improved 
conditions.157
4.5 Synthesis of the “Click” Series
Having established a viable route to convert the 4-chloroquinoline 
precursors to the desired quinolone products, the final step was to establish 
a reliable method of hydrolysing the 4-chloro bond without hydrolysing the 
ester group. It was found that simply refluxing the compounds in ethanol for 2 
- 3 hours, followed by extracting with chloroform to remove any remaining 4-
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chloroquinoline gave the target compounds in high yields, 75 - 90% (Scheme 
4.14).
Cl o
58b X = 4-OCFj
58c X = 4-CI
58d X = 4-F
58f X = 2,4-F
Eton
90 °C
60f X = 2,4-F
Scheme 4.14: Thermal hydrolysis of the 4-chloroquinolines 58a-f to the quinolone targets 
60a-f using ethanol.
Seven compounds were synthesised by this method in total. Six were 
generated using benzyl azides (synthesised as described), and a seventh 
using an A/-ethylphthalimido azide (synthesised by a literature method) 
(Scheme 4.15).156
Scheme 4.15: Synthesis of 2-(2-azidoethyl)isoindoline-1,3-dione 62
In addition to the seven benzyloxy type quinolone triazoles synthesised, a 
single, directly linked quinolone-triazole compound was prepared by MChem 
student Walid Abd El Magid using a similar synthetic route (Scheme 4.16).
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o o
POCIs
A
L-prollne
Sodium Ascorbate 
Na2CO, 
CuS0«.5H20
EtOH, A
SWQ15
Scheme 4.16: Synthetic route taken to SWQ15
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4.6 Biological Evaluation of Quinolone-Triazole Compounds
Compared to the majority of previously synthesised library targets, the 
triazole compounds did exhibit improved solubility, although they were still 
relatively insoluble (requiring the use of DMSO-cf6 for NMR analysis).. Once 
purified, the eight compounds were evaluated for biological activity against 
cultured 3D7 P.falciparum parasites in vitro (Table 4.1).
Table 4.1: Biological results for the quinolone-triazole series.
IC5o versus 
3D7
parasites
CLogP by 
ALog 
PS2.16
Code Structure
2.95 ±
4.06 ±
3.63 ±
3.12 ±
' Average value from at least 3 independent experiments, 
'http://www. vcclab.org/lab/alogps/c No activity at 1 pM.
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Table 4.1 continued: Biological results for the quinolone-triazole series.
IC5o versus 
3D7
parasites
CLogP by 
ALog 
PS2.1b
Code Structure
3.11 ±
3.22 ±
1.88 ±
SWQ 3.55 ±
' Average value from at least 3 independent experiments. 
'http://www.vcclab.org/lab/alogps/c No activity at 1 pM.
4.7 Summary
After the encouraging modelling results that identified these compounds 
as viable targets, the lack of activity in vitro was puzzling. We surmise that 
this is a result of the computer model being unable to account for several 
factors that contribute to a compounds biological activity. The docking 
simulation only models the interaction of the compound with the target 
protein, regardless of whether the compound would actually reach that point.
The in vitro testing of the compounds is carried out in whole cell infected 
erythrocytes. Consequently, before the compounds reach their intended
-158-
target, they must pass through several cell membranes (belonging both to 
the parasite and the infected red blood cell). It is possible that having 
lowered the CLogP of the compounds (in an attempt to increase aqueous 
solubility), we have reduced the lipophilicity of the compounds to the extent 
that it has been detrimental to their ability to pass through biological 
membranes. This could prevent them from reaching therapeutic 
concentrations at their intended site of action. This theory is in part supported 
by the observation that only the trifluoromethoxy compound 60b, with the 
highest CLogP of the compound set, exhibits any measurable activity.
4.8 Experimental
Commercially available starting materials were sourced from Sigma- 
Aldrich, Alfa Aesar, Acros Organics or Apollo Scientific Ltd. and used without 
additional purification. Solvents were obtained from either Fisher Scientific or 
VWR and used without purification unless otherwise stated.
Flash column chromatography purification was carried out using silica gel 
(particle size 40-63 pm) sourced from Sigma-Aldrich and thin layer 
chromatography (TLC) was carried out using Merck aluminium backed 
sheets 20 x 20 cm Silica gel 60 F254. TLC plates were visualised using an 
ultraviolet lamp (254 nm).
Analysis
1H NMR spectra were recorded using a Bruker Avance 400 (400 MHz) 
machine; 13C spectra were recorded on the same machine (100 MHz). 
Chemical shifts (6) are recorded in ppm relative to an internal 
tetramethylsilane standard. Deuterated solvents were supplied by Sigma- 
Aldrich and Cambridge Isotope Laboratories and were used without 
additional purification. * 1H spectra multiplicities are recorded as singlet (s), 
broad singlet (bs), doublet (d), triplet (t), quartet (q), doublet of doublets (dd), 
doublet of triplets (dt) or multiplet (m), coupling constant J values are given in 
Hz where appropriate.
High resolution mass spectroscopy (HRMS) was carried out by Miss M. 
McCarron via electrospray ionisation (El) using a Micromass LCT Mass 
Spectrometer. Samples were injected as methanol or tetrahydrofuran
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solutions, as appropriate, using a direct infusion syringe pump. Compound 
53 was analysed at the EPSRC National Mass Spectroscopy Centre in 
Swansea using a LTQ Orbitrap XL system.
Melting points and decomposition temperatures, where reported, were 
identified using a Gallenkamp melting point apparatus and are reported 
uncorrected in °C.
Synthesis of 3-(prop-2-yn-1-yloxy)aniline (53)
To a suspension of 3-nitrophenol 2 (8.0 g, 57.5 mmol) and potassium 
carbonate (11.2 g, 81.0 mmol) in acetonitrile (30 mL) was added propargyl 
bromide solution (80% in toluene, 7.6 mL, 68.4 mmol). The reaction mixture 
was heated to reflux (~ 90 °C) and progress monitored by thin layer 
chromatography. Upon full consumption of the starting material (~ 21/4 hours) 
the solution was diluted with water (50 mL) and the resulting biphasic mixture 
extracted with ethyl acetate (3 x 75 mL). Combined organics extracts were 
dried over magnesium sulphate and evaporated to give crude 1-nitro-3- 
(prop-2-yn-1-yloxy)benzene as a brown solid.
The crude nitro compound was dissolved in a mixture of methanol and 
water (1:1, 120 mL). Ammonium chloride (20.6 g, 388 mmol) was added 
followed by iron powder (13.6 g, 242 mmol) and the resulting mixture was 
stirred vigorously and heated to 80 °C for 4 hours. The reaction mixture was 
then cooled and diluted with methanol (200 mL) before the inorganic solids 
were removed by filtering through a layer of celite. The filtrate was 
concentrated by evaporation under reduced pressure and the aqueous 
residue extracted with ethyl acetate (3 x 250 mL). The combined organic 
extracts were washed with water (250 mL) and brine (100 mL) respectively, 
before drying over magnesium sulphate and evaporation to give the crude 
product as a cloudy brown oil. Purification by column chromatography (4% 
methanol/chloroform) gave the pure product as a clear brown oil.
(4.76 g, 56.3%)
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'H NMR (CDCb) 5 7.09 - 7.05 (t, 1H, J=7.9 Hz), 6.40-6.37 (ddd, 1H, J 
= 8.2, 2.4, 0.8 Hz), 6.35 - 6.32 (ddd, 1H, J = 7.8, 2.2, 0.8 Hz), 6.32 - 6.30 (t, 
1H, J = 2.2), 4.65 - 4.64 (d, 2H, J = 2.4 Hz), 3.68 (s, NH2), 2.52 - 2.51 (t, 1H, 
J = 2.4 Hz);
13C 5 159, 148, 130, 109, 105, 102, 79, 75, 56;
HRMS: [M+Hf C9H10NO requires 148.0757, found 148.0756.
Synthesis of diethyl 2-(((3-(prop-2-yn-1-
yloxy)phenyl)amino)methylene)malonate (54)
53 (4.76 g, 32.4 mmol) was combined with diethyl
ethoxymethylenemalonate 1 (6.5 mL, 32.4 mmol) and heated to 100 °C 
overnight. On cooling the reaction mixture solidified. Washed with n-hexane 
and dried under vacuum to yield an off-white solid.
(10.27 g, 99.9%)
Melting point: 76 - 78 °C
’H NMR (CDCh) 5 11.00- 10.97 (d, NH, J= 12.4), 8.52-8.49 (d, 1H, J = 
13.5), 7.31 - 7.27 (appt, 1H), 6.79 - 6.76 (m, 3H), 4.71 (s, ArCH2C=), 4.34 - 
4.22 (m, 4H), 2.56 (s, C3CH), 1.40-1.31 (m, 6H);
13C NMR 5 169.4, 165.9, 159.1, 152.1, 140.9, 131.1, 111.3, 110.8, 104.7, 
94.1, 78.4, 76.4, 60.8, 60.5, 56.3, 14.8, 14.7;
HRMS: [M+Na]+ CiyHigNOsNa requires 340.1161 found 340.1172.
Synthesis of ethyl 4-chloro-7-(prop-2-yn-1-yloxy)quinoline-3-carboxylate (56)
Cl o
o
54 (10.26 g, 32.3 mmol) was suspended in phosphoryl chloride (45 mL) 
and heated to 95 °C overnight, under nitrogen. Evaporation of the phosphoryl 
chloride under reduced pressure followed by co-evaporation with xylene (2 x 
50 mL) gave a bright red wax. The residue was dissolved in dichloromethane 
(100 mL) and washed with NaOH solution (1 M, 100 mL). The organic layer
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was then concentrated and the residue redissolved in ethyl acetate (400 mL). 
The organic solution was then washed with water (100 mL) and brine (75 
mL) respectively, before drying over magnesium sulphate and evaporation to 
give the product as a pale yellow solid.
(7.82 g, 83.5%)
Melting point: 133 - 135 °C (decomposition)
’H NMR (CDCI3) 5 9.18 (s, 1H), 8.35 - 8.32 (d, 1H, J = 9.3), 7.56 (d, 1H, J = 
2.5), 7.39 - 7.36 (dd, 1H, J = 9.3, 2.6), 4.89 - 4.88 (dd, 2H, J = 3.9, 2.5), 
4.52 - 4.46 (q, OCH2CH3, J = 7.1) 2.60 (s, C=CH), 148 - 1.45 (t, OCH2CH3, 
J = 7.1);
13C 6 165.0, 160.8, 151.5, 149.5, 131.7, 127.5, 124.1, 121.9, 110.9, 109.5, 
77.0, 76.7, 62.3, 56.6, 14.7;
HRMS: [M+Na]* CisH^CINOsNa requires 312.0403 found 312.0405.
General Method E for the Synthesis of benzyl azides
Substituted benzyl bromide (1 eq.) was added to stirring 
dimethylformamide (10 mL) under a nitrogen atmosphere. Sodium azide (2 
eq.) was added carefully and the resulting solution stirred at room 
temperature for 3 hours. The solution was diluted with water (20 mL) and 
extracted with ethyl acetate (3 x 25 mL). Organic extracts were washed with 
water (25 mL) and brine (25 mL). Organic solution was concentrated to a 
crude oil which was suspended in water (10 mL) and extracted with n- 
pentane (3x10 mL). Dried over magnesium sulphate and evaporated to give 
the products as clear oils.
Benzyl azide (59a)
Synthesised from benzyl bromide 57a according to general method E. 
(0.59 g, 75.7%)
'H NMR (CDCI3) 5 7.39 - 7.29 (m, 5H), 4.31 (s, 2H);
13C NMR 5 135.8, 129.3 (2C), 128.8, 128.7 (2C), 55.2.
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4-(Trifluoromethoxy)benzyl azide (59b)
n-
.n-
Synthesised from 4-(trifluoromethoxy)benzyl bromide 57b according to 
general method E.
(0.47 g, 69.9%)
'H NMR (CDCI3) 5 7.37 - 7.34 (dt, 2H, J =9.3, 2.7), 7.25 - 7.23 (d, 2H, J = 
7.9), 4.37 (s, 2H);
13C NMR 6 134.5, 129.9 (3C), 121.7 (2C), 99.9, 54.3.
4-Chlorobenzyl azide (59c)
Synthesised from 4-chlorobenzyl bromide 57c according to general 
method E.
(1.36 g, 81.9%)
1H NMR (CDCI3) 6 7.55 - 7.07 (m, 4H), 4.32 (s, 2H);
13C NMR 6 137.0, 131.3, 130.4 (2C), 128.7 (2C), 55.0.
4-Fluorobenzyl azide (59d)
Synthesised from 4-fluorobenzyl bromide 57d according to general 
method E.
(1.17 g, 80.9%)
1H NMR (CDCI3) 5 7.31 - 7.28 (m, 2H), 7.10 - 7.05 (m, 2H), 4.31 (s, 2H);
13C NMR 5 164.3, 161.8, 131.6, 130.4 (2C), 116.2 (2C), 54.5.
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3-Fluorobenzyl azide (59e)
Synthesised from 3-fluorobenzyl bromide 57e according to general 
method E.
(1.20 g, 83.3%)
'H NMR (CDCI3) 6 7.38-7.32 (m, 1H), 7.11 - 7.02 (m. 3H), 4.35 (s, 2H);
13C NMR 6 164.6, 138.3, 130.8, 124.1, 115.7, 115.3, 54.6.
2,4-Difluorobenzyl azide (59f)
Synthesised from 2,4-difluorobenzyl bromide 57f according to general 
method E.
(1.15 g, 73.3%)
1H NMR (CDCb) 6 7.35 - 7.29 (m, 1H), 6.93 - 6.84 (m, 2H), 4.37 (s, 2H);
13C NMR 6 164.7, 164.6, 162.6, 162.2, 162.1, 160.3, 160.1, 131.8 - 131.6, 
112.1 -111.9, 104.7, 104.4,48.4.
General Method F for Click Coupling (58a and 58b)
56 (0.28 g, 1 mmol) was dissolved in dimethylsulphoxide and water (9:1, 
10 ml_). To the stirring solution was added sodium carbonate (0.02 g, 0.2 
mmol), L-proline (0.02 g, 0.2 mmol), sodium ascorbate (0.02 g, 0.1 mmol) 
and copper (II) sulphate pentahydrate (0.01 g, 0.05 mmol). The resulting blue 
solution was heated to 65 °C before addition of the desired benzyl azide (2.2 
mmol). After 24 hours the reaction was diluted with water (25 mL) and 
extracted with ethyl acetate (3 x 25 mL). Combined organic extracts were 
washed with brine (25 mL) and dried over magnesium sulphate before 
evaporation to give crude product as yellow solids which were purified by 
flash column chromatography (ethyl acetate/n-hexane).
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Ethyl 7-( (1-benzyl- 1H-1,2,3-triazol-4-yl)methoxy)-4-chloroquinoline-3-
carboxylate (58a)
Synthesised from 56 and 59a according to general method F to yield a 
pale yellow powder.
(0.16 g, 37.3%)
Melting point: > 250 °C
1H NMR (CDCh) 5 9.18 (s, 1H), 8.32 - 8.30 (d, 1H, J = 9.3), 7.61 (s, 1H), 
7.55 (d, 1H, J = 2.4), 7.40 - 7.34 (m, 4H), 7.32 - 7.29 (m, 2H), 5.57 (s, 2H), 
5.34 (s, 2H), 4.51 - 4.46 (q, OCH2CH3, J = 7.1), 1.48 - 1.44 (t, OCH2CH3, J 
= 7.1);
13C NMR 6 165.0, 161.8, 161.6, 151.4, 145.5, 141.4, 136.3, 129.6 (2C), 
129.3, 128.6 (2C), 127.4, 123.3, 121.9, 115.7, 109.1, 62.7, 62.3, 54.8, 14.7; 
HRMS: [M+Na]' C22Hi935CIN403Na requires 445.1043 found 445.1043.
Ethyl 4-chloro-7-((1 -(4-(trifluoromethoxy)benzyl)-1 H-1,2,3-triazol-4-
yl)methoxy)quinoline-3-carboxylate (58b)
Synthesised from 56 and 59b according to general method F to yield a 
white solid.
(0.18 g, 35.1%)
Melting point: 184 - 187 °C (decomp.)
'H NMR (CDCI3) 5 9.17 (s, 1H), 8.31 - 8.28 (d, 1H, J = 9.3), 7.67 (s, 1H), 
7.54 (d, 1H, J = 2.2), 7.36 - 7.33 (m, 3H), 7.24 - 7.22 (m, 2H), 5.57 (s, 2H), 
5.35 (s, 2H), 4.51 - 4.46 (q, OCH2CH3, J = 7.1), 1.48 - 1.44 (t, OCH2CH3, J 
= 7.1);
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13C NMR 5 164.9, 161.4, 151.8, 151.4, 149.8, 148.9, 143.9, 143.8, 133.4, 
130.0 (2C), 127.4, 123.4, 122.0 (2C), 121.8, 121.4, 119.4, 109.1, 62.6, 62.3, 
53.8, 14.6;
HRMS: [M+Na]‘ C23Hie35CIF3N404Na requires 529.0866 found 529.0850.
General Method G for Click Coupling (58c~f)
The appropriate azide (1.3 mmol) was mixed with ammonium carbonate 
solution (2 M(aq), 1.5 mL) and acetonitrile (1.5 mL). 56 (0.28 g, 1.0 mmol) was 
suspended in the mixture followed by copper (II) sulphate solution (1 M(aq), 
0.1 mL) and copper (0) powder (64 mg, 1.0 mmol). The mixture was stirred 
at room temperature and reaction progress monitored by thin layer 
chromatography. Upon completion the mixture was suspended in water (10 
mL) and extracted with ethyl acetate (3x10 mL). Combined extracts were 
washed with water (15 mL) and brine (15 mL) respectively, dried over 
magnesium sulphate and evaporated to give the crude products. Purification 
by flash column chromatography (ethyl acetate/n-hexane) gave the pure 
products as off-white to yellow powders.
Ethyl 4-chloro- 7-((1-(4-chlorobenzyl)- 3-triazol-4-yl)methoxy)quinoline-
3-carboxylate (58c)
Synthesised from 56 and 59c according to general method G to give a 
yellow solid.
(0.21 g, 46.1%)
Melting point: 134 - 138 °C
’H NMR (CDCI3) 6 9.17 (s, 1H), 8.32 - 8.30 (d, 1H, J = 9.3), 7.61 (s, 1H), 
7.55 - 7.54 (d, 1H, J = 2.5), 7.38 - 7.34 (m, 3H), 7.25 - 7.23 (m, 2H), 5.54 (s, 
2H), 5.35 (s, 2H), 4.51 - 4.46 (q, OCH2CH3, J = 7.1), 1.48 - 1.44 (t, 
OCH2CH3, J = 7.1);
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13C NMR 5 164.9, 161.4, 151.9, 151.4, 143.9, 143.8, 135.4, 133.2, 129.9 
(2C), 129.8 (2C), 127.4, 123.2, 121.9, 121.8, 121.4, 109.1, 62.6, 62.3, 53.9, 
14.6;
HRMS: [M+Hf C22Hi935Cl2N403 requires 457.0834 found 457.0830.
Ethyl 4-chloro- 7-(( 1-(4-fluorobenzyl)- 1H-1.2,3-triazol-4-yl)methoxy)quinoline- 
3-carboxylate (58d)
Synthesised from 56 and 59d according to general method G to give a 
cream solid.
(0.19 g, 43.6%)
Melting point: 110-112 °C
’H NMR (CDCI3) 8 9.17 (s, 1H), 8.32 - 8.30 (d, 1H, J = 9.3), 7.61 (s, 1H), 
7.55 - 7.54 (d, 1H, J = 2.5), 7.37 - 7.34 (dd, 1H, J = 9.3, 2.6), 7.31 - 7.28 
(m, 2H), 7.11 - 7.05 (tt, 2H, J = 8.6, 3.0), 5.53 (s, 2H), 5.34 (s, 2H), 4.51 - 
4.46 (q, OCH2CH3, J = 7.1), 1.48-1.44 (t, OCH2CH3, J = 7.1);
13C NMR 8 164.9, 161.5, 151.9, 151.4, 143.9, 143.8, 130.6, 130.5 (2C), 
130.4, 127.4, 123.1, 121.9, 121.8, 121.4, 116.7, 116.5, 109.1, 62.6, 62.3, 
53.9, 14.6;
HRMS: [M+H]* C22Hi935CIFN403 requires 441.1130 found 441.1124.
Ethyl 4-chloro-7-((1-(3-fluorobenzyl)-1 H-1,2,3-thazol-4-yl)methoxy)quinoline- 
3-carboxylate (58e)
Synthesised from 56 and 59e according to general method G to give a 
cream solid.
(0.19 g, 43.4%)
Melting point: 108-111 °C
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1H NMR (CDCI3) 8 9.17 (s, 1H), 8.32 - 8.30 (d, 1H, J = 9.3), 7.64 (s, 1H), 
7.56 - 7.55 (d, 1H, J = 2.5), 7.39 - 7.33 (m, 2H), 7.08 - 7.04 (m, 2H), 7.00 - 
6.98 (d, 1H, J = 9.2), 5.56 (s, 2H), 5.36 (s, 2H), 4.51 - 4.46 (q, OCH2CH3, J = 
7.1), 1.48-1.44 (t, OCH2CH3, J = 7.1);
13C NMR 5 164.9, 161.5, 151.9, 151.4, 144.0, 143.8, 137.0, 131.3, 131.2,
127.4, 124.1, 124.0, 123.3, 121.9, 121.8, 121.4, 116.4, 116.2, 115.6, 115.3, 
109.2, 62.6, 62.3, 54.0, 14.6;
HRMS: [M+Hf C22Hi935CIFN403 requires 441.1130 found 441.1121.
Ethyl 4-chloro-7-((1-(2,4-difluorobenzyl)-1 H-1 t2,3-triazol-4-
yl)methoxy)quinoline-3-carboxylate (58f)
Synthesised from 56 and 59f according to general method G to give a 
white solid.
(0.17 g, 38.1%)
Melting point: 138 - 141 °C
1H NMR (CDCI3) 5 9.14 (s, 1H), 8.28 - 8.26 (d, 1H, J = 9.3), 7.71 (s, 1H), 
7.53 - 7.52 (d, 1H, J = 2.5), 7.34 - 7.29 (m, 2H), 6.91 - 6.84 (m, 2H), 5.56 (s, 
2H), 5.32 (s, 2H), 4.49 - 4.42 (q, OCH2CH3, J = 7.1), 1.46 - 1.42 (t, 
OCH2CH3, J= 7.1);
13C NMR 8 164.9, 161.5, 151.9, 151.4, 143.9, 143.8, 132.3 - 132.1, 127.4,
123.5, 121.9, 121.8, 121.4, 118.3, 118.1, 112.8 - 112.5, 109.1, 105.1 -
104.6, 62.6, 62.3, 47.7, 14.7;
HRMS: [M+Naf C22Hi735CIF2N403Na requires 481.0855 found 481.0842.
General Method H for Hydrolysis of 4-chloroquinolines to quinolones
4-chloroquinoline (approx. 0.2 mmol) was suspended in ethanol (5 mL) 
and heated to reflux for 24 hours. The resulting precipitate was recovered by 
vacuum filtration of the still hot solution. The recovered solid was then 
washed with diethyl ether and chloroform and dried in a vacuum desiccator 
to yield the product as a white powder.
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Ethyl 7-((1 -benzyl- 3-triazol-4-yl)methoxy)-4-oxo-1,4-dihydroquinoline-
3-carboxylate (60a)
Synthesised from 58a according to general method H to give a white 
solid.
(53.9 mg, 74.0%)
Melting point: > 250 °C
1H NMR (DMSO-d6) 5 12.51 - 12.13 (d, NH, J = 6.6), 8.49 - 8.47 (d, 1H, J = 
6.6), 8.33 (s, 1H), 8.06 - 8.04 (d, 1H, J = 8.9), 7.39 - 7.31 (m, 4H), 7.15 (d, 
1H, J = 2.2), 7.08 - 7.05 (dd, 1H, J = 8.9, 2.2), 5.62 (s, 2H), 5.27 (s, 2H), 
4.23-4.17 (q, OCH2CH3, J = 7.1), 1.29-1.25 (t, OCH2CH3, J = 7.1);
13C NMR not obtained due to poor solubility;
HRMS: [M+Na]+ C22H2oN404Na requires 427.1382, found 427.1401.
Ethyl 4-oxo-7-((1-(4-(trifluoromethoxy)benzyl)- 1H-1,2,3-triazol-4-yl)methoxy)- 
1,4-dihydroquinoline-3-carboxylate (60b)
Synthesised from 58b according to general method H to give a white 
solid.
(66.9 g, 76.1%)
Melting point: > 250 °C
1H NMR (DMSO-d6) 8 12.16 - 12.15 (d, NH. J = 6.3), 8.50 - 8.48 (d, 1H, J = 
6.4), 8.36 (s, 1H), 8.07 - 8.05 (d, 1H, J = 8.9), 7.47 - 7.37 (d, 2H, J = 8.7), 
7.39 - 7.37 (d, 2H, J = 8.3), 7.16 - 7.15 (d, 1H, J = 2.3), 7.08 - 7.06 (dd, 1H, 
J = 8.9, 2.4), 5.68 (s, 2H), 5.28 (s, 2H), 4.23 - 4.18 (q, OCH2CH3, J = 7.1), 
1.29 - 1.26 (t, OCH2CH3, J = 7.1);
,3C NMR not obtained due to poor solubility;
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HRMS: [M+Na]+ C23Hi9F3N405Na requires 511.1205, found 511.1198.
Ethyl 7-( (1 -(4-chlorobenzyl)-1 H-1,2,3-triazol-4-yl)methoxy)-4-oxo-1,4-
dihydroquinoline-3-carboxylate (60c)
Synthesised from 58c according to general method H to give a cream 
solid.
(87.3 mg, 90.9%)
Melting point: > 250 °C
'H NMR (DMSO-d6) 5 12.16 - 12.14 (d, NH, J = 6.7 Hz), 8.49 - 8.47 (d, 1H, 
J = 6.6 Hz), 8.34 (s, 1H), 8.06 - 8.04 (d, 1H, J = 8.9 Hz), 7.46 - 7.44 (d, 2H, 
J = 8.5 Hz), 7.36 - 7.34 (d, 2H, J = 8.6 Hz), 7.15 - 7.14 (d, 1H, J = 2.4 Hz), 
7.08 - 7.05 (dd, 1H, J = 8.9, 2.4 Hz), 5.63 (s, 2H), 5.27 (s, 2H), 4.23 - 4.17 
(q, OCH2CH3, J = 7.1 Hz) 1.29 - 1.25 (t, OCH2CH3, J = 7.1 Hz);
13C NMR not obtained due to poor solubility;
HRMS: [M+Na]* C22Hi935CIN404Na requires 461.0993, found 461.0977.
Ethyl 7-(\(1-( 4-fluorobenzyl)-1 H-1,2,3-triazol-4-yl)methoxy)-4-oxo-1,4-
dihydroquinoline-3-carboxylate (60d)
Synthesised from 58d according to general method H to give a cream 
solid.
(76.6 mg, 80.5%)
Melting point: > 250 °C
1H NMR (DMSO-d6) 6 12.14 - 12.12 (d, NH, J = 6.4), 8.48 - 8.47 (d, 1H, J = 
6.8), 8.32 (s, 1H), 8.06 - 8.04 (d, 1H, J = 8.9), 7.42 - 7.38 (dd, 2H, J = 8.2, 
5.6), 7.23 - 7.19 (t, 2H, J = 8.8), 7.15 - 7.14 (d, 1H, J = 2.2), 7.07 - 7.05 (dd,
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1H, J = 9.0, 2.2), 5.61 (s, 2H), 5.26 (s, 2H), 4.23 - 4.17 (q, OCH2CH3, J = 
7.1), 1.29 - 1.25 (t, OCH2CH3, J = 7.0);
13C NMR not obtained due to poor solubility;
HRMS: [M+H]+ C22H20FN4O4 requires 423.1469, found 423.1476.
Ethyl 7-(( 1-(3-fluorobenzyl)-1 H-1,2,3-triazol-4-yl)methoxy)-4-oxo-1,4-
dihydroquinoline-3-carboxylate (60e)
Synthesised from 58e according to general method H to give a white 
solid.
(90.3 mg, 92.9%)
Melting point: > 250 °C
1H NMR (DMSO-d6) 5 12.15-12.13 (d, NH, J = 6.4), 8.49-8.47 (d, 1H, J = 
6.6), 8.36 (s, 1H), 8.06 - 8.04 (d, 1H, J = 8.9), 7.46 - 7.39 (m, 1H), 7.19 - 
7.14 (m, 4H), 7.08 - 7.05 (dd, 1H, J = 8.9, 2.4), 5.66 (s, 2H), 5.28 (s, 2H), 
4.23 - 4.17 (q, OCH2CH3, J = 7.1), 1.29 - 1.25 (t, OCH2CH3, J = 7.1);
13C NMR not obtained due to poor solubility;
HRMS: [M+Hf C22H20FN4O4 requires 423.1469, found 423.1483.
Ethyl 7-(( 1-(2,4-difluorobenzyl)-1 H-1,2,3-triazol-4-yl)methoxy)-4-oxo-1,4-
dihydroquinoline-3-carboxylate (60f)
Synthesised from 58f according to general method H to give a white 
solid.
(86.8 mg, 98.5%)
Melting point: > 250 °C
1H NMR (DMSO-d6) 6 12.15-12.13 (d, NH, J= 6.6), 8.49-8.47 (d, 1H, J = 
6.6), 8.31 (s, 1H), 8.06 - 8.04 (d, 1H, J = 8.9), 7.52 - 7.46 (m, 1H), 7.36 -
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7.30 (td, 1H, J = 10.4, 2.5), 7.16-7.11 (m, 2H), 7.08-7.05 (dd, 1H, 8.9,
2.4), 5.67 (s, 2H), 5.26 (s, 2H), 4.23-4.17 (q, OCH2CH3, J = 7.1), 1.29 - 1. 
25 (t, OCH2CH3, J = 7.1);
13C NMR not obtained due to poor solubility;
HRMS: [M+H]+ C22H19F2N4O4 requires 441.1374, found 441.1385.
Synthesis of 2-(2-azidoethyl)isoindoline-1.3-dione (62)
o
(2-Bromoethyl)phthalimide 61 (6.01 g, 23.7 mmol), sodium azide (3.94 g, 
60.6 mmol), and sodium iodide (0.53 g, 3.5 mmol) were dissolved in 
acetone/water (5:1, 100 mL). The solution was refluxed for 24 h, diluted with 
water (50 mL), and extracted with ethyl acetate (3 x 75 mL). The organic 
phase was dried over magnesium sulphate and evaporated to yield the 
product as a sticky crystalline solid.
(4.10 g, 80.0%)
1H NMR (CDCb) 8 7.91 - 7.72 (m, 4H), 3.92 - 3.89 (t, NCH2CH2N3. J = 6.0), 
3.62 - 3.59 (t, NCH2CH2N3,, J = 6.1);
13C NMR 5 168.5 (2 C=0), 134.6 (2C), 132.3 (2C), 123.9 (2C), 49.4, 37.3.
Synthesis of ethyl 4-chloro-7-((1-(2-(1,3-dioxoisoindolin-2-yl)ethyl)-1 H-1.2,3- 
thazol-4-yl)methoxy)quinoline-3-carboxylate (63)
Cl o
o
Synthesised from 56 and 62 according to general method G to give a 
pale yellow solid.
(0.23 g, 44.7%)
Melting point: 162 - 165 °C
1H NMR (CDCb) 6 9.16 (s, 1H), 8.30 - 8.28 (d, 1H, J = 9.3), 7.80 - 7.77 (m, 
3H), 7.72 - 7.67 (m, 2H), 7.53 - 7.52 (d, 1H, J = 2.5), 7.35 - 7.32 (dd, 1H, J
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= 9.3, 2.5), 5.35 (s, CCH20), 4.75 - 7.72 (t, NChbCHaN, J = 5.9), 4.52 - 4.46 
(q, OCH2CH3, J = 7.1), 4.21 - 4.18 (t, NCH2CH2N, J = 6.2), 1.48 - 1.45 (t, 
OCH2CH3, J = 7.1);
,3C NMR 5 168.0 (2 C=0), 165.0 (C=0), 161.5 (C-CI), 151.9, 151.4, 143.8, 
143.7, 134.7 (2C), 132.0, 127.4, 124.0 (2C), 123.8, 121.9 (2C), 121.3, 109.2, 
62.6, 62.3,48.5, 38.1, 14.7;
HRMS: [M+Naf C25H2035CIN5O5Na requires 528.1051 found 528.1039.
Synthesis of ethyl 7-((1 -(2-(1,3-dioxoisoindolin-2-yl)ethyl)-1 H-1,2,3-triazol-4- 
yl)methoxy)-4-oxo-1,4-dihydroquinoline-3-carboxylate (64)
Synthesised from 63 according to general method H to give a white 
powder.
(67.4 mg, 65.2%)
Melting point: > 250 °C
1H NMR (DMSO-d6) 5 12.12 - 12.10 (d, NH, J = 6.7), 8.47 - 8.46 (d, 1H, J = 
6.6), 8.32 (s, 1H), 8.05-8.03 (d, 1H, J= 8.9), 7.81 (s, 3H), 7.12-7.11 (d, 
1H, J = 2.3), 7.04 - 7.02 (dd, 1H, J = 8.9, 2.4), 5.23 (s, 2H), 4.68 - 4.65 (t, 
NCHjCHjN, J = 5.0), 4.23 - 4.18 (q, OCH2CH3, J = 7.1), 4.03 - 4.00 (t, 
NCH2CH2N, J= 5.9), 2.09 (s, 1H), 1.29-1.26 (t, OCH2CH3, J = 7.1);
,3C NMR not obtained due to poor solubility;
HRMS: [M+H]* C25H22N5O6 requires 488.1570, found 488.1568.
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Chapter 5
Conclusions and Future Work
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5. Conclusions and Future Work
We have been successful in our aim to design and synthesise a small 
library of quinolone-based compounds with high levels of potency against 
P. falciparum with compounds 39 and 48 achieving ICso’s of less than 1 nM in 
vitro.
o o
Issues with poor solubility have been highlighted and successfully tackled 
through the development of carbamate prodrugs, 46 and 47, with the 
resulting compounds demonstrating rapid parasite clearance at low doses in 
vivo in mouse models.
46 X = O
47 X = CH2
Testing against protein isolates has confirmed that the compounds are 
active against the parasite protein complex target as planned, however 
only low levels of selectivity for the parasite protein over the corresponding 
mammalian protein have been observed at present. Some progress has 
been made towards improving selectivity but further biological testing is 
required before true conclusions can be drawn from this work. Further 
improving levels of selectivity needs to be the focus of future work on these 
compounds along with further improvement of the current resistance profile 
as cross-resistance with atovaquone is currently evident. The development
-175-
of a more efficient synthetic route would also be worthy of future 
consideration.
Computer modelling has been successfully employed to elucidate the 
way in which the lead compounds may interact with the protein target. 
However, as demonstrated by the poor activity of the “click” series 
compounds, further work is needed before the modelling could be 
considered capable of predicting active structures.
In addition to these aims it would be of interest to further research the 
activity of compound 10; as while significantly less active than the lead 
compounds in vitro, this compound was the only compound tested to 
maintain similar levels of activity against atovaquone resistant parasites as 
was demonstrated against wild-type parasites. This may indicate that 
compound 10 exhibits a different mode of action to the rest of the 
compounds synthesised in this study.
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